


Protocol

Protocol for designing a peptide-based multiepitope vaccine targeting monkeypox using reverse vaccine technology



Reverse vaccine technology, supported by advancements in immunoinformatics, facilitates the development of multi-epitope vaccines for rapidly evolving pathogens, thereby strengthening the immune defense. Here, we present a protocol for a peptide-based multi-epitope vaccine targeting monkeypox virus (MPXV) using an open-source approach. We describe steps for evaluating physicochemical properties and allergenicity. We then detail procedures for validating pattern recognition receptor (PRR)-binding affinity and stable major histocompatibility complex (MHC) I/II presentation. Molecular dynamics (MD) simulations confirm immune receptor interactions, enhancing vaccine stability.

Publisher's note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.

Amit Kumar, Garima Nagar, Prithwik Bhowmik, ..., Rakesh Kundu, Indrakant Kumar Singh, Tanmay Majumdar

majumdart@nii.ac.in

Highlights

Steps for predicting specific epitopes for B cells, T cells, and IFN-gamma

Instructions for the construction of 3D vaccine structure and its validation

Steps for molecular docking and MD simulation with PRRs

Guidelines on *in silico* cloning and immune simulation

Kumar et al., STAR Protocols 6, 103671 March 21, 2025 © 2025 The Author(s). Published by Elsevier Inc. https://doi.org/10.1016/ j.xpro.2025.103671

CellPres OPEN ACCES

1

Protocol

Protocol for designing a peptide-based multi-epitope vaccine targeting monkeypox using reverse vaccine technology

Amit Kumar,^{1,5} Garima Nagar,^{2,5} Prithwik Bhowmik,^{2,5} Geetika Kumari,^{1,5} Rasmiranjan Muduli,¹ Mayami Das,¹ Pritha Chakraborty,³ Anupamjeet Kaur,¹ Kumari Shikha,¹ Suprabhat Mukherjee,³ Rakesh Kundu,⁴ Indrakant Kumar Singh,² and Tanmay Majumdar^{1,6,7,*}

¹National Institute of Immunology, New Delhi, India

²Department of Zoology, Deshbandhu College, University of Delhi, New Delhi, India

³Department of Animal Science, Kazi Nazrul University, Asansol, West Bengal, India

⁴Department of Zoology, Visva-Bharati University, Santiniketan, West Bengal, India

⁵These authors contributed equally

⁶Technical contact

⁷Lead contact

*Correspondence: majumdart@nii.ac.in https://doi.org/10.1016/j.xpro.2025.103671

SUMMARY

Reverse vaccine technology, supported by advancements in immunoinformatics, facilitates the development of multi-epitope vaccines for rapidly evolving pathogens, thereby strengthening the immune defense. Here, we present a protocol for a peptide-based multi-epitope vaccine targeting monkeypox virus (MPXV) using an open-source approach. We describe steps for evaluating physicochemical properties and allergenicity. We then detail procedures for validating pattern recognition receptor (PRR)-binding affinity and stable major histocompatibility complex (MHC) I/II presentation. Molecular dynamics (MD) simulations confirm immune receptor interactions, enhancing vaccine stability.

For complete details on the use and execution of this protocol, please refer to Kaur et al.¹

BEFORE YOU BEGIN

Reverse vaccine technology is a bioinformatics-driven approach for vaccine development that identifies immunogenic epitopes directly from a pathogen's genome/proteome. Simultaneous targeting of multiple epitopes triggers an elevated immunogenic response. The present protocol includes mapping of immune response predicting epitopes of MPXV that could foster long-lasting memory immunity against its challenge.

- 1. Construct the multi-epitope vaccine, its 3D structure and examination of physicochemical properties.
- 2. Molecular docking and MD simulation to predict the binding affinity of the vaccine with receptors (MHC I, MHC II, and TLRs).
- 3. Ensure robust immunological response of the multi-epitope vaccine upon booster dosing via *in silico* cloning and immune simulation and assess cellular immune activation and protective immunity through cytokine production and antibody generation.







In this study, we present an insightful approach to improve protection against MPXV infection. We believe the method outlined provides a clear guide for developing a multi-epitope vaccine, and it could also be applied to other infectious disease outbreaks.

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Software and algorithms		
Ubuntu 24.04.1 LTS (Linux operating system)	Canonical Ltd.	https://ubuntu.com/tutorials/install-ubuntu-desktop#1-overview
PyMOL	Schrödinger, Inc.	https://PyMOL.org/dokuwiki/doku.php?id=installation
GROMACS	Abraham et al. ²	https://manual.gromacs.org/current/install-guide/index.html
LigPlot+	Laskowski et al. ³	https://www.ebi.ac.uk/thornton-srv/software/LigPlus/install.html
GraphPad Prism 10	GraphPad	https://www.graphpad.com/
Snapgene	SnapGene	https://support.snapgene.com/hc/en-us/articles/10304161780628- Download-Install-and-Register-SnapGene
NCBI database	National Library of Medicine (NLM)	https://www.ncbi.nlm.nih.gov/
VaxiJen	Doytchinova et al. ⁴	https://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html
AllerTOP v.2.0	Dimitrov et al. ⁵	https://www.ddg-pharmfac.net/AllerTOP/
Expasy ProtParam	Gasteiger et al. ⁶	https://web.expasy.org/protparam/
SOPMA	Geourjon et al. ⁷	https://npsa.lyon.inserm.fr/cgi-bin/npsa_automat.pl?page=/ NPSA/npsa_sopma.html
PSIPRED	McGuffin et al. ⁸	http://bioinf.cs.ucl.ac.uk/psipred/
NetCTL 1.2	Larsen et al. ⁹	https://services.healthtech.dtu.dk/service.php?NetCTL-1.2
IEDB MHC I and II, Antibody Epitope Prediction, Population coverage, Conservancy analysis	Vita et al. ¹⁰	http://tools.iedb.org/mhci/ http://tools.iedb.org/mhcii/, http://tools.iedb.org/bcell/, http://tools.iedb.org/population/ http://tools.iedb.org/conservancy/
NetMHCIIpan - 3.2	Jensen et al. ¹¹	https://services.healthtech.dtu.dk/service.php?NetMHCIIpan-3.2
IFNepitope server	Dhanda et al. ¹²	https://webs.iiitd.edu.in/raghava/ifnepitope/predict.php
SoluProt	Hon et al. ¹³	https://loschmidt.chemi.muni.cz/soluprot/
Robetta	Kim et al. ¹⁴	https://robetta.bakerlab.org/queue.php
Galaxy refine	Heo et al. ¹⁵	https://galaxy.seoklab.org/cgi-bin/submit.cgi?type=REFINE
MolProbity	Williams et al. ¹⁶	http://molprobity.biochem.duke.edu/
ClusPro 2.0	Kozakov et al. ¹⁷	https://cluspro.org/help.php
PRODIGY	Xue et al. ¹⁸	https://rascar.science.uu.nl/prodigy/
ToxinPred	Sharma et al. ¹⁹	http://crdd.osdd.net/raghava/toxinpred/
EMBOSS Backtranseq	Rice et al. ²⁰	https://www.ebi.ac.uk/Tools/st/emboss_backtranseq/
C-IMMSIM	Castiglione et al. ²¹	
Other		
System requirements Intel Core i9-10850K 3.60 GHz, Windows 11 Pro, 64 GB RAM, 1 TB ROM, 64-bit OS.	N/A	N/A

STEP-BY-STEP METHOD DETAILS

Part 1: Retrieval of protein sequence

© Timing: 30 min

This section enlists the steps for retrieving the protein sequence from the NCBI Database. The NCBI database is an open resource for accessing all genomic and biomedical data information related to advance science and health.

- 1. Access NCBI for free by using https://www.ncbi.nlm.nih.gov/ link (Figure 1A).
- 2. Click on the dropdown menu next to the search bar and select the "protein" option.



Protocol




Figure 1. Retrieval of protein sequence using the NCBI database

Retrieved protein FASTA sequences from the NCBI database and compiled a library of target proteins with detailed descriptions. (A) Home page of NCBI.

- (B) Search protein of interest-A29L.
- (C) Result of NCBI searched protein.
- (D) Word document of protein sequences in FASTA format.
- 3. In the search, enter the protein name (A29L, A30L, A35R, L1R, M1R, or E8L) (Figure 1B).

Note: If the desired results are not found, try adding the specific name of the organism next to the protein name to refine the search.

- △ CRITICAL: Please ensure you have a thorough understanding of the proteins you plan to select for candidate vaccine design. In this case, we have chosen the glycoproteins of the mpox virus for consideration in multiepitope vaccine development.
- 4. Click on FASTA below protein name (Figure 1C).
- 5. Copy each sequence separately and paste them into a Word document in FASTA format (Figure 1D).

Part 2: Estimation of antigenicity, allergenicity, physiochemical, and secondary structure prediction of selected glycoproteins

© Timing: 4 h

This section enlists the procedure and analysis of selected glycoproteins, assessing antigenic properties using VaxiJen v.2.0, allergenic properties with AllerTOP v.2.0, physicochemical characteristics via ProtParam, and secondary structure predictions using SOPMA and PSIPRED 4.0.

- 6. Open VaxiJen v.2.0 webserver for antigenicity prediction (Figure 2A).
- 7. Paste the individual protein sequence in the "Enter a PROTEIN sequence here" column.



Protocol

	 	* ± • (*********************************	B ↔ σ E ddg.ghann □ ni nan ⊗ Antone Antone	hborsely-angine/houldes/hould	🖈 🛓 0 (Reband bit upder)
	VaxiJen 2.0	D Al Iniciali	C rux G morrow	VaxiJen 2.0	
	Valiba: Preliation of Protocles Andgess and Indust Vacions. Prejide evaluation of the Preliation of			Yankher Prediction of Prediction Antiputs and Enhant Vacians. Sub-Columbus Science Control Minkow@gharent and Ap.	
	Zero 2010 TET Stream And			Entra IFOCIDE sequerative provingence prov	
	Main an Under Of Malakanian Malakanian Tanan and Anton			Men : EMICE ORGANINA AND AND AND AND AND AND AND AND AND A	
	Taninikin Der Oberheinisteren Gesen Desemilterenensteren			halalishiy bishalalan fash ketimapatan	
	Orber FATT Reinformeter Teh ferer Janlar Lefter MRCent Lefter REISORT			One DPR Biolowick Webber Jacks Edite Light ERBIT	
	Ethorit.Jorea.JordinaleEthori.EtholigEconnatAd			[Edward.Social-billed][Doy/Dovin/Down][Link][Contex135]	
с	 S (f) Abgestentiszert szejeczbenye (telefony zározásta) warwa (b) zároz zonana 	🖈 🛃 🔕 (Kennin supers)			
	VaxiJen 2.0				
	Vasles 50301.03				
	Model selected: virus				
	Threshold for Bis societ, 8.4				
	Nar fereneri metri interesta alla programma da programma da programma da programma da programma da programma da programma da programma da programma da programma en la construcción de programma da programma da programma da programma da programma da programma da programma d en la construcción de programma da programma da programma da programma da programma da programma da programma d en la construcción de programma da programma da programma da programma da programma da programma da programma de en la construcción de programma da programma da programma da programma da programma da programma da programma de en la construcción da programma da				
	Oversal Froderance for the Protector Assigns = 8.3277 (Probable 300%-6.33116428).				

Figure 2. Analysis of antigenicity of selected glycoproteins using VaxiJen v.2.0

(A) Homepage of VaxiJen v2.0 webserver.

(B) Entered protein sequence and selection.

(C) Result page of searched protein.

- 8. Choose the Virus option from the drop down "select a TARGET ORGANISM" section (Figure 2B).
- 9. Keep the threshold value as default 0.4 (to designate the glycoproteins as antigens with an antigenicity score > 0.4) and click "Submit" to display the result (Figure 2C).

Note: Results will be displayed if the sequence entered is Probable ANTIGEN or NON-ANTIGEN and an antigenicity score. Score below 0.4 is non-antigenic and above 0.4 is antigenic in nature.

- 10. Open AllerTOP v.2.0. for allergenicity prediction (Figure 3A).
- 11. Paste individual protein sequence and click on "Get the results" option (Figure 3B).

Note: Results will be displayed as "PROBABLE ALLERGEN" or "PROBABLE NON-ALLERGEN" (Figure 3C).

- 12. Prepare an Excel table as shown in Figure 3D comprising name of protein, antigenicity score, antigenicity and allergenicity status.
- 13. Examine the physiological parameters using the Expasy ProtParam webserver (Figure 4A).
- 14. Paste individual protein sequence in "Enter a protein sequence" column and click on "compute parameters" option to display results (Figures 4B and 4C).
- 15. Prepare an Excel table including size, molecular weight, theoretical pl, instability index, aliphatic index and GRAVY (Figure 4D).
- 16. Analyze the secondary structure components of the glycoproteins by using the SOPMA prediction model (Figure 5A).
- 17. Paste the protein sequence in "Paste a protein sequence below" column and click on submit to obtain result option keeping the default parameters (Figures 5B and 5C).
- 18. Prepare an Excel table compiling different secondary structure parameters generated by this webserver for all the proteins (Figure 5D).
- 19. Re-validate the protein secondary structure by entering the sequence on PSIPRED 4.0 webserver, click on the submit button (Figures 6A and 6B).





 O Construction (Alter 104) 			û 🛛 🖓 🖉 1		ddg-phannfac.net/iklier109/				* ± 0 🖷
i 🖬 taullalar 🛃 Maya 🗛 Darakatar 🔿 Maraa 💽 Ag				- +1 com @ +00000	loster				1
		Contact						Contact	
	101	a set of the					wsore	A REAL PROPERTY AND	
	AllerTOP v. 2.0	8 43		1.1		Aller	TOP v. 2.0	18, 13	
	Bioinformatics tool for allergenicity	doxidu daxxii xdxxi kono oo				Bioinformatio	es tool for allergenicity		
	prediction according						prediction BINDERS		
	Enter a PROTEIN sequence have as a plain text (see letter code)					Color a Months o	Annual of the set of the first from the set of the set	N DOCUMENT OF THE OWNER	
						ACCHRADEVL/R	L DWHATTL BAAHISLAKKIDVQ TCRHPYE		
				C.					
	Get the vector	495				Gerthe	nesult		
							C 2 101 (Sample) (Sample Classifier Sample Solution Sciences Solution		
	The first-out frage is from the bootstance independence is a set of the second se					Contraction of the second	an ta tana ta ta tanàna ta dia 2014. Ilay kaominina dia kaominina dia kaominina dia kaominina dia kaominina dia Jeografia		
				1					
2 12 52 phones.e .e.s.r/00/10/10/10/10			2 🕹 🙆 (Read to get 1)	D 8500			w/advascess - 6-a		6973 00
Q S 44 provide state (10 % 10 millions) /	Elecis Statutes Electrotecryption	2 canar	e d (maaraanii)	D Receipt	- Popiana Annas Bai N 2011 - 1 - 1 - 1 21 9 - 1 - 2 - 2 - 1	nor Rom Poly 2007 () Marakar The Poly I Planda The Poly I Planda Th		ford Ford	Spon 00 Antiper - Spor D Sate Secto Foods Gare - Fare Sector
0 🔮 tig personalitie "Statistical Ø minimum	#20 #2	2 min		Falls Scary - Palls - Formerbanes Outboard - C	The face former that the forme	none line line (2027) Maradaa Taraa (2027) Maradaa Taraaa (2027) Maradaaa Taraa (2027) Maradaa Taraa (202		Soul North	
C appendix (100%) millions y	dana danan orderari	2 Statest Statest		Fath Copy - Fath Copy - Custors 040000	[Const - (m → K - K 0 - Z - 9 - (m → K - K Fort - 6	T = 100 P + 27 Hay Nat T = 10 0 E E E E E E E E E E E E E E E E E	- Candidate Security Candidates		Chatelium * Surg O Chat - Sord Finds Char - Sord Finds Find - Sold - Ad Soring Ad
C en grannen sector/Orbitalisas;	AllerTOP v. 2.0 Bioinformatics tool for allergenicity			Falls Scary - Palls - Formerbanes Outboard - C	Consi - [0 -] A' A' 0 - Z - 2 -] □ -] Δ - Δ - Feet - 6	er he he file (bescher er he he file) e e e e e e e e e e e e e e e e e e e		Seed North	
	AllerTOP v. 2.0			Anno Copy - Parts Copy - Copy-set Ball - A 1 2 Name	Constant of the second	C Antigenicity (VaxiJen v2.0)	Allergenicity (AllerTop v. 2.0)		Chatelium * Surg O Chat - Sord Finds Char - Sord Finds Find - Sold - Ad Soring Ad
	AllerTOP v. 2.0 Bioinformatics tool for allergenicity			A 1 A A A A A A A A A A A A A A A A A A	Image: Bit is a state Image: Bit is a state	C Antigenicity (Vaxilien v2.0) NON-ANTIGEN	Allergenicity (AllerTop v. 2.0) PROBABLE NON-ALLERGEN		Chatelium * Surg O Chat - Sord Finds Char - Sord Finds Find - Sold - Ad Soring Ad
6 Operations	AllerTOP v. 2.0 Bioinformatics tool for allergenicity prediction			A A A A A A A A A A A A A A	Email Image: Control Image: Control<	B = 0 + 17 Weeks B = 0 + 17 Weeks B = 0 = 0 = 16 Weeks C C Antigencicity (Vaxilen v2.0) NON-ANTIGEN ANTIGEN	D Allergenicity (AllerTop v. 2.0) PROBABLE NON-ALLERGEN		Chatelium * Surg O Chat - Sord Finds Char - Sord Finds Find - Sold - Ad Soring Ad
	AllerTOP v. 2.0 Bioinformatics tool for allegeneich prediction			A A A A A A A A A A A A A A	Cons (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	C C Antigencity (Vaxilen v2.0) NON-ANTIGEN ANTIGEN	Allergenicity (Aller Top v. 2.0) Probable Non-AllERGEN Probable Non-AllERGEN Probable Non-AllERGEN		Chatelium * Surg O Chat - Sord Finds Char - Sord Finds Find - Sold - Ad Soring Ad
C en grandina sectoral di Anna anna anna anna anna anna anna ann	AllerTOP v. 2.0 Bisinformatics tool for allegraticity prediction			A 1 2 Name 3 A29L 4 A30L 5 A35R 6 L1R	B Antigenicity Score 0.4277 0.6212 0.4998 0.3459	C Antigencicity (Vaxilen v2.0) NON-ANTIGEN NON-ANTIGEN NON-ANTIGEN	Allergenichy (Aller Top v. 2.0) PROBABLE NON-ALLERGEN PROBABLE NON-ALLERGEN PROBABLE ALLERGEN		Chatelium * Surg O Chat - Sord Finds Char - Sord Finds Find - Sold - Ad Soring Ad
(a (generation the formation) and the	AllerTOP v. 2.0 Bisinformatics tool for allegencity prediction			A A A A A A A A A A A A A A A A A A A	Com Office A C A A A A A A A A A A A A A A A A A	C Antigenciary (Vaxilen v2.0) NON-ANTIGEN ANTIGEN NON-ANTIGEN ANTIGEN ANTIGEN	V 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		Chatelium * Surg O Chat - Sord Finds Char - Sord Finds Find - Sold - Ad Soring Ad
C appendix of the first of the	AllerTOP v. 2.0 Bisinformatics tool for allegraticity prediction			A construction of the second s	B Antigenicity Score 0.4277 0.6212 0.4998 0.3459	C Antigencicity (Vaxilen v2.0) NON-ANTIGEN NON-ANTIGEN NON-ANTIGEN	Allergenichy (Aller Top v. 2.0) PROBABLE NON-ALLERGEN PROBABLE NON-ALLERGEN PROBABLE ALLERGEN		Chatelium * Surg O Chat - Sord Finds Char - Sord Finds Find - Sold - Ad Soring Ad
2 Elegenmentoritations:	AllerTOP v. 2.0 Bisinformatics tool for allegraticity prediction			A A A A A A A A A A A A A A A A A A A	Com Office A C A A A A A A A A A A A A A A A A A	C Antigenciary (Vaxilen v2.0) NON-ANTIGEN ANTIGEN NON-ANTIGEN ANTIGEN ANTIGEN	V 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		Chatelium * Surg O Chat - Sord Finds Char - Sord Finds Find - Sold - Ad Soring Ad
C By performance in with instances manual sectors and a sector	AlterTOP v. 2.0 Bioinformatic tool for altergration prediction			A 1 A 1 A 2 Name 3 A29L 4 A30L 5 A35R 6 L1R 7 M1R 8 E8L 9 10	Com Office A C A A A A A A A A A A A A A A A A A	C Antigenciary (Vaxilen v2.0) NON-ANTIGEN ANTIGEN NON-ANTIGEN ANTIGEN ANTIGEN	V 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		Chatelium * Surg O Chat - Sord Finds Char - Sord Finds Find - Sold - Ad Soring Ad
Contraction of the second s	AlterTOP v. 2.0 Bioinformatic tool for altergration prediction			A construction 0 11 12	Com Office A C A A A A A A A A A A A A A A A A A	C Antigenciary (Vaxilen v2.0) NON-ANTIGEN ANTIGEN NON-ANTIGEN ANTIGEN ANTIGEN	V 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		Chatelium * Surg O Chat - Sord Finds Char - Sord Finds Find - Sold - Ad Soring Ad
 G to previou com/c0/minter; Minimum 	AlterTOP v. 2.0 Bioinformatic tool for altergration prediction			A A 1 A 2 Name 3 A29L 4 A30L 5 A35R 6 L1R 7 MIR 8 E8L 9 10 11 12 12 13	Com Office A C A A A A A A A A A A A A A A A A A	C Antigenciary (Vaxilen v2.0) NON-ANTIGEN ANTIGEN NON-ANTIGEN ANTIGEN ANTIGEN	V 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		Chatelium * Surg O Chat - Sord Finds Char - Sord Finds Find - Sold - Ad Soring Ad
2 2 Anomano contrator or more	AlterTOP v. 2.0 Bioinformatic tool for altergration prediction			A 1 A 1 2 Name 3 A29L 4 4 3 A30L 5 A39L 6 LIR 7 MIR 8 8 8 8 10 11 12 13 14 13 14 14 15 13 14 15 15 15 15 15 15 15 15 15 15	Com Office A C A A A A A A A A A A A A A A A A A	C Antigenciary (Vaxilen v2.0) NON-ANTIGEN ANTIGEN NON-ANTIGEN ANTIGEN ANTIGEN	V 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		Chatelium * Surg O Chat - Sord Finds Char - Sord Finds Find - Sold - Ad Soring Ad
C in protocol/officers.cg	AlterTOP v. 2.0 Bioinformatic tool for altergration prediction			A A 1 A 2 Name 3 A29L 4 A30L 5 A35R 6 L1R 7 MIR 8 E8L 9 10 11 12 12 13	Com Office A C A A A A A A A A A A A A A A A A A	C Antigenciary (Vaxilen v2.0) NON-ANTIGEN ANTIGEN NON-ANTIGEN ANTIGEN ANTIGEN	V 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		Chatelium * Surg O Chat - Sord Finds Char - Sord Finds Find - Sold - Ad Soring Ad

Figure 3. Analysis of allergenicity of selected glycoproteins using AllerTOP v.2.0

- (A) Homepage of AllerTOP v.2.0 webserver.
- (B) Entered protein sequence and submission.
- (C) Result page of searched protein.
- (D) Combined excel table containing antigenicity and allergenicity of selected glycoproteins.
- 20. Download the results generated (as sequence plot) from the right side by clicking the "Get zip file" option (Figure 6C).

Part 3: Prediction of T cell-specific epitopes: MHC I

© Timing: 6 h

This section enlists the steps, and focuses on the prediction of T cell-specific epitopes via IEDB MHC I and NetCTL-1.2 servers, which are restricted to MHC class I molecules.

- 21. Go to MHC I binding predictions tool of Immune Epitope Database (IEDB) (Figure 7A).
- 22. Paste protein sequence in the dialog box. Click on the "Select HLA allele reference set" checkbox (Figure 7B).

Note: The following list of alleles will be automatically selected- HLA-A*01:01, HLA-A*01:01, HLA-A*02:01, HLA-A*02:01, HLA-A*02:03, HLA-A*02:03, HLA-A*02:06, HLA-A*02:06, HLA-A*03:01, HLA-A*03:01, HLA-A*03:01, HLA-A*11:01, HLA-A*101, HLA-A*23:01, HLA-A*23:01, HLA-A*24:02, HLA-A*24:02, HLA-A*26:01, HLA-A*26:01, HLA-A*30:01, HLA-A*30:01, HLA-A*30:02, HLA-A*30:02, HLA-A*31:01, HLA-A*31:01, HLA-A*32:01, HLA-A*33:01, HLA-A*33:01, HLA-A*33:01, HLA-A*33:01, HLA-A*668:01, HLA-A*668:01, HLA-A*668:02, HLA-A*668:02, HLA-B*07:02, HLA-B*07:02, HLA-B*08:01, HLA-B*08:01, HLA-B*15:01, HLA-B*15:01, HLA-B*35:01, HLA-B*35:01, HLA-B*51:01, HLA-B*51:01, HLA-B*53:01, HLA-B*53:01, HLA-B*53:01, HLA-B*53:01, HLA-B*57:01, HLA-B*57:01, HLA-B*58:01, HLA-B*58:01, HLA-B*57:01, HLA-B*57:01, HLA-B*58:01, HLA-B*58:01, HLA-B*57:01, HLA-B*57:01, HLA-B*57:01, HLA-B*58:01, HLA-B*58:01, HLA-B*57:01, HLA-B*57:01, HLA-B*57:01, HLA-B*58:01, HLA-B*58:01, HLA-B*57:01, HLA-B*57:01, HLA-B*58:01, HLA-B*58:01, HLA-B*57:01, HLA-B*57:01



Protocol

O CO E sebespayorg					B ····	ube 😻 Maps 💁 Tanubre	the first the fig							
		ProsParam							ProtParam					
sy ^a ≜ Home	@ Documentation	Reference	Contact		Expasy ^a	A Home		Documentation	Refere	ice .	-	Contact		
		ProtParam							ProtParam					
	ProtParam [Documentation / Reference] is a tool which allows the comp	putation of various physical and chemical parameters for a given					ProtParam (Documentation / Refe	nce] is a tool which allows the con	mputation of various physical and cher	ical parameters for a given	protein stored in UniProtKB	or for a		
	user entered protein sequence. The computed parameters include the in estimated half-life, instability index, alphatic index and grand average of	nolecular weight, theoretical pl. amino acid composition, atomic i if hydropathicity (GRAVY) (Disclaimar).	composition, extinction coefficient,				user entered protein sequence. The estimated half-life, instability index,	computed parameters include the alphatic index and grand average	molecular weight, theoretical pl, amin of hydropathicity (GRAVY) (Disclaime	acid composition, atomic of	composition, extinction coeffic	cient,		
	Enter a protein sequence Press enter one UniProtKB ACID (e.g. P05130 or KPC1_DROME).						Enter a protein sequence Please enter one UniProtKI AC/ID	e g. P05130 or KPC1_DROME						
	Atematively, enter one protein sequence in single letter code (e.g. ABC	DEFGHIKLMVOPORSTUVWXY)					Atternatively, enter one protein seg	ence in single letter code (e.g. AD	CDEFGHIRLANOPORSTUVIOCY)					
							MDGTLFPGDDDLAIPATEFFSTKA KKITNITTKFEQIEKCCK/INDEVL/	NONPETKREANKAYGDDNEETLX RLENHAETLRAAMTSLAKKOVQT	KORLINLE					
	RESET Compute parameters						RESET Compute parameters							
	Multi Compare parameters						ACOCI Compose parameters							
	Experty is open	rated by the SIB Swiss institute of Bioinformatics Terms of Use Privacy policy		Back to the top	14. Sie			Expany is opt	enaled by the SIB Sense Institute of Br Terms of Use Privacy policy	informatica			в	Bec
	Expany is oper			Back to the top	58 58			Expeny is ope	enaled by the SIB Swiss Institute of Bin Terms of Use Privacy policy	informatics			B	Bec
					588			Expany is ope	Terms of Use Privacy policy	internatica				Bed
a (B neperatorsky objectu)				2 2 0 Minerson 1	D		wat Outs Rovies Keen Help X	597 Q Salancestergouwertsedo	Terms of Use Privacy policy we particulated to a				Spain 00	-
O Adole Acrolat					D			597 Q Salancestergouwertsedo	Terms of Use Privacy policy we particulated to a		Mental II 24 3	× 💽 Σtaster	Spain 00	•
O Admine Accelent		Terms of Use Privacy policy	Correct	2 2 0 Minerson 1		(Called	- X X = = = ₩+ 8mm 0+ ▲+ = = = 0.0 000	SV ♀ Mincole presented Int Alterna ♀ ♀ % ★ 15 21	Terms of Use Privacy policy		Nector C	Kana Maria Cari	Spain 00	•
Ø Adobe Acrobat	protosan-jungsavan	term of the (Privacy policy Profilation Distance		2 2 0 Minerson 1		(Called		207 Q Manuahayoo waxaa da Taa ah Canaa Q - 16 + 12 J	Terms of Use Privacy policy		Mandadi Ngay Caral	X Santara In Anna In	Spon 00	
8 Adulte Acculat	a Counciliante B Counciliante Pro	Terms of Use Physicy policy ProtParam		2 2 0 Minerson 1	D Company	5 7 8 × 10 × 10 × 10 × 10 × 10 × 10 × 10 ×	$a \rightarrow b^{+} a^{+} = = a^{+} b^{+} + b^{+} a^{+}$ $b^{+} = a^{+} = a^{-} = a^{+} = a^{$	202 Q Not the other gase want to do that a B Center ↓ Q + S + 1 S = 0 Namber 0	Terres of Use Privacy policy MI (2010), USA (11) + End MI (2010), USA (11) + End Continued Terres in Calculation (11) Freedom - Main -	d Good C.C.C. IIII Gylenetroy Debs			Spon 00	-
Ø Adobe Acrobat	anterentioner g Documentator User-previded segurence:	Professor Profes		2 2 0 Minerson 1	D A	Comm	$A \neq a$ $b + \Delta + a$ c C c c c c c c c c	D2 Determined you want to do The the Comment of the Comment of the the Comment of the Comment of the Determined of the Determined of the Comment of the Determined of the Det	Terres of Use Privacy policy MP_SOCI_UNAVES - See MP_SOCI_UNAVES - See Terrestory - Terrestory - Selections - D E Ry Index Allphatic Ind	F Ex G5	G	н	Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As	-
Addition Accession	a Counciliante B Counciliante Pro	Professor Profes		2 2 0 Minerson 1	D Contraction Con	Const → 0 8 7 8 × 10 × 10 × 7 or 1 8 5 × 5 5 8 5ize (AA) Molec 110	A A B	202 Q Marca and you avert to be formed Compatibility Compatibity Compatibity Compatibility </td <td>Terms of Use Privacy poly (W) 2010 (MAXY) + find Comments - Terms Comments - Te</td> <td>f Good F Grand Contractory Bains F GF 73.73</td> <td>G 40.1</td> <td>н</td> <td>Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As</td> <td>-</td>	Terms of Use Privacy poly (W) 2010 (MAXY) + find Comments - Terms Comments - Te	f Good F Grand Contractory Bains F GF 73.73	G 40.1	н	Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As	-
Addition According	อาจจะหว่างระดะ g Gouversteins Pro ประกรุณร์เส้น หรือเสนอร์ คือ สนอนร์ อาจจะการสู้ เหล	Professor Profes		2 2 0 Minerson 1	D A	Comm	$A \neq a$ $b + \Delta + a$ c C c c c c c c c c	D2 Determined you want to do The the Comment of the Comment of the the Comment of the Comment of the Determined of the Determined of the Comment of the Determined of the Determined of the Comment of the Determined of the Comment of the Determined of the Dete	Terres of Use Privacy policy Mit (SCR) (VALVES - Even All phasic Index All phasic Index	F Ex G5	G	H 75 57	Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As	-
Addition According	anterentioner g Documentator User-previded segurence:	Professor Profes		2 2 0 Minerson 1	D 6 50 0000 6 500 00000 6 500 0000 6 500 0000000000 6 5000000000000000000000000000000000000	Come	C C 16603.68 20023.43 17795.39	D/ Material processes to do Tot Image: Section of the section o	Terms of Use (Privacy policy Control process + fault Privacy - State Typindex 22.28 22.97 41.03 33.33	6 Savet	G WVY -0.3 -0.25 -0.25	H 75 57 16 57	Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As	-
Adole Acrolat	อาจจะหว่างระดะ g Gouversteins Pro ประกรุณร์เส้น หรือเสนอร์ คือ สนอนร์ อาจจะการสู้ เหล	Professor Profes		2 2 0 Minerson 1	A 2 A29L 3 A39L 4 A35R 5 L1R 6 MaR	s / u + D +	C C C C C C C C C C C C C C	Off One to end yre want to the definition Image: Control of the top of top of the top of t	Emers of Use (Privacy policy Employ and the initial policy Exploration Big and the initial policy Big and policy </td <td>/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48</td> <td>G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00</td> <td>H 75 57 16 57 04</td> <td>Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As</td> <td>-</td>	/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48	G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00	H 75 57 16 57 04	Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As	-
Addition Accession	្រូវបាលមានការ 2 (ចាលមានការ Barrysende sequence: នាការជូន សាលាហ៊ី អាណាហ៊ី នាលាណាគឺ នាញាក់ផ្លាំ ហោ ការបន្តេនើ សាលាហ៊ី អាណាហ៊ី នាសាណាគឺ នាញាក់ផ្លាំ សាលាហ៊ី	Professor Profes		2 2 0 Minerson 1	D 6 50 0000 6 500 00000 6 500 0000 6 500 0000000000 6 5000000000000000000000000000000000000	Come	C C C 12559.24 16603.68 20023.43 17795.39	D/ Material processes to do Tot Image: Section of the section o	Terms of Use (Privacy policy Control process + fault Privacy - State Typindex 22.28 22.97 41.03 33.33	6 Savet	G WVY -0.3 -0.25 -0.25	H 75 57 16 57 04	Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As	
Addition Accession	ฐานแหละแหน่ง อายารางให้เหลือเหลือเหลือเหลือ เหลือเหลือเหลือเหลือเหลือเหลือเหลือเหลือ	Professor Profes		2 2 0 Minerson 1	D A A A A A A A A A A A A A A A A A A A	s / u + D +	C C C C C C C C C C C C C C	Off One to end yre want to the definition Image: Control of the top of top of the top of t	Emers of Use (Privacy policy Employ and the initial policy Exploration Big and the initial policy Big and policy </td <td>/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48</td> <td>G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00</td> <td>H 75 57 16 57 04</td> <td>Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As</td> <td></td>	/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48	G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00	H 75 57 16 57 04	Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As	
Addition Accession		Professor Profes		2 2 0 Minerson 1	D C C C C C C C C C C C C C C C C C C C	s / u + D +	C C C C C C C C C C C C C C	Off One to end yre want to the definition Image: Control of the top of top of the top of t	Emers of Use (Privacy policy Employ and the initial policy Exploration Big and the initial policy Big and policy </td <td>/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48</td> <td>G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00</td> <td>H 75 57 16 57 04</td> <td>Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As</td> <td></td>	/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48	G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00	H 75 57 16 57 04	Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As	
8 Adulte Acculat	তু (countres) তু (countres) Pro- Pro	Professor Profes		2 2 0 Minerson 1	D C C C C C C C C C C C C C C C C C C C	s / u + D +	C C C C C C C C C C C C C C	Off One to end yre want to the definition Image: Control of the top of top of the top of t	Emers of Use (Privacy policy Employ and the initial policy Exploration Big and the initial policy Big and policy </td <td>/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48</td> <td>G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00</td> <td>H 75 57 16 57 04</td> <td>Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As</td> <td></td>	/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48	G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00	H 75 57 16 57 04	Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As	
Ø Adobe Acrobat	তু (countres) তু (countres) Pro- Pro	Professor Profes		2 2 0 Minerson 1	D	s / u + D +	C C C C C C C C C C C C C C	Off One to end yre want to the definition Image: Control of the top of top of the top of t	Emers of Use (Privacy policy Employ and the initial policy Exploration Big and the initial policy Big and policy </td <td>/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48</td> <td>G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00</td> <td>H 75 57 16 57 04</td> <td>Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As</td> <td>-</td>	/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48	G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00	H 75 57 16 57 04	Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As	-
O Adole Acrolat	ত্র বিজ্ঞালয়ের ত বিজ্ঞালয়ের বিজ্ঞান বিজ বিজ্ঞান বিজ্ঞান বিজে বিজ্ঞান বিজ	Professor Profes		2 2 0 Minerson 1	2 A394 2 A394 3 A394 4 A358 5 L1R 6 Mar 7 Eal 8 9 10 11 12 13 14	s / u + D +	C C C C C C C C C C C C C C	Off One to end yre want to the definition Image: Control of the top of top of the top of t	Emers of Use (Privacy policy Employ and the initial policy Exploration Big and the initial policy Big and policy </td <td>/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48</td> <td>G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00</td> <td>H 75 57 16 57 04</td> <td>Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As</td> <td>-</td>	/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48	G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00	H 75 57 16 57 04	Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As	-
Ø Addie Accelet	Convertence C	Professor Profes		2 2 0 Minerson 1	D	s / u + D +	C C C C C C C C C C C C C C	Off One to end yre want to the definition Image: Control of the top of top of the top of t	Emers of Use (Privacy policy Employ and the initial policy Exploration Big and the initial policy Big and policy </td <td>/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48</td> <td>G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00</td> <td>H 75 57 16 57 04</td> <td>Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As</td> <td>-</td>	/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48	G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00	H 75 57 16 57 04	Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As	-
Ø Addite Accelent	و (درمینه) و (درمینه) کی (درمی) کی (درمینه) کی (درمی	Professor Profes		2 2 0 Minerson 1	A A A A A A A A A A A A A A A A A A A	s / u + D + s / u + D + per / b B Size (AA) Molec 110 146 181 152 250	C C C C C C C C C C C C C C	Off One of the standard proceeded from weath the standard proceeded from weath the standard proceeded from weather sta	Emers of Use (Privacy policy Employ and the initial policy Exploration Baseline Alliphatic Ind 32.28 29.97 41.03 33.33 33.47	/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48	G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00	H 75 57 16 57 04	Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As	•
a (tig untercompany) of the second s		Professor Profes		2 2 0 Minerson 1	Antiparties and a second secon	s / u + D + s / u + D + per / b B Size (AA) Molec 110 146 181 152 250	C C C C C C C C C C C C C C	Off One of the standard proceeded from weath the standard proceeded from weath the standard proceeded from weather sta	Emers of Use (Privacy policy Employ and the initial policy Exploration Baseline Alliphatic Ind 32.28 29.97 41.03 33.33 33.47	/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48	G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00	H 75 57 16 57 04	Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As	Add in a
Ø Addite Accelent	رو المحمد الله المحمد المحمد الله المحمد محمد الله المحمد ال المحمد المحمد المحم المحمد المحم المحمد المحم المحمد	Professor Profes		2 2 0 Minerson 1	C C C C C C C C C C C C C C C C C C C	s / u + D + s / u + D + per / b B Size (AA) Molec 110 146 181 152 250	C C C C C C C C C C C C C C	Off One of the standard proceeded from weath the standard proceeded from weath the standard proceeded from weather sta	Emers of Use (Privacy policy Employ and the initial policy Exploration Baseline Alliphatic Ind 32.28 29.97 41.03 33.33 33.47	/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48	G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00	H 75 57 16 57 04	Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As	•
Ø Addie Accelet	رو المحمد الله المحمد المحمد الله المحمد محمد الله المحمد ال المحمد المحمد المحم المحمد المحم المحمد المحم المحمد	Professor Profes		2 2 0 Minerson 1	D C C C C C C C C C C C C C C C C C C C	s / u + D + s / u + D + per / b B Size (AA) Molec 110 146 181 152 250	C C C C C C C C C C C C C C	Off One of the standard proceeded from weath the standard proceeded from weath the standard proceeded from weather sta	Emers of Use (Privacy policy Employ and the initial policy Exploration Baseline Alliphatic Ind 32.28 29.97 41.03 33.33 33.47	/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48	G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00	H 75 57 16 57 04	Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As	•
O Adole Acrolat		Professor Profes		2 2 0 Minerson 1	D C C C C C C C C C C C C C C C C C C C	s / u + D + s / u + D + per / b B Size (AA) Molec 110 146 181 152 250	C C C C C C C C C C C C C C	Off One of the standard proceeded from weath the standard proceeded from weath the standard proceeded from weather sta	Emers of Use (Privacy policy Employ and the initial policy Exploration Baseline Alliphatic Ind 32.28 29.97 41.03 33.33 33.47	/ боол разонатор – Бан F GS 73.73 86.78 72.76 91.71 87.48	G 6 WVY -0.7 -0.00 -0.31 -0.25 -0.00	H 75 57 16 57 04	Sprin 00 * Arr O Est & Post & Piler = Estes - Isting As	•

Figure 4. Analysis of physicochemical properties of selected glycoproteins using ProtParam

- (A) Homepage of ProtParam webserver.
- (B) Entered protein sequence and submission.
- (C) Result page of searched protein.
- (D) Combined excel table containing physicochemical properties.
- 23. Sort peptides by "Percentile Rank" and show by "IC50 below(cutoff) nM" and submit (Figure 7C and 7D).
- 24. Scrutinize and screen the resultant epitopes based on IC50 value \leq 85 and arrange them alphabetically in an Excel file (Figure 8A).
 - a. Epitopes showing correlation with multiple alleles are considered as efficacious binders which are selectively sorted.
 - b. Club and arrange epitopes with multiple alleles in an Excel sheet. (Figures 8B-8D).
- 25. Subject the glycoproteins to the NetCTL-1.2 server (DTU Health Tech) for MHC I epitope prediction (Figure 9A).
- 26. Paste the individual protein sequence in the dialog box, selecting "A1 supertype" and submit the sequence by opting the default parameters (Figure 9B).
- 27. Select the result ending with (< E) which signifies epitope being MHC I positive (Figures 9C and 9D).
- 28. Repeat steps 24–25 for a single protein by opting different supertypes.
- 29. Paste the results in an Excel sheet and sort the data as step 23 on the basis of peptides with their respective supertype hits (Figures 10A–10C).
- 30. Highlight and select peptides with multiple and overlapping supertypes.
- 31. Prepare the combined data from IEDB MHCI and NetCTL.1.2 server, displaying the peptides with their respective supertypes and HLA alleles. (Figure 11A).

Note: Two software tools are used to validate MHC I T-cell epitopes for accurate prediction.

32. Select the multiple HLA alleles binding epitopes on the basis of VaxiJen v.2.0 and AllerTop v 2.0 prediction as done in steps 5–10(Figures 11B and 11C).

Protocol



() Q (and a spectral point of the second dispert of the sec	☆ 0 Q 8 1	B ← → α (\$ restpoleses/typlotes.com/pt/spect/Micro.com	🖈 速 🔕 (Maunah su updan
M dowl 😆 hauften 🔮 Maja Sag hausten 🔮 Haust 🔛 lig		🗅 ti can 🚯 Atop Appar	🖂 At lapon
NPS@: Network Protein Sequence @nalysis		NPS@: Network Protein Sequence @nalysis	
This size is a field of the original PRABS 325 at server		This site is a first of the original PRABI X228 server	
HOME) (DESCRIPTION) (HELP) (SERVI) (CONTACT) (Smith)		proved (description) (print) (series) (contact) (second	
Ady 30, 2024: NPK@ spland (see XU273)		July 30, 2020. NPNg: spiked (art 20203).	
SOPMA protein secondary structure prediction		SOPMA protein secondary structure prediction	
[Ahman1] [2753].held [Oviginal server]		Educated (S255), held (Original server)	
Sequence assue (sptimal)		Sequence name (optional) :	
Path a provide sequence below : <u>help</u>		Print a preside sequence to the 100 - Print and print	
		(
Output width : [7]		Ourport width : [1]	
Subart CLEAR		SUBAT CLEAR Parameters	
Parameters Number of conformational states (1) (yels, Store, Cal) v		Parameters Number of conformational states : [2 [Hote, Short Cot]] ~ ~	
Namber of conformational states : [2](bits, Street, Col) v Window width s [17		Window with 1 12	
Similarity threshold : 8		Similarity threshold : 0	
Law and Brains fine : The Jpr 11 11-12 30 2010 Convert fine : Int Tay 21 47 59 43 2016 Unit : public [] 13 110 200 118.		LearnendBlutten direc 776-021 77 12 29 7201 Clarent direc 3 to 3pg 12 98 72 721 721 721 721 721 721 721 721 721	
energia insern grave toperate		e malator 💿 inserm gazar layonan	
 C S response to point program 	e) ± 0 (manumi)		Kyya 10 - 0
 a G (a deformant/a subscription/clash) 	۰) کا (محمد محمد) ا ت داندست (ت داندست)		
O C Representative transmittance O C C Representative transm		D 0	
C C Registrometric transmissioners C C C Registrometric transmissioners C C C Registrometric transmissioners C C Registrometric transmissioners C C Registrometric transmissioners Registrometric transmissioners C Registrometric transmissioners Registrometric transmissi Registrometric transmissioners Registrometric transmiss			Added The Second Secon
Comparison of the second			Image: State of the s
1			1 2 Point Statute
1			
Comparison of the second			1 1 1 2 1 4
Image: Second			Image: Section of the sectio
			Image: Section of the sectio
Provide a state of the state of			Image: Section of the sectio
Contract Contende Contract Contract Contract Contract Contract Contract Contrac			Image: Section of the sectio

Figure 5. Secondary structure prediction using SOPMA

- (A) Homepage of SOPMA.
- (B) Entered protein sequence and selection of parameters.
- (C) Result page.

(D) Excel sheet containing secondary structure parameters.

33. Combine data of all proteins to generate a final excel file of all selected CTL epitopes with their allergenicity and antigenicity (Figure 11D).

Part 4: Prediction of T cell-specific epitopes: MHC II

© Timing: 6 h

This section focuses on steps and analysis of the prediction of T cell-specific epitopes via IEDB MHC II and NetMHCpan-4.0 servers, which are restricted to MHC class II molecules.

- 34. Open IEDB MHC II Binding Predictions tool (Figure 12A).
 - a. Paste the protein sequence in FASTA format.
 - b. Select the 7-HLA allele reference set.
 - c. Click the "Submit" opting default parameters for rest.
 - d. Sort peptides according to percentile rank and multiple alleles against a single epitope (Figures 12B and 12C).

Note: The peptide scoring is based on percentile rank, and epitope sorting is done as step 24 in an Excel datasheet.

- 35. Use the NetMHCIIpan-4.0 tool for MHC II binding prediction to identify the HLA alleles that recognize epitopes.
 - a. Paste the protein in FASTA format.
 - b. Opting for peptide length 15 (Figure 13A).
 - c. Select loci for 20 alleles at a time.



Protocol




Figure 6. Secondary structure prediction using PSIPRED 4.0 (A) Homepage of PSIPRED.

- (B) Entered protein sequence.
- (C) Result page.
 - d. Set the threshold for strong binders to 2%. Repeat this process to cover the remaining alleles (Figure 13B).
- Select results ending with "(<=SB)," indicating that the epitope is a strong binder with MHC II. Epitope sorting will be same as in MHC I (Figure 13C).
- 37. Compile epitopes from both the epitope prediction tools in an Excel file comprising peptides (epitopes) with their respective alleles.
- 38. Arrange the peptides alphabetically, select those epitopes with multiple alleles (Figure 13D).
- 39. Select the multiple HLA alleles binding epitopes on the basis of VaxiJen v.2.0 and AllerTop v 2.0 prediction as done in steps 5–10 (Figure 14A and 14B).
- 40. Repeat this process for each protein, create a final Excel spreadsheet, and organize it as described in step 33 (Figures 14C and 14D).

Part 5: Prediction of population coverage of selected T cell epitopes

© Timing: 2 h

This section focuses on steps to predict the population coverage of selected T-cell epitopes using the IEDB Population Coverage tool.

41. In an Excel sheet, compile the overlapping CTL and HTL epitopes along with their supertypes and HLA alleles individually for each protein (Figure 15A).

Note: Repeat the steps for all proteins.

- 42. Transfer the data to a notepad file sequentially, using peptides (epitopes) on the left and supertype alleles on the right and save it for individual protein (Figure 15B).
- 43. Use the IEDB population coverage tool for population coverage.

Protocol



ng Chail 🗰 Thulan 😰 Than Sa Tanatan 🕲 Tana 🔃 Ig		🖸 Alber
EDB Analysis Resource	IEDB Analysis Resource	
ad generation floors allo availabed. In your team strengthed and you find on our need generation flows site. Head over to https://neegondoos.act.org/pipeline/flow/hot for a comparing indexigned core experience.	Normal Market (Market) (Research (Constant)	
ana May Kaanaa Kawana Kawana Kawana	MHC-I Binding Predictions Predictions 2010/2012/present	
HC-I Binding Predictions	(4)(4)(4)(4)(4)(4)(4)(4)(4)(4)(4)(4)(4)(
Addition Statebook Version Version Version Statebook Version Ve Version Version Ve	COLORED AND AND AND AND AND AND AND AND AND AN	
	David Standing and	
or Johns answersing or FNSTA.Manual in althonguna argueded Seguences	On salest lin serviceing arguments). Descent Film fold the photon Fill to the photon Fill	
	Concess of Analysis Method Production Producti	
Internet Research Conserve File Vier Research Conserve & Descent Research Conserve & Descent and Research	Specify which is not a body apolitic base to: MiCl source species Apolitic The Specify Specific Specif	
sees to the set of the	NAME SHOLE	
Causta packas human w	HA-MM1 10 0 HA-MM1 9 0 HA-MM2 10 0	
una dagandy paragraphi wa 🛛 (*) dana 🛛 babali Ulifici panaly Vali (*) analy alta analy faith and the (*)	NAANDEN 9 00 NAANDEN 9 00 NAANDEN 9 00 NAANDEN 9 00	
Serviti Orbust	ноллеров э 0 ноллеров 0 ноллеров э 0 ноллеров 10	
ppdina ky Pedidad Gaar discand w artinast X/104, talia w	RAAME \$ 0 HAAME	
nal anteres (splana)	HLAND 0 0 HLAND 0 0 HLAND 0 0	
Balant Prost	PRAFYSE 10 0 PRAFYSE 5 0	
NAK-2010 EDE Annue Top In Canada controls a control from the <u>Editoric Letters Alderon and Editoric Decemps</u> a conservation of the this out investing in the Department of the Internet Services.	Raafden 0 0 Raafden 0 0 Raafden 0 0	
 Ø (Antenne https://littlef.org/100/ 	(5, φ) D (● 1) (← -3, Φ) (∞) ▲ traver tabletoprototal()(w)	୍ର ଦ ଓ ଜ
Ann	🗅 Al Baccardos 🔛 🛏 Creal 🧿 Validor 😻 Maya 🗞 Taraires 🔿 Nore 🔂 Ng	କ୍ର ନ) 0 ମ କ
Lan	California Di Nota Di	9.9) • 4 : i i
NT	C Diffusion P H Gau G Buller B Han G Hone C Dy C Diffusion C Diffu	αρ Φα
2007 100 0 0 0 100 0 0 0 100 0 0 0 100 0 0 0 100 0 0 100 0 0 100 0 0 100 0 0 100 0	C Diffusion P H Gau G Buller B Han G Hone C Dy C Diffusion C Diffu	40 0 0 +4
Sector Sector Sector A (1) A (1) A (1) A (1) A (2) A (1) A (1) A (1) A (1) A (1) A (1) A (1)	C Diffusion P H Gau G Buller B Han G Hone C Dy C Diffusion C Diffu	4.9) Ø Q 4 4
58	C Diffusion P H Gau G Buller B Han G Hone C Dy C Diffusion C Diffu	4.0 ØQ.84
Set Set <td>C Diffusion P H Gau G Buller B Han G Hone C Dy C Diffusion C Diffu</td> <td>4 0 9 0 4 4</td>	C Diffusion P H Gau G Buller B Han G Hone C Dy C Diffusion C Diffu	4 0 9 0 4 4
50 50 50 50 50 50 50 50 50 50	C Diffusion P H Gau G Buller B Han G Hone C Dy C Diffusion C Diffu	4.0) 9 .0 - 8 4
50 50 50 50 50 50 50 50 50 50	C Diffusion P H Gau G Buller B Han G Hone C Dy C Diffusion C Diffu	40 9 0 *
50 50 50 50 50 50 50 50 50 50	C Diffusion P H Gau G Buller B Han G Hone C Dy C Diffusion C Diffu	4.9 9. 2 . 4 *
50 50 50 50 50 50 50 50 50 50	C Diffusion P H Gau G Buller B Han G Hone C Dy C Diffusion C Diffu	4 B Ø G # 4
50 50 50 50 50 50 50 50 50 50	C Diffusion P H Gau G Buller B Han G Hone C Dy C Diffusion C Diffu	R 8) ♥ Q . €
58 59 50 50 50 50 50 50 50 50 50 50	C Diffusion P H Gau G Buller B Han G Hone C Dy C Diffusion C Diffu	50 0 4 4
Image: Section 1 Image: Section 2 Image: Section 2<	C Diffusion P H Gau G Buller B Han G Hone C Dy C Diffusion C Diffu	4 9 9 4 4
54 55 55 55 55 55 55 55 55 55	C Diffusion P H Gau G Buller B Han G Hone C Dy C Diffusion C Diffu	6.0 9.0 **
30 0	C Diffusion P H Gau G Buller B Han G Hone C Dy C Diffusion C Diffu	40 0 0 +4
Image: Image	C Diffusion P H Gau G Buller B Han G Hone C Dy C Diffusion C Diffu	4.0 9 Q . 4 4
Image: Section 1 Image: Section 2 Image: Section 2<	C Diffusion P H Gau G Buller B Han G Hone C Dy C Diffusion C Diffu	40 9 0 **
Text		4.0 ¥ Q . 4 4

Figure 7. MHC I binding prediction using IEDB MHC I

(A) Homepage of MHC I Binding prediction (B) Entered protein sequence (C) list of all selected HLA alleles reference set. (D) Result page.

- 44. Select "Class I and II combined" along with "World" option (Figure 16A).
- 45. Select the saved notepad file in step 42 from "Choose file" option and "Submit" (Figure 16B).
- 46. Select "View coverage of individual epitope in world" and paste the data in an Excel sheet (Figures 16C and 16D).
- 47. Merge the epitopes with their respective classes, supertypes, HLA alleles, and the population coverage percentage along with the overall population coverage percentage.
- 48. Select the epitopes with a cut-off value for CTL>50% and HTL>25%.
- 49. Create an Excel file of the same including all selected proteins (Figure 17A).
- 50. Enter the selected epitopes from step 46 in the "epitopes" column and their alleles in "MHC restricted alleles" column of the IEDB population coverage tool manually (Figure 17B).
- 51. Click on submit to identify the overall population coverage % of selected T cell epitopes (Figure 17C and 17D).

Part 6: Prediction of B cell-specific epitopes

© Timing: 2 h

This section enlists the steps and analysis on predicting the B cell specific epitopes using the Antibody epitope prediction tool of IEDB.

- 52. Use the "Antibody Epitope Prediction" tool of IEDB Analysis Resource to delineate the epitopes for selected proteins.
- 53. Paste the protein sequence. Select "Bepipred Linear Epitope Prediction 2.0" method and submit (Figures 18A and 18B).
- 54. Use VaxiJen v.2.0 and AllerTop v 2.0 for antigenicity and allergenicity of predicted epitopes (Figure 18C).
- 55. Repeat steps 50–52 for all the protein sequences and compile it in an excel file (Figure 18D).



Protocol

l 45 + 22 − 1	B [t 19 - cl - a e Hone Inet Paptamet Samu						-	
X Colores - Colores - (1 - K K) = = = + 0 Non-bat Conned	The second state of the se	Came - In	$ - \left \begin{array}{c} A \\ c \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \\ \hline a \end{array} \right ^{2} = \left \begin{array}{c} \hline a \end{array} \right$	General -	Navad 👔	ad Soud	Nextual 1	X Interest	τ P •
Construint IF J V ·	Defer Former Other Former Other Service Service Address Former Service Address Former	Famat Painter B Z U - U - Int	A - B = E = E E E E Mapeli Ger 5 E E E E E E E E E E E E E E E E E E E	for - 10 - 16 - 11 - 21 Con Face	atting + 386 +	New Contractory	input . input 0	Char - Kit	har Selet -
in a name a name a species : → [× √ δ]		• 0 X = A							
а в с о в Р <u>о</u> н и и к к м м о Р о в			6 6 6						
40 Bindrey Prediction Neurals		INCI Binding Prodesor/lesubs Tethol used and							
the sag num start and length paytole An'T100 2 20 29 BAMMLACK		afele seq_num start end lo	ngh peptide						
RAP14522 2 16 24 9 ACTUAAAN RAP1200 2 20 90 9 AANSLAN	8	HLA-Bree32 2 18 24 HLA-Ar0203 2 22 30	9 ARTUKAANI 9 ANISLAKKI						
54/2001 1 18 26 SUPERAME 64/2001 1 18 26 SUPERAME	7	HLAA72201 3 35 26 HLAA78201 3 35 26	PETERAAK DETENDAAK						
K.4970371 3 45 54 39 TULKOUTAL		HLADV001 1 45 54 HLADV001 1 6 14	20 EFLEQRUTHL 9 FREEDOLAN						
ALAF3101 1 6 14 9740000AA HAP3031 1 6 15 18 FR0000AA		HLAD1501 1 6 14	9 FPGCCCLAI						
A-491501 2 15 28 9 MATTAGAM A-491501 1 46 20 18 INTOCODE	13	HLAB/35.01 2 15 23 HLAA/601 3 64 20	9 HACT/RAAM	·					
4.A-Y2101 1 64 70 13 HTD 024K KA-Y2201 1 57 65 9 K0/HTD/ A.AY2101 1 48 56 9 K0/HTD/	15	HLAA/3201 1 57 65 HLAA/3201 1 57 65	9 KORUTKU 9 KORUTKUK						
4.4-3001 1 48 57 12 KONTINEKK	17	HLAA/3001 1 48 56 HLAA/3001 1 48 57 HLAA/1801 1 12 20	30 KORUTNLEKK						
HLAM2001 1 12 20 9 LAMA2009 HLAM2001 1 12 20 9 LAMA2009	19	HLAD/1501 1 12 20 HLAD/1501 1 12 20	9 LANATON 9 LANATON						
HEARTISTI 1 12 30 9 LEARTINY HEARTISTI 1 5 14 30 UPG000LAI	29	HLADYSON 1 12 28 HLADYSON 1 5 14 HLADYSON 1 47 54	30 UPPGOODLAN						
NA-F2009 1 47 56 18 K00KTNLKK NA-F21101 2 20 28 9 RAAMSLAK	23	HLAA*1101 2 20 28	P FAAM SLAK						
NLAH-2001 2 20 28 9 NAAN93LAK NLAH-20101 2 29 28 9 NAAN93LAK	25	HLAA2001 2 20 28 HLAA2001 2 20 28 HLAA2101 2 20 29	9 RAAMSLAK 9 RAAMSLAK						
HLAATION 2 29 29 18 BAAANSUARK HLAATION 2 29 29 19 18 AAANSUARK	9	MAA10001 2 20 29	DD RAAMSLARK DD RAAMSLARK						
HLA41200 1 46 54 9 TAX2HINA HLA40001 1 48 56 9 TAX2HINA		HLAA9200 1 46 54 HLA690001 1 46 54	9 TUXORUNA. 9 TUXORUNA. 9 TUXORUNA.						
MLA-Y1200 2 18 26 9 TUBAANISI MLA-Y2001 2 18 26 9 TUBAANISI	11	HLA-A'3001 2 55 26	TRACTOR						
HAANI200 2 18 27 18 TUBAANIGA HAANI001 1 42 30 9 TINKKOUK	22	HLAA1200 2 16 27 HLAA1201 1 62 70 HLAA1101 1 63 70	90 TURAAMSLA 9 TTOFGOOX						
MLA-1101 1 42 70 9 THREQUE MLA-2001 1 42 70 9 THREQUE		HLAATION 1 42 70 HLAATION 1 42 70	9 TTO/EDBX 9 TTO/EDBX						
	- 52		58 118 M18 DL Sheet1 Sheet2						
ADK ADK ADK ADK S BOOK BOOK BOOK BOOK BOOK BOOK BOOK B		 A2% A2% Seri A3X A3 boultana (§ Accessibility: Investigate 	St LUC MOR EDL Sheet) Sheet2	Deed Dapetypes A29c CTL co	depena principles contento -	- (9) (0)		THE N	E
Pyri i Billahanskill jaar Tana hapital fanada tana kan kan kan kan kan kan kan kan kan		9 45 + ct - s Hone Issue Reproport formu		Q Tel municipa verto de	100 seaded MHC1 - Event				918 B -
		Pox c+ x c Hone Hout Papelayout formul C Calles → [11]	In pro Aprice View Help (1.557) $ K K$ $= = \bigoplus_{i=1}^{m} \Phi_{i-i} \pm \frac{1}{2}$ Weights $ K = \sum_{i=1}^{n} \overline{\Phi}_{i-i} \pm \frac{1}{2}$ Weights $ K = \overline{K}$ $= \frac{1}{2}$	General		ed Seed : Instantion byte:	Neutral been 0	No. No. 1	an a -
	Especial III - 0 X C D Especial III - 0 X C C C C C C C C C C C C C	Operation None None Pape (sport Some None	 - K K = ○ ◆ - ☆waytet → ▲ - ○ ○ ○ ● ○<td>ner - 12 - 16 - 15 - 25 - 50</td><td></td><td>erf Geed Sector : Byte :</td><td>Neutral Data D</td><td>Normal States</td><td>an a -</td>	ner - 12 - 16 - 15 - 25 - 50		erf Geed Sector : Byte :	Neutral Data D	Normal States	an a -
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		0 + 0 - 1 Ford tool. Ford tool. Ford tool. 0 Cont - 0 - 1 - 0 - 1 0 Cont - 0 - 1 - 0 - 1 0 Cont - 0 - 1 - 10 - 1 1 - 10 A	 - K K = ○ ◆ - ☆waytet → ▲ - ○ ○ ○ ● ○<td>ner - 12 - 16 - 15 - 25 - 50</td><td></td><td><mark>of Core</mark> Applementary Type: K L M</td><td>Neurosi Companya Comp</td><td>Normal States</td><td>and De -</td>	ner - 12 - 16 - 15 - 25 - 50		<mark>of Core</mark> Applementary Type: K L M	Neurosi Companya Comp	Normal States	and De -
	The second secon	40 - 1 + Papt space format 8 - Res None Papt space format 8 - Res - Res - 9 - Res - Res - 9 - Res - Res - 9 - Res - - -	X X =	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and De -
		9 - 1 - 1 - 1 1 - 1000 Your Forpstanz Some 1 - 1000 -1000 -1000 -1000 1 - 1000 -1000 -1000 -1000 1 - 1000 -1000 -1000 -1000 1 - 1000 -1000 -1000 -1000 1 - 1000 -1000 -1000 -1000 1 - 1000 -1000 -1000 -1000 1 - 1000 -1000 -1000 -1000 1 - 1000 -1000 -1000 -1000 1 - 1000 -1000 -1000 -1000 1 - 1000 -1000 -1000 -1000 1 - 1000 -1000 -1000 -1000 1 - 1000 -1000 -1000 -1000 1 - 1000 -1000 -1000 -1000 1 - 1000 -1000 -1000 -1000 1 - 1000 -1000 -1000 -1000 1 - 1000 -1000 -1000 -1000 1 - 1000 -1000 </td <td> X X = </td> <td>the '</td> <td></td> <td>apa.</td> <td></td> <td>Medic Format Con Medic Format Con Medica Con Con Medica Con M</td> <td>and De -</td>	X X =	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and De -
		0 0	X X =	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and De -
Image:		Bits Design of the second	X X =	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and De -
Image: Section 1 Control 1 Control 2 Contro 2 Control 2 Control 2		Total Topp (sold Fund No. No. No. No. No. No. No. No. Orient/Total No.	X X =	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and De -
Image: Notation Out of a location		0 0 0 4	X X = X X X X = X X = X X X X = X X	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and De -
Image: Notation Control		Prof. Prof. Prof. Prof. Monto Application Application Application Monto Biologication Host Application Application Monto Biologication Host Application Host Application Monto Biologication Host Application Host Application Monto Host Application Host Application Host Application Monto Host Application Host Application Host Application	X X = X X X X = X X = X X X X = X X	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and B -
A B C D E F G H I I ACC B C B F G H I		Project Target content Despective Despective Reference R	X X = X X X X = X X = X X X X = X X	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and B -
Image: Section 1 Image: Section 2 Image: Section 2<		Para da la conservación de la co	X X = X X X X = X X = X X X X = X X	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and B -
Image: Section 100 Column 100 No. 100 </td <td></td> <td>0 0</td> <td> X X = X X X X = X X = X X X X = X X </td> <td>the '</td> <td></td> <td>apa.</td> <td></td> <td>Medic Format Con Medic Format Con Medica Con Con Medica Con M</td> <td>and B -</td>		0 0	X X = X X X X = X X = X X X X = X X	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and B -
And the set of the se		В лите Полновит	X X = X X X X = X X = X X X X = X X	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and B -
No. No. <td></td> <td>0</td> <td> X X = X X X X = X X = X X X X = X X </td> <td>the '</td> <td></td> <td>apa.</td> <td></td> <td>Medic Format Con Medic Format Con Medica Con Con Medica Con M</td> <td>and B -</td>		0	X X = X X X X = X X = X X X X = X X	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and B -
Angene C I <td></td> <td>Description Description <thdescription< th=""> <thdescription< th=""></thdescription<></thdescription<></td> <td> X X = X X X X = X X = X X X X = X X </td> <td>the '</td> <td></td> <td>apa.</td> <td></td> <td>Medic Format Con Medic Format Con Medica Con Con Medica Con M</td> <td>and B -</td>		Description Description <thdescription< th=""> <thdescription< th=""></thdescription<></thdescription<>	X X = X X X X = X X = X X X X = X X	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and B -
No. No. <td></td> <td>Description Description <thdescription< th=""> <thdescription< th=""></thdescription<></thdescription<></td> <td> X X = X X X X = X X = X X X X = X X </td> <td>the '</td> <td></td> <td>apa.</td> <td></td> <td>Medic Format Con Medic Format Con Medica Con Con Medica Con M</td> <td>and De Constantino Transferencia de la constantino de la constantina de la constantina de la constanti</td>		Description Description <thdescription< th=""> <thdescription< th=""></thdescription<></thdescription<>	X X = X X X X = X X = X X X X = X X	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and De Constantino Transferencia de la constantino de la constantina de la constantina de la constanti
No. No. <td></td> <td>Image Desc Feature Feature Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image</td> <td> X X = X X X X = X X = X X X X = X X </td> <td>the '</td> <td></td> <td>apa.</td> <td></td> <td>Medic Format Con Medic Format Con Medica Con Con Medica Con M</td> <td>and De and The Fields the fi</td>		Image Desc Feature Feature Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image Image	X X = X X X X = X X = X X X X = X X	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and De and The Fields the fi
And C D E C D			X X =	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and De and The Fields the fi
Image: Section 1 C Image: Section 1 Image: Section 1 <t< td=""><td></td><td></td><td> X X = </td><td>the '</td><td></td><td>apa.</td><td></td><td>Medic Format Con Medic Format Con Medica Con Con Medica Con M</td><td>and De and The Fields the fi</td></t<>			X X =	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and De and The Fields the fi
Image: Section 1 Control 1 Contro 1 Control 1 Control 1		Annu Annu Annu Annu North North North North North North	X X =	the '		apa.		Medic Format Con Medic Format Con Medica Con Con Medica Con M	and De and The Fields the fi

Figure 8. Epitope sorting of MHC I restricted alleles

(A) Excel file of selected epitopes.

(B) Highlighted epitopes.

(C) Filtered highlighted epitopes.

(D) Compiled file of highlighted epitopes against selected alleles.

Part 7: IFN-gamma epitope selection and conservancy analysis of all selected epitopes

© Timing: 6 h

This section describes the procedure for prediction of IFN-gamma epitopes via IFNepitope tool, and conservancy analysis of all T cell, B cell and IFN-gamma epitopes via Epitope Conservancy Analysis of IEDB.

- 56. Utilize the "IFNepitope" tool to predict and design epitopes inducing IFN-gamma for all proteins.
- 57. Cleave the protein into 15 amino acid chains.
- Submit by selecting "Motif and SVM hybrid" and "IFN-gamma versus non-IFN-gamma" option (Figures 19A and 19B).
- 59. Repeat the process for all proteins and create an Excel sheet selecting the epitopes with POSITIVE as result (Figure 19C).
- 60. Use VaxiJen v.2.0 and AllerTop v 2.0 for antigenicity and allergenicity of predicted epitopes (Figure 19D).

▲ CRITICAL: Repeat steps for all the proteins and compile the data in an excel file to select one epitope from each protein that shows highest SVM/ MERCI score (the score will be displayed in the last column of your result page (Figure 19E).

Note: Select the available epitopes by prioritizing the "SVM" (Support Vector Machine) algorithm method first. If no epitopes are available from this method, then select from the "MERCI" (Maximum Entropy-based Prediction of Immunogenicity) method.

Protocol



	Tech	Contact DTU	DTU Health Tech Contac	DTU
	t of Health Technology	=	Department of Health Technology	Ħ
	Education Collaboration Services and Products News About		Research Education Collaboration Services and Products News About	**
	1 > SERVICES HID PRODUCES > MONOMINES SERVICES > MERCE-1 2	SHARE ON D D D	for which for a structure of hours a memory which are structure of the str	000
	Submission	1	Submission	
	Anno a single sequence private in angeneses in Addit & Anno a lang Private Anno a lang		And an and the control of an annual and the control of the control of the product and the control of the cont	
	[Mum] (See Mill) Find Stress Find Find Find Find Find Find Find Find		(Maint) Charanting Henchicking and HCCOD approves per administrative and sequences not need that 202000 antime acids and not bars thanks acids for all not 300000 Permission acids studied Interfacting permission. The Administrative acids that defends of the processing.	
	The sequences are well contrabuted and will be deleted after processing.		The sequences are sept contractor and will be detected after processing.	
	For publication of results, alwase cite:		For publication of results, stease cite	
	Current version:		Current version:	
	NetT1-12		Control retrains Note: The Control of Control	
-> -> -> -> -> -> -> -> -> -> -> -> -> -	ethad.coloci-60774300000199990056aat-00	0 0 0 T A 0 1	🔄 O	\$ 9 G 4
Grait 😆 YouTube 🔮 htgs: 💺 Tarobte 🌚 tiers: 🎇 ig			C (* → ⊙) ((x)) 1 isomerinantechandeopherinatechandeopheri	
	jobid=66E7CF420003B01F697B5EFD&wait=20 Server Output - DTU Health Tech	i	A na samanana pa banakan na inakan na janan kaja kana kana kana kana	
CfL-1-2 predictions using MMC supertype AL. Threshold 0	25666		55 25 00040311.1 pap 00270271 aff 0.0488 aff_venue 0.0207 (ie 0.2171 (ie) -0.1240 0201 0.0207 56 20 00040411.1 pap 00270271 aff 0.0488 aff_venue 0.0207 (ie 0.2171 (ie) -0.1240 0201 0.0207 56 20 00040411 ie) 0.00170270 aff 0.0488 aff_venue 0.0200 (ie 0.017) 1ep 0.0210 0200 0.0207	
	K.2014 C.6 A.510 Lo A.510 So A.517 K.2014 C.6 A.510 Lo A.510 So A.517 A.517 K.2014 C.6 A.510 Lo A.517 A.		B) Control 1, and Control	

Figure 9. MHC I binding prediction using NetCTL-1.2

(A) Homepage of NetCTL-1.2 (B) Entered protein sequence (C) Result page.

(D) Result page with binding allele shown as <-e (number 101).

- 61. Perform Conservancy analysis of all selected epitopes, go to the NCBI homepage.
- 62. Select "Protein" from the dropdown menu in the search bar, and search for the protein of interest (Figures 20A and 20B).

Note: In this case, we have shown the example for B cell epitopes of A35R MPXV protein.

- 63. Copy the full protein sequence(s) displayed in FASTA format. Paste all sequences into a notepad file and save it (Figure 20C).
- 64. Go to "IEDB Population coverage analysis" and paste final selected epitope sequences (B cell, T cell and IFN-gamma) in the input box (Figures 21A and 21B).
- 65. Enter multiple epitopes in FASTA format separately.
- 66. Select the "Epitope linear sequence conservancy" as the "Analysis type" option to display the amino acid sequence of the specific protein entry with "100%" sequence identity as threshold and submit (Figure 21C).
- 67. The results will display the conservation percentage for each epitope (Figure 21D).

Note: 90–100% matches indicate highly conserved epitopes ideal for targeting across strains or species.


Part 8: Construction of 3D vaccine structure

© Timing: 10 h

This section details the procedure and analyzes construction of 3D vaccine candidate from the selected epitopes, assessing its antigenicity, allergenicity, physicochemical characteristics, secondary and tertiary structure predictions of the designed sequence. This designed candidate is our final vaccine protein which will be further used for docking and simulation.



Protocol



8 <u>9 - e -</u> -																	Sign in St		
	ent Papelaport formulas			Q 14	me shelyne n	ed to de													
Copy -		$\begin{vmatrix} X & Z \\ \cdot & \Delta \cdot \end{vmatrix} = = \begin{bmatrix} 0 & 0 & -1 \\ 0 & 0 & 0 \end{bmatrix} = = \begin{bmatrix} 0 & 0 & -1 \\ 0 & 0 & 0 \end{bmatrix}$			General Si - % + Number		Canditional Fac	Narra nat as (calcol bb v		2011	Good Dyslenetory	Neutral Echoned		Inset Debe	100	544 ·	Pr P	Add ins	
s • i [8 V B																		
A A	8	c	D		1	G	н	1	2 consists	ĸ	L	м	N	0	P	Q	R	5	
	Peptide	Supertype																	
	DVQTGRHPY	Al																	
	TLEPGDOOL	A2																	
	TURAAMISL	A2																	
	KOFLITNLEK	A3																	
	TREEGER	A3																	
	RAAMISLAK	A3																	
	AAMISLAKK	A3																	
	DVQTGRHPY	A26																	
	FPGDODLAI	87																	
	IPATEFFST	87																	
	NPETKREAI	87																	
	HAETLEAAM	87																	
	TURAAMIS	87																	
	NPETKREAI	85																	
	TLXQRLTNL	0.8																	
	COMPADENT	0.8																	
	HAETLEAAM	0.5																	
	KREATVKAY	827																	
	KORLTNLEK	827																	
	QRETNEEKK	827																	
	KOTNITTK	827																	
	KRNDEVLER	827																	
	RAAMISLAK	827																	
	KODVQTGR	827																	
	YGDDNEETL	839																	
	BNDEVLFRL	839																	
	NEETLKOPIL	844																	
	A29, 501 A30, A398					1294													

Figure 10. Epitope sorting of MHC I restricted alleles through NetCTL-1.2

(A) Excel file of selected epitopes of single supertype.

(B) Combined excel sheet of epitopes of all supertypes.

(C) Highlighted epitopes with more than one supertypes.

- 68. Join the selected MHC I, II and IFN-gamma epitope sequences with the "GPGPG" or "AAY" linker and PADRE peptide as adjuvant. For adjuvant, use the "EAAAK" linker to join adjuvant in Excel file (Figure 22A).
- 69. Paste the formed sequence in a Word file (Figure 22B).
- 70. Proceed for the antigenicity prediction using VaxiJen v.2.0 (Figures 22C and 22D).
- 71. Use AllerTop v 2.0 for allergenicity prediction (Figures 23A and 23B).

 \triangle CRITICAL: If the sequence does not pass antigenicity and allergenicity use other epitopes and redo the steps.

- 72. Use the Expasy-ProtParam server to predict the physiological parameters of designed protein sequence as described in step 13–15 (Figures 23C and 23D).
- 73. Use "Protein Scanning" tool of ToxinPred webserver to find any toxic regions in protein sequence.
- 74. Paste the designed protein sequence and click on "Run Analysis" keeping the default parameters (Figures 24A and 24B).

 \triangle CRITICAL: If the sequence shows toxic epitopes or sequences, reshuffle or change the epitopes and repeat from step 68.

- 75. Use "SOLUPROT v.1.0" tool to asses solubility of designed protein expression in *Escherichia* coli.
- 76. Paste the sequence and click on submit to predict the Solubility score (Figures 24C and 24D).

▲ CRITICAL: If the protein shows no solubility, reshuffle or change the epitopes and repeat from step 68.

CellPress OPEN ACCESS



Bacay - 9 / 8 - 1	(B) X X = = H · B log ba	(fexcel)	toplanatory.	followed them	inter Delete fo	∑ Autów - An Star - Son Cour - Like Látny	6 Find-5 Add-ires	Pade & Farmet Painter Copenset Sp	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	antar - 🥸 - 16 - 12 23 Ca	enditional Formation (Calculation matting + Table +	Bud Good No 1223322 Blance Contention (1) Spece	A Deat	Debeter Farmat	Char - Sant.B. Fin Char - Athar - San Sannag	ad da adl = Add ins add = add ins
	1 · D · A · S S S M M M Mapph Carbo · O · S · M B Conditional Formation Cabulations					Editing						99/40				1 400-010
046447 5 Per	t 6 Algoret 6 funiter 6	Byles						N 1 1 1 1							1994	
A	8	с	D	E _ F	G	н	J K	A A	8		C		t F	G	8 1	1
CTL	Supertypes/HLA Alleles							1 CTL 2 DVQTGRHP	Supertypes/HLA Alleles	A	ntigenicity (>0.4)	Allergenicity NON-ALLERGEN				
DVQTGRHPY	A1, A26								A1, A26 HLA-B*58:01, HLA-A*02:03		0.5320	ALLERGEN				
EFFSTKAAK	HLA-B*58:01, HLA-A*02:03								HLA-B*08:01, HLA-A*32:01	-0.006	63 (non-antigen)	ALLEROEN				
FPGDDDLAI	HLA-B*08:01, HLA-A*32:01							s HAETLRAAM			6 (non-antigen)					
FVFILTAIL	B39, B62							6 KORLTNLEK				NON-ALLERGEN				
HAETLRAAM	B7, B8							7 LAIPATEFF	HLA-B*15:01, HLA-A*68:01, HLA-B*35	5:01 -0.018	86 (non-antigen)					
KORLTNLEK	A3, B27							8 NPETKREAI	87, 88	0.228	(non-antigen)					
LAIPATEFF	HLA-B*15:01, HLA-A*68:01, HLA-B*35:01							RAAMISLAK	A3, B27, HLA-A*11:01, HLA-A*11:01,	HLA-A*30:01,	0.9296	ALLERGEN				
NPETKREAI	B7, B8							2	HLA-A*11:01, HLA-A*11:01, HLA-A*3	0:01	0.9296	ALLERGEN				
RAAMISLAK	A3, B27, HLA-A*11:01, HLA-A*11:01, HLA-A*30:01, HLA-							10 RAAMISLAK	HLA-A*02:03, HLA-B*53:01		1.3677	ALLERGEN				
nonimi suna	A*11:01, HLA-A*11:01, HLA-A*30:01								HLA-A*30:01, HLA-B*08:01			NON-ALLERGEN				
RAAMISLAKK									A2, B7, HLA-A*02:03, HLA-A*03:01			NON-ALLERGEN				
	HLA-A*02:03, HLA-B*53:01							13 TTKFEQIEK	HLA-A*03:01, HLA-A*30:01, HLA-A*6	8:01 0.3471	l (non-antigen)					
TLKQRLTNL	HLA-A*30:01, HLA-B*08:01							14								
TLRAAMISL	A2, B7, HLA-A*02:03, HLA-A*03:01							16								
TTKFEQIEK	HLA-A*03:01, HLA-A*30:01, HLA-A*68:01							17								
								19								
								20								
				5				41								
LIR MIR EB She	rti Sheet2 Sheet3 Supertypes A264. CTL compilation Supertypes compilation CTL Aller and arti Sheet3							• 22								
Py m (2 m v Rome meat Population X Cat	Tende Do Base Rai Ng 5,520 🗘 Minedatorsanti Di Annatatika - Sait Tende Do Base Rai Ng 5,520 🖉 Minedatorsanti D	Red .	Good	Newford		Σtation · δο			Page Laguest Formulas (Jura Marcon View Holy 10,550) marchine Roman = (2 = 1) K K (2 = 1) = (2 = 100 Å K (2 = 100 Å))	Tel me sharyou want to de General	500 seesse MAX1 - Grad	Bud Good No	out 👔 🗊	Σ	Sign in	• -
Total Participation None None Total Participation Stream Participation Operative Participation T T T T T T	Deside Deside <thdesid< th=""> <thdeside< th=""> <thdeside< th="" th<=""><th>Bed LICE COLUMN</th><th>Seed Exploratory -</th><th>Newload Impost</th><th></th><th>Σenten · je</th><th>en DO - O</th><th>A Reny Section () And To The Top () X Col Top () Col Top () X Col Top () Col Top () Col Col Top () Col Top () Col Col C</th><th>Pop Scale formula for $K = \frac{1}{2}$</th><th>Tel me sharyou want to de General</th><th>500 seesse MAX1 - Grad</th><th>Bud Good No</th><th>continue o</th><th>Data Parata</th><th>Sign in</th><th>• - • •</th></thdeside<></thdeside<></thdesid<>	Bed LICE COLUMN	Seed Exploratory -	Newload Impost		Σenten · je	en DO - O	A Reny Section () And To The Top () X Col Top () Col Top () X Col Top () Col Top () Col Col Top () Col Top () Col Col C	Pop Scale formula for $K = \frac{1}{2} $	Tel me sharyou want to de General	500 seesse MAX1 - Grad	Bud Good No	continue o	Data Parata	Sign in	• - • •
None Poplant X Cri 10 C	Date Date State State Or model State <	Bad Djós	Sood Deplocatory _	New World	Inet Debte To	Extension - An Effect - Sec rel Char - Tak	en DO - O	Teary Section () from Tear Tome Tome Tear Tome Tome Section () from Section () from Se	Pop Scant formula for $K = \frac{1}{2} $	C Tell from which you want to de Command	500 seesse MAX1 - Grad	Bud Good No	and fig.	Didde Frend om	Spain Antoine * App J All * Sector Sec	• - • •
Py → Pop Py + Sol Soly → Formal Anime A → Pop Lyon Pop Lyon	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Discourse Disc	Diplocatory .	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	en DO - O	D Provide States	Provide the second sec	$\begin{array}{c c} \hline & \mbox{ Interval } p_{12} \mbox{ or the field} \\ \hline \\ $	KOD see See M.K.1 - Even The See See See See See See See See See S	Bud Good No	metika i had	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	D - C AB AB AB AB AB AB AB AB AB AB
Py = 1 Point set Opp Load X Ga X	Characteria internet	Discourse Disc	Diplocatory .	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam		Пуланда Пуланда Салаба бар. Кар. 199. 0135 2 салабаната 2 са 2 с 2 с 2 с б толика С в волика С в волика С в с в с с с с с с с с с с с с с с с с	C Tel en cada po susten de mer - C - C - C - C - C - C - C - C - C -	KOR seeded MKC1 - Exert The Seeded MKC1 - Exert The Seeder MKC1 - Exert Marchael M	Bod Gold Pe Internet Contraction - Ed Byte:	metika i had	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	- 20 A B Aldrine Aldrine
Open Cont Page (apped) None Next Page (apped) Orange Open T Open Open T No Supertypes/ML Supertypes/ML V0010089Y A1, A26 Supertypes/ML	And the function of the second	Discourse Disc	Diplocatory .	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam		Appland Date Date <thdate< th=""> Date Date</thdate<>	C to record presents to me - C - S - S - S - S - S summer - C - S - S - S - S - S summer - C - S - S - S - S - S - S - S - S - S	KOR seeded MKC1 - Exert The Seeded MKC1 - Exert The Seeder MKC1 - Exert Marchael M	Bod Gold Pe Internet Contraction - Ed Byte:	metika i had	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	- 20 A B Aldrine Aldrine
20 1 1 200 Lond Work Mark Optical 0 Work Cale 0 0 Work 0 0 0 0 A Supertypes/ML Supertypes/ML VICIOSUPY A), B27	Allow Allow <td< td=""><td>Discourse Disc</td><td>Diplocatory .</td><td>(input</td><td>Cells</td><td>net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set</td><td>T P Adam Adam Adam</td><td></td><td>$\label{eq:second} \begin{array}{ c c c c c c } \hline \begin{tabular}{c c c c } \hline \begin{tabular}{c c c c c c } \hline \begin{tabular}{c c c c c c c } \hline \begin{tabular}{c c c c c c c c c c c c c c c c c c c$</td><td>Valenciado yo suart to di Valenciado yo suart to di V</td><td>KOR seeded MKC1 - Exert The Seeded MKC1 - Exert The Seeder MKC1 - Exert Marchael M</td><td>Bod Gold Pe Internet Contraction - Ed Byte:</td><td>metika i had</td><td>Cells</td><td>Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting</td><td>- 20 A B Aldrine Aldrine</td></td<>	Discourse Disc	Diplocatory .	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam		$\label{eq:second} \begin{array}{ c c c c c c } \hline \begin{tabular}{c c c c } \hline \begin{tabular}{c c c c c c } \hline \begin{tabular}{c c c c c c c } \hline \begin{tabular}{c c c c c c c c c c c c c c c c c c c $	Valenciado yo suart to di V	KOR seeded MKC1 - Exert The Seeded MKC1 - Exert The Seeder MKC1 - Exert Marchael M	Bod Gold Pe Internet Contraction - Ed Byte:	metika i had	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	- 20 A B Aldrine Aldrine
Open Name Application Total Application Application Total Color Color Total Application Total A Color Color A Application Total A Support Application B X Application Support Application Application A Support Application A Application Application Application Application Application Application Application Application Application Application Application Application	Note No N	Discourse Disc	Diplocatory .	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam		Appland Date Date <thdate< th=""> Date Date</thdate<>	Idencial products in The scale products in The scale of t	KOR seeded MKC1 - Exert The Seeded MKC1 - Exert The Seeder MKC1 - Exert Marchael M	Bod Gold Pe Internet Contraction - Ed Byte:	metika i had	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	D - C AB AB AB AB AB AB AB AB AB AB
Open Name Application Your Name Application Your Context Context Your Context If it is - i Fore Your Context X If it is - i Your Context X If it is - i Your Context X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i	Note No N	Discourse Disc	Diplocatory .	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam		Non-On-On-On-On-On-On-On-On-On-On-On-On-On	Manual and provided into and provided into and provided into and provided into an an and provided into an and provided into an and provided into an an and provided into an and provided into an an and provided into an and provided into an an an and provided into an an and provided into an an an and provided into an	KOR seeded MKC1 - Exert The Seeded MKC1 - Exert The Seeder MKC1 - Exert Marchael M	Bod Gold Pe Internet Contraction - Ed Byte:	metika i had	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	D - C AB AB AB AB AB AB AB AB AB AB
Open Name Application Your Name Application Your Context Context Your Context If it is - i Fore Your Context X If it is - i Your Context X If it is - i Your Context X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i	Note No N	Djes	Diplocatory .	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam			C Table of any water both mmy - <td>KOR seeded MKC1 - Exert The Seeded MKC1 - Exert The Seeder MKC1 - Exert Marchael M</td> <td>Bod Gold Pe Internet Contraction - Ed Byte:</td> <td>metika i had</td> <td>Cells</td> <td>Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting</td> <td>- 20 A B Aldrine Aldrine</td>	KOR seeded MKC1 - Exert The Seeded MKC1 - Exert The Seeder MKC1 - Exert Marchael M	Bod Gold Pe Internet Contraction - Ed Byte:	metika i had	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	- 20 A B Aldrine Aldrine
Open Name Application Your Name Application Your Context Context Your Context If it is - i Fore Your Context X If it is - i Your Context X If it is - i Your Context X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i	Non- No N	Djes	Diplocatory .	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam		Non-control All All <th< td=""><td>Q Market de para cent tale mm -<td>KOR seeded MKC1 - Exert The Seeded MKC1 - Exert The Seeder MKC1 - Exert Marchael M</td><td>Bod Gold Pe Internet Contraction - Ed Byte:</td><td>metika i hari</td><td>Cells</td><td>Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting</td><td>- 20 A B Aldrine Aldrine</td></td></th<>	Q Market de para cent tale mm - <td>KOR seeded MKC1 - Exert The Seeded MKC1 - Exert The Seeder MKC1 - Exert Marchael M</td> <td>Bod Gold Pe Internet Contraction - Ed Byte:</td> <td>metika i hari</td> <td>Cells</td> <td>Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting</td> <td>- 20 A B Aldrine Aldrine</td>	KOR seeded MKC1 - Exert The Seeded MKC1 - Exert The Seeder MKC1 - Exert Marchael M	Bod Gold Pe Internet Contraction - Ed Byte:	metika i hari	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	- 20 A B Aldrine Aldrine
Open Name Application Your Name Application Your Context Context Your Context If it is - i Fore Your Context X If it is - i Your Context X If it is - i Your Context X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i	Non- No N	Djes	Diplocatory .	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam			0. Material processity (b), march = 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	KOR seeded MKC1 - Exert The Seeded MKC1 - Exert The Seeder MKC1 - Exert Marchael M	Bod Gold Pe Internet Contraction - Ed Byte:	metika i hari	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	- 20 A B Aldrine Aldrine
Open Name Application Your Name Application Your Context Context Your Context If it is - i Fore Your Context X If it is - i Your Context X If it is - i Your Context X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i	Non- No N	Djes	Diplocatory .	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam			O Mail on add parametric dit. mm Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit. Image: Mail on add parametric dit.	KOR seeded MKC1 - Exert The Seeded MKC1 - Exert The Seeder MKC1 - Exert Marchael M	Bod Gold Pe Internet Contraction - Ed Byte:	metika i hari	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	D - C AB AB AB AB AB AB AB AB AB AB
Open Name Application Your Name Application Your Context Context Your Context If it is - i Fore Your Context X If it is - i Your Context X If it is - i Your Context X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i	Non- No N	Dipot	a replenetary	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam			Intervention Intervention<	KOR seeded MKC1 - Exert The Seeded MKC1 - Exert The Seeder MKC1 - Exert Marchael M	Bod Gold Pe Internet Contraction - Ed Byte:	metika i hari	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	- 20 A B Aldrine Aldrine
Open Name Application Your Name Application Your Context Context Your Context If it is - i Fore Your Context X If it is - i Your Context X If it is - i Your Context X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i If it is - i X If it is - i	Non- No N	Dipot	Diplocatory .	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam			14 14 44 44 44 44 44 44 44 44 44 44	KOR seeded MKC1 - Exert The Seeded MKC1 - Exert The Seeder MKC1 - Exert Marchael M	Bod Gold Pe Internet Contraction - Ed Byte:	metika i hari	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	- 20 A B Aldrine Aldrine
Open Name Appl Lapud York Name Appl Lapud York Grant France York Supertypes/PRL France R Supertypes/PRL France R Supertypes/PRL Supertypes/PRL R Supertypes/PRL Appl Appl Appl Appl Appl Appl Appl Appl	Non- No N	Dipot	a replenetary	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam			O Market avec setted avec	KOD see See M.K.1 - Even The See See See See See See See See See S	Bod Gold Pe Internet Contraction - Ed Byte:	metika i hari	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	- 20 A B Aldrine Aldrine
Open Name Appl Lapud York Name Appl Lapud York Grant France York Supertypes/PRL France R Supertypes/PRL France R Supertypes/PRL Supertypes/PRL R Supertypes/PRL Appl Appl Appl Appl Appl Appl Appl Appl	Non- No N	Dipot	a replenetary	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam			14 101-04	KOD see See M.K.1 - Even The See See See See See See See See See S	Bod Gold Pe Internet Contraction - Ed Byte:	metika i hari	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	- 20 A B Aldrine Aldrine
Open Name Appl Lapud York Name Appl Lapud York Grant France York Supertypes/PRL France R Supertypes/PRL France R Supertypes/PRL Supertypes/PRL R Supertypes/PRL Appl Appl Appl Appl Appl Appl Appl Appl	Non- No N	Dipot	a replenetary	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam			O Note of a construction mer - <td>KOD see See M.K.1 - Even The See See See See See See See See See S</td> <td>Bod Gold Pe Internet Contraction - Ed Byte:</td> <td>metika i hari</td> <td>Cells</td> <td>Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting</td> <td>- 20 A B Aldrine Aldrine</td>	KOD see See M.K.1 - Even The See See See See See See See See See S	Bod Gold Pe Internet Contraction - Ed Byte:	metika i hari	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	- 20 A B Aldrine Aldrine
Open Name Appl Lapud York Name Appl Lapud York Grant France York Supertypes/PRL France R Supertypes/PRL France R Supertypes/PRL Supertypes/PRL R Supertypes/PRL Appl Appl Appl Appl Appl Appl Appl Appl	Non- No N	Dipot	a replenetary	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam				KOD see See M.K.1 - Even The See See See See See See See See See S	Bod Gold Pe Internet Contraction - Ed Byte:	metika i hari	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	Address ad B address address
Open Name Appl Lapud York Name Appl Lapud York Grant France York Supertypes/PRL France R Supertypes/PRL France R Supertypes/PRL Supertypes/PRL R Supertypes/PRL Appl Appl Appl Appl Appl Appl Appl Appl	Non- No N	Dipot	a replenetary	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam			0 Market Anzentik B mm		Bod Gold Pe Internet Contraction - Ed Byte:	metika i hari	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	- 20 A B Aldrine Aldrine
Open Name Appl Lapud York Name Appl Lapud York Grant France York Supertypes/PRL France R Supertypes/PRL France R Supertypes/PRL Supertypes/PRL R Supertypes/PRL Appl Appl Appl Appl Appl Appl Appl Appl	Non- No N	Dipot	a replenetary	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam			Advancement of memory of the second sec		Bod Gold Pe Internet Contraction - Ed Byte:	metika i hari	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	- 20 A B Aldrine Aldrine
A Cot Cotos Premat Patien Catas Premat Patien Catas Premat Patien Catas Premat Patien Catas Premat Patien Catas Premat Patien Catas Premat Patien Catas Premat Patien Premat Patien A	Non- No N	Dipot	a replenetary	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam			2 Mandahamanananananananananananananananananan		Bod Gold Pe Internet Contraction - Ed Byte:	metika i hari	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	- 20 A B Aldrine Aldrine
Open Name Appl Lapud York Name Appl Lapud York Grant France York Supertypes/PRL France R Supertypes/PRL France R Supertypes/PRL Supertypes/PRL R Supertypes/PRL Appl Appl Appl Appl Appl Appl Appl Appl	Non- No N	Dipot	a replenetary	(input	Cells	net Charter - An Chart - Set Chart - Set Chart - Set Set of Set of Set of Set	T P Adam Adam Adam					I Constant and a second and as second and a	metika i hari	Cells	Tops in Autobase * Aug J All * Local & Au Chai * Hau * Lan Letting	D - C AB AB AB AB AB AB AB AB AB AB

Figure 11. Combined epitopes sorting of MHC I binding prediction and NetCTL-1.2

- (A) Combined excel sheet of epitopes of both servers.
- (B) Antigenicity and allergenicity of predicted epitopes.
- (C) $\ensuremath{\mathsf{Excel}}$ sheet of final selected epitopes of single protein.
- (D) Excel sheet of final selected epitopes of all glycoproteins.
- 77. Use SOPMA for secondary structure prediction of designed protein. Use as described above step 16-18 (Figures 25A and 25B).
- 78. To predict tertiary structure of protein use "Robetta" tool (Figure 26A).
- 79. Paste the designed protein sequence in "Protein sequence" column.
- 80. Enter the "Target Name" and "Submit" the job using default parameters (Figure 26B).

II Pause Point: It might take 1–2 days to complete the run.

- 81. Download the designed protein structure in .pdb format (Figure 26C).
- 82. Use GalaxyWEB server to refine the predicted protein structure from Robetta (Figure 27A).
- 83. Upload the downloaded protein structure file (.pdb) in the GalaxyWEB server and submit after adding "Job name" (Figure 27B).

II Pause Point: It might take 1–2 days to complete the run.

- 84. Download the refined structure (Figure 27C).
- 85. Visualize the 3D structure utilizing MolProbity to check the Ramachandran plot and rotamers.
- 86. Upload the refined structure. Keep all default parameters and "upload" the job (Figure 28A).
- 87. Click on continue after new web page appears (Figure 28B).
- 88. In the next webpage, select "analyze geometry without all atom contacts". Keep parameters default and submit (Figures 28C and 28D).

Note: Verify the structure with the Ramachandran favored percentage (>95% - Valid) (Figure 28E). The verified protein structure will be saved as Final protein.pdb.



IEDB Analys	sis Resource	IEDB Analysis Resource
	Reference Download Contact	
NORM Help LIGHTPH H	Revenues contract	
MHC-II Binding I	Predictions Specify Sequence()	MH-GI Binding Prediction Results we have been been been been been been been bee
		Pretession method: exemptions, ull chi plan soler - gane theless Constante areas della
Enter protein sequence(s) in FA3		No. 0 Test Dire Operating Compared Compared
Or select file containing sequence	No forward detected.	NA.000*1140000F101 1 1 9 29 6 7/F0am Ref[1]140 6 6 6 6 6 7 7 7 7 8 7 7 7 7 7 7 7 7 7 7
	Choose a Trudiction Method	RALDWY2004994946 1 5 9 9 9 9 9192000 20091000 0.00 609 84,559714956294949 1 9 9 2 9 19192000 2009194000 0.00 68
Prediction Method (*) Show all the method versions	Net/HCIIpan 4.1 EL (recommended epicpe predictor 2022.09) v Hole on method activities	Machine Displayments 1 0 16 16 (Entrement Processing and Add Add
show at the method versions:		Academication 1 3 8 Napples Surgicity of Particular 64 exclorer/software 1 3 9 Particular 94 9
	Specify what to make binding predictions for	HLADGEVERINGEVERIN 1 26 49 10 VERINGEVEN, DWERKEN,
Select species/locus	Human, HLA-GR v	8-5-50711992071939 1 2 2 6 B V VVV288 8426242092051 6669 613 84-50471199207196 1 2 0 4 0 V VV288 442624209205255, 6699 613
lelect MHC allele(s) lelect α & β chains separately if i	and the C Mills	HADDWTDDDTTTDD 1 15 79 16 ADDDTDTDD 0270 037 037
ielect full HEA reference set.	(f) value and a second of the	NL-3897/95 1 5 9 5 70 100 000 000 000 000 000 000 000 000
ielect 7-allele HLA reference set	±0.0	HU-DH/H23109619301 1 H 39 N //FEGUIN 279/HEGUINET 0370 031
	entaut 12-13 as is	N.A.MOVTENDOPTEN 1 [3 / 7 / 9 / MCANA ACCURENT GARGADONE 4666 44 N.A.MOVTENDOPTEN 1 [3 / 7 / 9 / MCANA ACCURENT GARGADONE 466 44
Gelect length(s)	11 12 13 14 15 16 17 18 19 20	8L-DRIVED/050919701 1 6 75 0 4850000 2006 2006 040 040 040 040
	23 22 23 24 25 26 27 20 29 30	KLAD2476540001788 1 36 48 98 values 445 48 48 values 4453 444
	Specify Oxeput	RAMPURE 1 19 0 0 Particular 0.4001 0.401 <th0.401< th=""> <th0.401< th=""> <th0.401< td="" th<=""></th0.401<></th0.401<></th0.401<>
Cont peopleten by	Percentie Bank w	PAADBINAIS 1 35 49 55 marmark construction 4805 444
Sector a		
X Car P3 Capy v & Ferral Fairler Cables & F K v	2 for a fair to be for the fair to be of the f	
Sca Bitopy - offendation opened : X - K	2 form for the first set of the first	
See Booy - "Foundhing of a 7 K - Openet is . X - S	2 france for δer δer δer δer 20 ° 20 ° 20 ° 20 ° 20 ° 20 ° 20 ° 20	
% Col Collection % Formal Particle 0 * × * × * × * × * × * × * × * × * × * × * × * × * × * × * × * ×	2 form for the first set of the first set of the set	
X CA Collect (Kongy) Collect Cybernell Fairling 0 * 1		
A (a) Control Control 0 7 % Objected 0 7 % <td>A Forder De La <thde la<="" th=""> De La</thde></td> <td></td>	A Forder De La De La <thde la<="" th=""> De La</thde>	
	A Forder De La De La <thde la<="" th=""> De La</thde>	
No Color Color Source	A Forder De La De La <thde la<="" th=""> De La</thde>	
Kore (From Participation) Entransition Stransition In the Stransition (From Participation) In the Stransition (From Participation) Image: Stransition (From Participation) In the Stransition (From Participation) In the Stransition (From Participation) Image: Stransition (From Participation) In the Stransition (From Participation) In the Stransition (From Participation) Image: Stransition (From Participation) In the Stransition (From Participation) In the Stransition (From Participation) Image: Stransition (From Participation) In the Stransition (From Participation) In the Stransition (From Participation) Image: Stransition (From Participation) In the Stransition (From Participation) In the Stransition (From Participation) Image: Stransition (From Participation) In the Stransition (From Participation) In the Stransition (From Participation) Image: Stransition (From Participation) In the Stransition (From Participation) In the Stransition (From Participation) Image: Stransition (From Participation) In the Stransition (From Participation) In the Stransition (From Participation) Image: Stransition (From Participation) In the Stransition (From Participation) In the Stransition (From Participation) Image: Stransition (From Participation) In	A Forder De La De La <thde la<="" th=""> De La</thde>	
Krac Entra - Strand State State Strand State State Strand State State		
A Goog Construction 0		
Konger Conger		
	Norm C D <thd< th=""> <thd< th=""> <thd< th=""> <thd< th=""></thd<></thd<></thd<></thd<>	
	Norm C D <thd< th=""> <thd< th=""> <thd< th=""> <thd< th=""></thd<></thd<></thd<></thd<>	
Kon B Cap - Construction Copeser I X - K		

Figure 12. MHC II binding prediction using IEDB MHC II (A) Homepage of MHC II binding prediction server.

(B) Result page.

(C) Epitope sorting of MHC II binding prediction.

△ CRITICAL: Confirm that the 3D epitope-linker combinations meet a Ramachandran plot quality score of at least 95%. If this criterion is not achieved, repeat from step 64 reconfigure and modify the arrangement of linkers and epitopes to create new combinations. Validate the updated 3D structure using the Ramachandran plot to ensure its suitability for further analysis.

Part 9: Molecular docking

© Timing: 1 day

This section details the procedure to perform the protein-protein interactions via protein docking platform ClusPro, its validation using PRODIGY webserver and analyze the site of interaction using Ligplot+.

89. Open the PDB website, search "TLR4 structure" and download the structure in PDB format (Figures 29A-29D).

Note: - If ligand is not available download the protein structure (here, PDB: 3FXI) pre- docked with any other molecule.

- 90. Open the downloaded structure in PyMOL and go to Display Sequence (Figure 30A).
- 91. Select and remove the extra unwanted sequences and molecules (if any) (Figure 30B).

△ CRITICAL: Verify the presence of any additional molecules and manually remove them; otherwise, the docking will not result in a valid structure.



Protocol

	OTU Health Tech	General DEB	DTU Health Tech	Contact DTU
	Department of Health Technology	=	Department of Health Technology	#
	Research Education Cellaboration Services and Products News About Investments Not 1 Services and Inducts 3 International Services 3 McCimicana and			**
	Submount Instructure Copy Format Wolf Vener Asstract Evaluation data sets Venuer History Countries	Sense On D D D	Research Education Collaboration Services and Products News About	
		NG .	OTUHEALTH TEOH > SERVICES AND PRODUCTS > BIOINFORMATIC SERVICES > NETHINEPAIN-4.0	SHARE ON 🖬 🖬 🗙
	PGDIMERULAL EVALUATION EDUNCED AND EDUCATION TO THE AND EDUCATION AND EDUC			
	Indolment/Mutivitation/dation/dation/		Threshold for strong binder: 36 Rank 2 0 Threshold for weak binder: 36 Rank 2 0	
	and a second second second		Make BA predictions 0	
	or apland a file in (<u>actin</u> formet directly from your local disk (Onosee File) to the desten		Sort by prediction score O O The threshold will	he indicated
	- or Mod Some sample data (Lost sample data)		Save predictions to XLS file 9 barre as 2% for SB	
	PEPTIOE LONCTH (speetly variable length as a comma separated list) 15 0		Submit Cear feids	
	Use context encoding O			
			Restrictions: At most \$000 sequences per submission: each sequence not more than 20.000 amino acids and not less tha	en R seniors script: Max 30
	SELECT SPECIES/LOCK @		Phil College per submission.	
	Hero Colla V		Confidentiality:	
	Select Alein(1) (max. 20 per submission)		The sequences are kept confidential and will be deleted after processing	
	Address A		CITATIONS	
	and a second sec		For publication of results, please cite:	
			NetNHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligan	d and Deatlide Diadian
			Affinity Data	and report bring
			Vanessa jutz; Sinu Paul, Massimo Andreatta, Paolo Mancatili, Bjoem Peters and Morten Nielsen The Journal of Immunology (2017) ji 170009/8; DOI: 10.4049/jimmunol.170009/8	
	 a type a list of noticules names separated by common without spaces (may 20 per submission) O per Units and Units (a) the dealer of the dealer of			
	The rest of the second control of the second s	A	 NetMHCpan-3.0: improved prediction of binding to MHC class I molecules integrating information receptor and peptide length data sets 	on from multiple
	GETTING HELP		Morten Nielsen and Massimo Andreatta	
	If you need help reperting technical issues (e.g. errors or missing results) contact Technical Support . Please include the name or have satected. If the error occurs ofter the jub has started naming please include the (2010) (the long cade that you see while the	of the service and version (e.g. Net/hos 4.0) and the options you	Genome Modicine (2016): 8:33 Foll text (2016) • NetHME(pan, a method for MMC class I binding prediction beyond humans	
	Ryup Innyvertanik (p) (nord + 667) 20170516100000000000000000000000000000000		β_5,	1. Jacobia (1997) - 10
 O (CO) to server heatment and a Norte (Happing Review Discover) 		< ☆ ● Q ♥ ★ ● I	File There Insult Replayor formular Bas Roview View Help 15597 Q Tell-member/youwaretto.do	
🛛 Youfube 🐮 Higo 💺 Transies 🔿 Here Historia	4 0 9	< ☆) ● Q ♥ ★ ● I	The Nome Load: Applepart Annula: Data Novie View 16(b 1150) ♥ Settinus dargenerates to be Novie Setting Set	Neutral
YouTube YouTube	d is is		File There Insult Replayor formular Bas Roview View Help 15597 Q Tell-member/youwaretto.do	
YouTube YouTube	d is is	K@ @Q. 4 * # I	Dir. Team Dir. Ver. How 1000 C Month How 1000 C Month	Versent Versent State Teams
YouTube YouTube	d is is	< c) € à ♥ ★ € I		Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube	d is is	< c) < d * * * 1		Versent Versent State Teams
YouTube YouTube	d is is	<0 € à * * * I		Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube YouTube	d is is	 < <		Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube	d is is	<0 € ά ! ♥ ★● I		Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube	d is is	. ¢) @ à * * ● I		Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube	d is is	K @ @ # # # I		Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube	d is is	< 0 0 0 1 * * • 1		Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube	d is is	 < <		Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube	d is is	< c) € à ♥ ★ € I		Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube	d is is	. ¢) @ d * * € I		Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube	d is is	(• a) • a • • • • ()		Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube	d is is	 4 ⊗ Ø ∅ * * ● 1 		Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube	d is is			Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube	d is is	40 0 d 1 * * * 1		Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube	d is is	. ↔ @ d * * • I		Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube	d is is	< 0 0 0 × + € 1		Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube YouTube	d is is	. ↔ • a • * • • •		Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube YouTube	d is is			Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube YouTube	d is is			Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube	d is is	. ↔ • a • * • • •		Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol
YouTube				Mandel Mark Delta Landon → Dy Poly Mark Delta Landon → Dy Pol

Figure 13. MHC II binding prediction using NetMHCpan 4.0

- (A) Homepage with entered protein sequence.
- (B) Parameters for selection.
- (C) Result page.

(D) Selected epitopes.

- 92. Delete one of the protein chains to retain a single arm of TLR4.
- 93. Export it as "PDB file" for molecular docking (Figures 30C and 30D).
- 94. The final exported file will be saved as TLR4.pdb.

Note: Here we have shown the steps for TLR4. For MHC molecules do not perform step 92.

- 95. To perform the molecular docking, register an official email ID on the ClusPro server (Figure 31A).
- 96. Specify the "Job name", select the receptor file (TLR4.pdb) and ligand/protein file (Final protein.pdb).
- 97. Select the "Dock" option and check the registered email ID for results (Figures 31B and 31C).

II Pause Point: It might take 6–8 h to complete the run.

- 98. Download the PDB of all models (Figure 31D).
- 99. Run PRODIGY server to validate the protein-protein interaction on the basis of ΔG values of the predicted models.
- 100. Specify the chain name, temperature (37 degrees) and "Submit Prodigy" by opting "I am not a robot" option to get the results (Figures 32A and 32B).
- 101. Select the docked structure with the lowest ΔG for further analysis (here: model.000.00.pdb) (Figure 32C).
- 102. Download LigPlot+ software (Figure 33A).
- 103. Open selected (model.000.00.pdb) file and opt to run to plot the protein-protein interactions of both chains (Figure 33B).
- 104. Select "DIMPLOT" and run (Figure 33C).



Protocol

Manufactore H I N	nan - M - X X == 🔜 R - R Mayhei - 💽 🕎 Mainal	Red Bood NewSol	Σ.	sin (m 🔎 🔸	B The Hane Louis Papelie	- M - A A 📰 = = 0 - 2 Map hat found - 👔 🕎 Manual	Bid Good Neutral	En In In Zandor	- (n - p) -
· remarked	$\begin{array}{c} \max_{\mathbf{n}} \cdots \ \mathbf{n}_{n} - \ \mathbf{k}_{n} - $	terreturn typereray televed by	bart Balte format	ar - Edur - Schut -	Parter of Farmed Painter B 2 5 Outboard D	t = □ + ≥ + ≥ = ≡ ≡ ≡ ≡ ≡ ⊡ Endersh Contra + test test test test test test test tes	a Investigation Sector followed my a	inter Delete Fernat	Sorth End b She'r Lebt -
* 1 × × 4					m •				
			0		4 A		5	D	t 1
peptide	allele				1 peptide	allele	Antigenicity score (> 4.0)	Allerginicity	
PERAAM/SLACK	WEATON 02/0001105/02 WEATON105/01/0001103/01	-			1 pepcide	anara	Antigenerty score (> 4.0)		
INTARSCOME ILS	HLA-00A1*05:01/0001*02:01. HLA-00A1*01:01/0001*05:01				2 AFTIRAAMPLAND	HLA-00A1*01.02/0091*06/02. HLA-00A1*05/01/0081*02/01	0.567	NON-ALLERGEN	
TEFFSTRAAANPET	HEA 0PA1"02:01/0P01"14:01, HEA 0801"09:01, HEA 0801"07:05, HEA 0PA1"02:01/0P01"05:01, HEA-				1 AVXAVGCONETLX	HUA-0QA1105:01/0Q81100:01; HUA-0QA1101:01/0Q81105:01	-0.3195 (Probable NON-ANTIGEN)	X	
	0QA1*04:01/0Q81*04:02, HLA-0883*02:02, HLA-0PA1*02:01/0P81*01:01, HLA-0881*08:02, HLA-				ATEPPSTKAAKNPET	HIA-0PA1'02:01/0P81'14:01, HIA-0881'09:01, HIA-0881'07:01, HIA-0PA1'02:01/0P81'05:01, HIA-	0.3161 (Probable NON-ANTIGEN)		
	07A1*03.01/07B1*04.02, HLA 0885*01.01, HLA-0CA1*03.01/00B1*03.02, HLA-07A1*01.03/07B1*04.01, HL 02B1*01.01, HLA-02B1*04:01	1.4-				DGA1104-05/DGB1104-02, HLA-0483102-02, HLA-04A1102-01/0401102-01, HLA-0485108-02, HLA-			
COTWITTO EQUE	HA-0851*04:05, HA-00A1*03.01/0081*03:02					DPA1132:01/DP61104:02, HLA-0R85101:01, HLA-DQA1103:01/DQB1102:02, HLA-DPA1101:03/DP61104 DP61101:01, HLA-0R81104:01	01, HLA-		
AETURAAMISLAKK	HLA-DQA1*01.02/0081*06:02, HLA-DQA1*05:01/0081*02:01				5 EDOTINITIETEDE	HLA-0881*04.05, HLA-00A1*03.05/0081*03.02	0.868	86 NON-ALLERGEN	
ATEFFSTRAANP	MA-0PA1*02.01/0P01*14:01, HA-0801*02:01, HA-0601*07:01, HA-0QA1*04:01/0081*04:02, HA-				6 INCLUSION SLAK	HLA 00A1*05.02/0081*06:02, HLA 00A1*05:01/0081*03:01	0.698	81 ALLERGEN	
	ORE3102.02, HLA OPA1102.01/0PE1105:01, HLA-OPA1102:01/0PE1101:01, HLA-OPA1103:01/0PE1104:02, HL 00A1105:01/00E1102:01	u			PATERSTKAAKNP	HIA-07A1102/01/0781114/01, HIA-0781102/01, HIA-0881107/01, HIA-02A1104/01/0081104/02, HIA	0.326	7 ALLERGEN	
CARGE CINEETLAG	0GA1*05-01/0G81*02:01 HLA-0GA1*05:02/0G81*02:01, HLA-0#88*03:01					D801102-02, HLA-0RA1102-01/DR01105-01, HLA-DRA1102-01/DR01101-03, HLA-0RA1103-01/DR0110H D0A1105-01/D001102-03	32, HLA-		
WINDOWETIKON	NATURAL CONTRACT OF ALL AND AN A				INVAYOODNEETLKQ	00A1*05/00/0081*02/00 HLA-00A1*05/01/0081*02/01 HLA-0883*08/01	-0.4446 (Probable NON-ANTIGEN)		
	HEA 0PA1102 01/0P61101.01, HEA 0PA1102 01/0P81105 01, HEA 00A1104 01/0081104 02, HEA				 WKAYGOONEETLKQ KANGCOWECTLKQAL 	HLA-6GA1105-01/0281102-01, HLA-0885101-01 HLA-60A1105-01/0281102-01, HLA-0885101-01	-0.13446 (Probable NON-ANTIGEN) -0.1344 (Probable NON-ANTIGEN)		
UTNITHFECHER	07A1*01533/0781*04:01				9 MARGEONEE IENGIL	HLA 6GA1*05 01/0081*02 01, HLA 0835*01 01 HLA 6RA1*02:01/0881*02:01, HLA 6RA1*02:01/0891*05:01, HLA 6GA1*04:01/0081*04:02, HLA			
RANNAYGOONEE	HLA-DQA1101.01/DQ81105.01, HLA-DQA1103.01/DQ81103.02				10 EXEMPTION EQUES	DPA1*01:03/0P61*04:01	0.563	31 NON-ALLERGEN	
DOUTMETRY DOL	HLA 0881*04.05, HLA-00A1*03-01/0081*03-02				11 KREAVYKANGEENEE	HLA-00A1*01-01/0081*05:01, HLA-00A1*03:01/0081*03:02	-0.2850 (Prebable NON-ANTIGEN)		
ATEFFSTRAARMPE	HLA-0PA1*02-03/0P81*14-01, HLA-0881*09-01, HLA-0PA1*02-03/0P81*05-05, HLA-0881*07-01, HLA-				12 LEODTWITTIFEOR	NLA-0881*04:05, HLA-00A1*03:01/0081*03:02		0 NON-ALLERGEN	
	0GA1*04.01/0GE1*04.02, HA 0883*02.02, HA 0PA1*02:03/0PE1*01.01, HA 0881*08.02, HA- 0PA1*08.01/0PE1*04.02, HA 0GA1*08.01/0GE1*08.02, HA 0885*01.01, HA 0885*01.01, HA-				PATEFFSTKANKNPE	HLA-0RA1102/01/0781114/01, HLA-0861109/01, HLA-0RA1102/01/0781105/01, HLA-0861107/01, HLA- 00A1104/01/0081104/02, HLA-0881102/02, HLA-04A1102/01/0781101/01, 01, HLA-0881108/02, HLA-	0.3425 (Probable NON-ANTIGEN).	k.	
	0PA1*03.03/0P61*04.01					DQA1'04/01/0281'04/02, HLA 0883'02/02, HLA 0841'02/01/081'02/01, HLA 0883'08/02, HLA DPA1'02/01/0P81'04/02, HLA-0883'02/02, HLA 0843'02/01, HLA-0885'01/01, HLA-0885'01/01, HLA-			
LAWKAYGOONEET	HLA-0QA3*01:01/0Q81*05:01, HLA-0QA3*03:01/0Q83*03:02				33	DPA1*01:03/0PE1*04:01			
TESTALKARTY	HA-0PA1102.03/0P93114:03, HIA-0881109:03, HIA-0881107:03, HIA-0883102:02, HIA- 0PA1102.03/0P93105.03				14 REALVEARSCONEET	HLA-00A1*01/01/0081*05/01, HLA-00A1*03/01/0081*09/02	-0.5020 (Probable NON-ANTIGEN)).	
ANCOUNT TO A CONTRACT OF A CONTRACTACT OF A CONTRACT OF A CONTRACT OF A CONTRACT OF A CONTRACT OF A	HA 00A1105/0081102/00 HA-0889101/01				15 TELESTRAMOUTE	HLA-0RA1102-01/0781114-01, HLA-0851109-01, HLA-0851107-01, HLA-0851102-02, HLA- 08511102-01/05931101-05	0.2836 (Probable NON-ANTIGEN).		
WTO DEMOLT COL	THE HARA VERY WEAK THE WARA VERY				IS TEFFSTRAAROPETE IS VEANEDONEETLEOR	0%1*02:01/0#91*01:01 HLA-0QA1*05:01/02:01, HLA-0#83*01:01	-0.0148 (Probable NON-ANTIGEN)		
					10 VICATOCOMELICICIE	Norodal application of the ones and	-0.0148 (Prediate NON-ANTIGEN)	<i>k</i>	
	D L Teat MAK (pan I combined MBK II cambined Anti and after)				54	A29), Not MPC par 1 combined MPC 1 combined Anti and after (3)			
Institut (§ Accelety Invest				H 0 0	danty Southart Of Astrophile by				1 10 FL
Xce		Red Social NewSol		Буда — • × С	Critical Critical	HV2 - Emel you Annula Mas Mains Ver Hily XXX Q Matendarysmetrics → X → X X ==== + + 12 Way Sec. Sec. + E	Boot Good Neutral	En In In Inde	Epsis 0 -
X Cut R Cupy v # Farmer Fairlan U X X	1 Termine Dete Rever Kann Inde KLSD	ad Sold Nector	· Inard Debte Annual / Or	ntion * Any D *	Calles	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	ATTAXAL Dynamicy _ televed mys a		m · Or P
X Cie S Copy - Standard Santar Sphered Santar	I Formulae Date Robert State 1949 XURD © Telline under pre-under to de	bad Sold Nectod Spin Sold Sold Sold Sold Sold Sold Sold Sold	i i i i i i i i i i i i i i i i i i i	α •••••• • • • •	Cellol Colored Captored Captored Callol C	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	bet Good Nexted	neat tente Fornat / Cesr+	• • • • •
X Cat Copy - France Factor	1 Termine Dete Rever Kann Inde KLSD	Spin	· Inard Debte Annual / Or	ntion * Any D *	Cellol Colored Captored Captored Callol C	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	See	Ces Ces	n - Or Den and Andrew A
X Cr Capy - Cable	1 control from 2 forces - Norm - (10, 2012)	type C	cm P	ntion * Any D *	Cellol Colored Captored Captored Callol C	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	ATTAXAL Dynamicy _ televed mys a	Ces Ces	n - Or Den and Andrew A
X Ge S Gay v V familiar tabled v i N v S	1 Termine Dete Rever Kann Inde KLSD	Spin	cm P	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	Cellol Colorer Captorer Captorer Callon Cellol B Z S	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	See	Ces Ces	n - Or Den and Andrew A
X Cer 10 Capy - 4 Forest Annue 1 X - V - K A Peptide	1 India (See) See) (10 (10 (10 (10 (10 (10 (10 (type C	Allergenicity	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	Cellol Colorer Captorer Captorer Callon Cellol B Z S	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	See	Ces Ces	n - Or Den and Andrew A
X Car (Carao Verson Later Verson Later Verson Later X Peptide ATTRAAMELAND	1 1000 0	C Antigenicity score (> 0.4) 0.5073	O Allergenicity	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	X Gal Case **** Ø Former Holes **** Ø Former Holes *** Ø Former Holes *** Ø *** Ø * * * * * * * * * * * *	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	See	Ces Ces	n - Or Den and Andrew A
X Gri Cony Contact Tomothins Contact Network C	Folder No.	C C Antigenicity score (> 0.4)	O Allergenicity NON-ALLERGEN NON-ALLERGEN	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	X Gal Case **** Ø Former Holes **** Ø Former Holes *** Ø Former Holes *** Ø *** Ø * * * * * * * * * * * *	40 Allow Al	See	Ces Ces	n - Or Den and Andrew A
X Car (Cather Carport Cather F Fromt Prices Patternet Patter		C C Antigenicity score (> 0.4) 0.5673 0.5673 0.5686	O Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	X Gal Case **** Ø Former Holes **** Ø Former Holes *** Ø Former Holes *** Ø *** Ø * * * * * * * * * * * *	Mode Data Mark <	See	Ces Ces	n - Or Den and Andrew A
X Gri Cony Contact Tomothins Contact Network C	1 1 0	C C Antigenicity score (> 0.4)	O Allergenicity NON-ALLERGEN NON-ALLERGEN	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	X Gal Case **** Ø Former Holes **** Ø Former Holes *** Ø Former Holes *** Ø *** Ø * * * * * * * * * * * *	And	See	Ces Ces	n - Or Den and Andrew A
X Cor 2 Corp. 2 Cor		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423	O Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	A B Control Co	And	See	Ces Ces	n - Or Den and Andrew A
X Cor 2 Corp. 2 Cor		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423	O Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	Non- Promotion Control	And Data	See	Ces Ces	n - Or Den and Andrew A
X Cor 2 Corp. 2 Cor		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423	O Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	Non- Promotion Control	And A a	See	Ces Ces	n - Or Den and Andrew A
X Cor 2 Corp. 2 Cor		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423	O Allergenicity NON-ALLERGEN NON-ALLERGEN	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	Non- transition Construction (Non- transition) Construction (Non- transition) Construction (Non- (Non- transition) <thconstruction (no<="" td=""><td>About A bound A</td><td>See</td><td>Ces Ces</td><td>n - Or Den and Andrew A</td></thconstruction>	About A bound A	See	Ces Ces	n - Or Den and Andrew A
		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423	O Allergenicity NON-ALLERGEN NON-ALLERGEN	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	A Ga Image: Comparison of the comparison of	Ander Aller	See	Ces Ces	n - Or Den and Andrew A
		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423	O Allergenicity NON-ALLERGEN NON-ALLERGEN	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	A Ga Image: Comparison of the comparison of	And	See	Ces Ces	n - Or Den and Andrew A
		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423	O Allergenicity NON-ALLERGEN NON-ALLERGEN	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	A Ga Image: Comparison of the comparison of	And A A Max Max <td>See</td> <td>Ces Ces</td> <td>n - Or Den and Andrew A</td>	See	Ces Ces	n - Or Den and Andrew A
		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423 0.5431	O Allergenicity NON-ALLERGEN NON-ALLERGEN	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	A Ga Image: Comparison of the comparison of	Note: Description Description <thdescripiint< th=""> <thdescription< th=""> <thde< td=""><td>See</td><td>Ces Ces</td><td>n - Or Den and Andrew A</td></thde<></thdescription<></thdescripiint<>	See	Ces Ces	n - Or Den and Andrew A
X Car (Cather Carport Cather F Fromt Prices Patternet Patter		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423 0.5431	O Allergenicity NON-ALLERGEN NON-ALLERGEN	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	A Ga Image: Comparison of the comparison of	Note: Description Description <thdescripi< th=""> <thdescripi< th=""> Descrip</thdescripi<></thdescripi<>	See	Ces Ces	n - Or Den and Andrew A
X Car (Cather Carport Cather F Fromt Prices Patternet Patter		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423 0.5431	O Allergenicity NON-ALLERGEN NON-ALLERGEN	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	A Ga Image: Comparison of the comparison of	All No. No. <td>See</td> <td>Ces Ces</td> <td>n - Or Den and Andrew A</td>	See	Ces Ces	n - Or Den and Andrew A
X Car (Cather Carport Cather F Fromt Prices Patternet Patter		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423 0.5431	O Allergenicity NON-ALLERGEN NON-ALLERGEN	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	A Ga Image: Comparison of the comparison of	400 100 <td>See</td> <td>Ces Ces</td> <td>n - Or Den and Andrew A</td>	See	Ces Ces	n - Or Den and Andrew A
		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423 0.5431	O Allergenicity NON-ALLERGEN NON-ALLERGEN	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	A Ga Image: Comparison of the comparison of	Note: Description Description <thdescripi< th=""> <thdescripi< th=""> Descrip</thdescripi<></thdescripi<>	See	Ces Ces	n - Or Den and Andrew A
X Car (Cather Carport Cather F Fromt Prices Patternet Patter		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423 0.5431	O Allergenicity NON-ALLERGEN NON-ALLERGEN	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address	A Ga Image: Comparison of the comparison of	400 100 <td>See</td> <td>Ces Ces</td> <td>n - Or Den and Andrew A</td>	See	Ces Ces	n - Or Den and Andrew A
X Car (Cather Carport Cather F Fromt Prices Patternet Patter		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423 0.5431	Allergenicity Non-Allergen Non-Allergen Non-Allergen	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address		Name Name <th< td=""><td>See</td><td>Ces Ces</td><td>n - Or Den and Andrew A</td></th<>	See	Ces Ces	n - Or Den and Andrew A
		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423 0.5431	Allergenicity Non-Allergen Non-Allergen Non-Allergen	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address			See	Ces Ces	n - Or Den and Andrew A
		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423 0.5431	Allergenicity Non-Allergen Non-Allergen Non-Allergen	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address		Note On Sec. Not one of the sec. Not of th	See	Ces Ces	n - Or Den and Andrew A
		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423 0.5431	Allergenicity Non-Allergen Non-Allergen Non-Allergen	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address		Note: Description Descripic is a strate is a strate is a strate is a strate	See	Ces Ces	n - Or Den and Andrew A
X Car () Carlos () C		C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423 0.5431	Allergenicity Non-Allergen Non-Allergen Non-Allergen	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address		And A a	See	Ces Ces	n - Or
Xon Service Service S	1 1	C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423	Allergenicity Non-Allergen Non-Allergen Non-Allergen	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address		Note: Note: <th< td=""><td>See</td><td></td><td>- (27) (20) Mate induction Mate induction M</td></th<>	See		- (27) (20) Mate induction Mate induction M
Xon Service Service S	• Robe Too • Robe	C C Antigenicity score (> 0.4) 0.5423 0.5423 0.5423	Allergenicity Non-Allergen Non-Allergen Non-Allergen	from - grap () = See & Friedda Harris - Batter - Batter Edding Address Address Address Address		Mark Mark Mark Mark Mark Mark Mark Mark	See		n - Or

Figure 14. Combined epitopes sorting of MHC II binding prediction and NetMHCpan 4.0

- (A) Excel sheet of combined epitopes.
- (B) Antigenicity and allergenicity of predicted epitopes.
- (C) $\ensuremath{\mathsf{Excel}}$ sheet of final selected epitopes of single protein.
- (D) Excel sheet of final selected epitopes of all glycoproteins.

105. The results will be displayed (Figure 33D).

Part 10: Molecular dynamic simulation

© Timing: 15 days

This section outlines the procedure to use the GROMACS package for conducting molecular dynamics simulation studies of the designed vaccine-receptor docked complex.

Note: Use GROMACS package for the Molecular dynamic simulation studies of the vaccine receptor docked complex. All the commands are taken from GROMACS tutorial.

X.cd (Colory - Colory -		AFILAMUSLAKI HL-DQ1*01.02, DQ1*06.02, HL-DQ1*05.03, DQ1*03.01 DPQTGBMPV AL, AS EXITELTIVITYEE HL-DQ1*06.05 HL-DQ1*03.01, DQ0*03.02 EXITELTIVEE HL-DQ1*04.03 HL-DQ1*03.01, HL-DQ1*05.01, HL-DQ1*04.01, DQ0*04.02, HLA-DW1*03.00 EXITELTIVEE HL-DQ1*04.02, DQ1*04.01, HL-DQ1*04.01, HL-DQ1*04.01, HL-DQ1*04.02, DQ1*04.02, HLA-DW1*03.00 EXITELTIVEE HL-DQ1*04.02, DQ1*04.01, HL-DQ1*04.01, HL-DQ1*04.01, HL-DQ1*04.02, DQ1*04.02, DQ1*04.02, DQ1*04.02,
A	в	KORTNELK AS, B27 LEKKITNITKFEQI HLA-DRB1°84:85, HLA-DQA1°83:01, DQB1°83:02
Overlapping CTL + HTL	Supertypes/HLA Alleles	LEKKITMITKELQI HLA-UKBIYOLUS, HLA-UQDIYUSIDI, UQBIYUSIDI TLKQRLTNL HLA-A*30:01, HLA-B*08:01 TLRAMISL A.2, 87, HLA-A*02:03, HLA-A*03:01
AETLRAAMISLAKKI	HLA-DQA1*01:02/DQB1*06:02, HLA-DQA1*05:01/DQB1*03:01	
DVQTGRHPY	A1, A26	
EKKITNITTKFEQIE	HLA-DRB1*04:05, HLA-DQA1*03:01/DQB1*03:02	
FVFILTAIL	B39, B62	
KKITNITTKFEQIEK	HLA-DPA1*02:01/DPB1*01:01, HLA-DPA1*02:01/DPB1*05:01, HLA-DQ	
KQRLTNLEK	A3, B27	
LEKKITNITTKFEQI	HLA-DRB1*04:05, HLA-DQA1*03:01/DQB1*03:02	
TLKQRLTNL	HLA-A*30:01, HLA-B*08:01	
TLRAAMISL	A2, B7, HLA-A*02:03, HLA-A*03:01	

Figure 15. Notepad file for population coverage

(A) excel sheet of combined overlapping epitopes of MHC I and II. (B) Notepad file of epitopes.





0 0 0 ······ 08

i> Q. 🚾 Attenuer taskieskoppopulat 4 dnal 🖬 taskes 🛃 Maja 🗞 Tankes 🖻 task 💽 Aj								B to deal O to date View State O Teres	14	
Please Next: The genergpic frequency is currently not working an		a internation.					×	populationiana Class combined		
opulation Coverage								Visited 74.42% 1.48 0.39		
Ramber of aphypetch 10 Set								Average 74.42 1.45 0.20 Standard deviation 0.0 0.0 0.0		
Overy by area country ethnicity = =								 projected papalation coverage entropy method of appropriate Nu / NA combinations recognized by manual methods of appropriate him / NA combinations acception by 	the providen	
Select available within population bit	Select calculation splice(s)								a wear we may population	
1566 E								Population: World		
Japan Jopan Joon Oriental	Closs I separate							MHC class Coverage combined 74.42%	Avenue hit PCI0 1.45 0.23	
Karea, South Karea, South Oriental										
Mongola Mongola Criental	Class II separate							World - Class combin	ned Coverage 100	
China China China									10 ft	
Hong Kong Hong Kong Oriental	Class I and II combined								- 00 <u>2</u>	
Add user provintion(1) (. Choose File No file chosen										
Erow splope / LINC restriction data in the form below or select a file	In (8) Choose File A2R, tot								50 2	
	Submit Reset							20 W	-40	
Population datasets generously provided by Derek Middleton	of The Alaia Pressency Hit Database							2	- 20 Bacca	
191094 10	III: Received Addre(c)								10	
	Drouse							Number of epitope hitsHLA co		
								View chart data in table format		
	Browse									
	(Brause)							Vew coverage of individual epispe in World Back to be		
								(Vew coverage of individual epispe in World) Backhabe 0.2005-2001 (IDDB Home 1 Min I Contag	halan Danga a surgement of the Solited Industry of Payable is the Degenerate of Haulti and Hause Sonicae.	
A fait access Southingth org (sopulation) result/repropriet	[Drawse]		1844				- • × & [We converge the should refer a filled. But have 0.20530110000 lines (bin forms) Support by a same time to be described and they will be 0.20530000000000000000000000000000000000	Gudagung CLastith, option - East New Yor Noj 20137 🖉 Selecular jurantesia	2 2
A Mit anow South and Long (population (multi-hydroped) In or Id Coverage	[Drawse]		1966 Maganory (N.) 11.4. 12.1. 12.1.7. 12.1.7. 12.1.7. 12.1.7.	16.4. 19.0.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1		2014-0 20173-0 10301 00019	• [View converged without stations Backshall 2015-2014 (EXTAINING View Converged without at the station of the s	Gudagung CLastith, option - East New Yor Noj 20137 🖉 Selecular jurantesia	
A bit move Southinds any population (multiplicity) fortid Epitope Counting	[Buos.]		HLA: HLA: A'1341 A'2341 (877) (A10)	НА. 1914 (1914) (2316) 	18.4 (03.6) (03.6)	- HLA - 2017-111 (FL30) 	R Toget R.A	Description Description Description C2000-0030-0023 https://doi.org/10.0002 Description Description C2000-0030-0023 Descript	Gudagung CLastith, option - East New Yor Noj 20137 🖉 Selecular jurantesia	
A for more south-left angle opt-station versity protocols Control Conversage Call and Cal		0001110332 000110632 H.A. 3.01 0.01 0.01 (8.50	H.A. H.A. A'2341 A'2341 (877) (818)				R Togetera	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	Gudagung CLastith, option - East New Yor Noj 20137 🖉 Selecular jurantesia	The second secon
Control Control Category Control 1 Category Control 1 Category Control 1 Party Control 1		00011103.02 0.01 0.01 0.01 0.0 0 0 0 0 0 0 0 0 0 0	H.A. H.A. A'2341 A'2341 (877) (818)			· ·	R Touritat ices 2 2 3		And the set of the set	C
A formula Statusticacy population multiply opport fully Execute Execute fully Execut Execut		0000740.02 (0.0) - +	HLA HAA ATLEN ATLEN ADAM ADAM ADAM ADAM ADAM ADAM ADAM ADA	· ·	•	· ·	C 1994/16.A 1994/16.A 2 2 3 3 2	Open menung of obtained appropriate (Same) Analysis 2-30-30 (c) (C	Construction of the second secon	C Population coverage %
Control Control		000779332 00077932 00077932 </td <td>HEAL (\$17) HEAL (\$27) HEAL (\$28) · · · · · · · · · · · · · · · · · · · · ·</td> <td>* * * * * *</td> <td>• • •</td> <td>· · ·</td> <td>R.</td> <td>Consequence of a consequence of a conseq</td> <td>Non Operations Neurophysics Neurophysics</td> <td>C Population coverage % 24.17</td>	HEAL (\$17) HEAL (\$27) HEAL (\$28) · · · · · · · · · · · · · · · · · · · · ·	* * * * * *	• • •	· · ·	R.	Consequence of a conseq	Non Operations Neurophysics	C Population coverage % 24.17
Common Common<		CONTRACT CONTRACT PERCENT	HLA HAA ATLEN ATLEN ADAM ADAM ADAM ADAM ADAM ADAM ADAM ADA	· ·	• • •	· · · · · · · · · · · · · · · · · · ·	R.	Consequence of children designs of the line of the lin	Barren 1990 Barren 1990 Barre	C Population coverage %
Instrume Company Faller Company A Faller Company A Faller A B Faller A B B Faller Faller B B B Faller Faller Faller B B		000779332 00077932 00077932 </td <td>HEAL (\$17) HEAL (\$27) HEAL (\$28) · · · · · · · · · · · · · · · · · · · · ·</td> <td>· · · · · · · · · · · · · · · · · · ·</td> <td>• • •</td> <td>· · · · · · · · · · · · · · · · · · ·</td> <td>R.</td> <td></td> <td>Bits Bits <th< td=""><td>C Population coverage % 24.17</td></th<></td>	HEAL (\$17) HEAL (\$27) HEAL (\$28) · · · · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	• • •	· · · · · · · · · · · · · · · · · · ·	R.		Bits Bits <th< td=""><td>C Population coverage % 24.17</td></th<>	C Population coverage % 24.17
▲ Lansa Lansa Barther Faired Campos Barther 0 Faired Campos Barther 0 Patter House Barther 0 0	Image: Image: <thimage:< th=""> <thimage:< th=""> <thimage:< td="" th<=""><td>CONTRACT CONTRACT PERCENT PERCENT</td><td>HEAL (\$17) HEAL (\$27) HEAL (\$28) · · · · · · · · · · · · · · · · · · · · ·</td><td>* * * * * *</td><td>• • •</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>R.</td><td>Consequence of children designs of the line of the lin</td><td>Barren 1990 Barren 1990 Barre</td><td>C Population coverage % 24.17</td></thimage:<></thimage:<></thimage:<>	CONTRACT CONTRACT PERCENT	HEAL (\$17) HEAL (\$27) HEAL (\$28) · · · · · · · · · · · · · · · · · · · · ·	* * * * * *	• • •	· · · · · · · · · · · · · · · · · · ·	R.	Consequence of children designs of the line of the lin	Barren 1990 Barren 1990 Barre	C Population coverage % 24.17
Instantionagraphiconsummers Catal Catal and All of all all of all all of all of all all of all of all all of all of all of all of all of all all of all of all of all of all of all all of all of all of all of all of all all of all of all of all of all of all of all of all of all of all of all of all of all of all of all of all o	Image: Image: <thimage:< th=""> <thimage:< th=""> <thimage:< td="" th<=""><td>CONTRAL CONTRAL <t< td=""><td>Hat Hat 413.61 472.61 63.75 62.91 - -</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>• • •</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>R.</td><td></td><td>Sopertypes/HA Alleles B HL. DOA1'05.02/DOB1'05.02 HLA POA1'02.02/DOB1'05.02</td><td>C Population coverage % 24.17 0 28.65 0</td></t<></td></thimage:<></thimage:<></thimage:<>	CONTRAL CONTRAL <t< td=""><td>Hat Hat 413.61 472.61 63.75 62.91 - -</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>• • •</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>R.</td><td></td><td>Sopertypes/HA Alleles B HL. DOA1'05.02/DOB1'05.02 HLA POA1'02.02/DOB1'05.02</td><td>C Population coverage % 24.17 0 28.65 0</td></t<>	Hat Hat 413.61 472.61 63.75 62.91 - -	· · · · · · · · · · · · · · · · · · ·	• • •	· · · · · · · · · · · · · · · · · · ·	R.		Sopertypes/HA Alleles B HL. DOA1'05.02/DOB1'05.02 HLA POA1'02.02/DOB1'05.02	C Population coverage % 24.17 0 28.65 0
		CONTRAL CONTRAL <t< td=""><td>Hat Hat 413.61 472.61 63.75 62.91 - -</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>• • •</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>R.</td><td>Contraction of the second second</td><td>Bits Bits <th< td=""><td>C Population coverage % 24.17 0 28.65 0</td></th<></td></t<>	Hat Hat 413.61 472.61 63.75 62.91 - -	· · · · · · · · · · · · · · · · · · ·	• • •	· · · · · · · · · · · · · · · · · · ·	R.	Contraction of the second	Bits Bits <th< td=""><td>C Population coverage % 24.17 0 28.65 0</td></th<>	C Population coverage % 24.17 0 28.65 0
		CONTRAL CONTRAL <t< td=""><td>Hat Hat 413.61 472.61 63.75 62.91 - -</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>• • •</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>R.</td><td>Consequence of control of sectors of the sectors Consequence of control of sectors of the sectors of t</td><td>Sopertyper/HA Alleles B HL. DOA! 105 20/D081 105:02 B BBS 104-05, HLA-DOA! 105:02/D081 105:02 B BL. DOB! 104:02, HLA-DOA! 105:02/D081 105:02, HLA-DOA! 105:02/D081 105:02 B</td><td>C Population coverage % 24.17 0 23.65 0 23.67 0</td></t<>	Hat Hat 413.61 472.61 63.75 62.91 - -	· · · · · · · · · · · · · · · · · · ·	• • •	· · · · · · · · · · · · · · · · · · ·	R.	Consequence of control of sectors of the sectors Consequence of control of sectors of the sectors of t	Sopertyper/HA Alleles B HL. DOA! 105 20/D081 105:02 B BBS 104-05, HLA-DOA! 105:02/D081 105:02 B BL. DOB! 104:02, HLA-DOA! 105:02/D081 105:02, HLA-DOA! 105:02/D081 105:02 B	C Population coverage % 24.17 0 23.65 0 23.67 0
A unit in inclusion procession of the proce		CONTRAL CONTRAL <t< td=""><td>Hat Hat 413.61 472.61 63.75 62.91 - -</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>• • •</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>R.</td><td>Construction of the second secon</td><td>Bits Bits Description <thdescription< th=""> Descrip is an an an an an an an an an</thdescription<></td><td>C Population coverage % 24.17 0 28.65 14.03 14.05</td></t<>	Hat Hat 413.61 472.61 63.75 62.91 - -	· · · · · · · · · · · · · · · · · · ·	• • •	· · · · · · · · · · · · · · · · · · ·	R.	Construction of the second secon	Bits Bits Description Description <thdescription< th=""> Descrip is an an an an an an an an an</thdescription<>	C Population coverage % 24.17 0 28.65 14.03 14.05
		CONTRAL CONTRAL <t< td=""><td>Hat Hat 413.61 472.61 63.75 62.91 - -</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>• • •</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>R.</td><td></td><td>Burget (Methods See 16 Burget (Methods S</td><td>C Population coverage % 24.17 0 28.65</td></t<>	Hat Hat 413.61 472.61 63.75 62.91 - -	· · · · · · · · · · · · · · · · · · ·	• • •	· · · · · · · · · · · · · · · · · · ·	R.		Burget (Methods See 16 Burget (Methods S	C Population coverage % 24.17 0 28.65
Column Column <thcolumn< th=""> <thcolumn< t<="" td=""><td></td><td>CONTRAL CONTRAL <t< td=""><td>Hat Hat 413.61 472.61 63.75 62.91 - -</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>• • •</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>R.</td><td>Construction of the second secon</td><td>Bits Bits Description <thdescription< th=""> Descrip is an an an an an an an an an</thdescription<></td><td>C Population coverage % 24.17 0 28.65 14.03 14.05</td></t<></td></thcolumn<></thcolumn<>		CONTRAL CONTRAL <t< td=""><td>Hat Hat 413.61 472.61 63.75 62.91 - -</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>• • •</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>R.</td><td>Construction of the second secon</td><td>Bits Bits Description <thdescription< th=""> Descrip is an an an an an an an an an</thdescription<></td><td>C Population coverage % 24.17 0 28.65 14.03 14.05</td></t<>	Hat Hat 413.61 472.61 63.75 62.91 - -	· · · · · · · · · · · · · · · · · · ·	• • •	· · · · · · · · · · · · · · · · · · ·	R.	Construction of the second secon	Bits Bits Description Description <thdescription< th=""> Descrip is an an an an an an an an an</thdescription<>	C Population coverage % 24.17 0 28.65 14.03 14.05

ANN ANN ANN ANN AN AN

Figure 16. Population coverage of selected T cell epitopes

(A) Homepage of IEDB population coverage tool.

(B) Screenshot of result page.

(C) Result page showing coverage of individual epitope in the world.

(D) Excel sheet of epitopes showing population coverage.

- 106. Generate topology: Save the selected docked file complex model.000.00.pdb in your respective folder for further steps (here we have saved the docked file in D:\Amit\Docking).
 - a. Use the following commands in the Ubuntu terminal for mapping the main directory. ${\tt cd}$ /mnt

cdd/Amit/Docking

b. Use the following command to generate a topology file with coordinates.

gmxpdb2gmx-fmodel.000.00.pdb-ocomplex.gro-watertip3p-ignh

Note: model.000.00.pdb is your docked file in .pdb format saved in the docking folder in previous step.

c. Enter "7" to select the "AMBER99SB -ILDN" force field (Figure 34A).

Note: You can choose force field according to your need and you can also choose your water model, here we have chosen tip3p.

d. Three files will be generated in the docking folder - topol.top; complex.gro and posre.itp.107. Define box and solvate: Run the following commands in terminal.

gmx editconf -f complex.gro -o newbox.gro -bt dodecahedron -d1.0 gmx solvate -cp newbox.gro -cs spc216.gro -p topol.top -o solv.gro



Protocol

Cuberd	ত মন ত	F S R S R S Annual State &	Image: Control Image: Control Image: Control Image: Control Address Control Edition Edition Address Address	Number of spikepethb				
	x -				area_country_athracity > 1	Select calculation periods to		
A	В	c	D E *	Selec	t area(b) and/or population(b):	Soluct calculation option(s):		
		CTL Epitopes		East Asia		Class I separate		
	ameEpitopes	Alleles	Population coverage	Japan Japan Oriental				
30L	SIFGFQAEV	HLA-A*23:01, HLA-A*02:01, HLA-A*01:01, HLA-B*44:03, HLA-A*30:02, HLA-A*68:02	61.93%	Korea, South Or Korea, South Or	ental			
35R	TMSAFLIVR	HLA-A*11:01, HLA-A*02:01	51.06%	Mongolia Mongolia Crients		Ciess I separate		
BL	RLKTLDIHY	HLA-A*01:01, HLA-A*02:06, HLA-A*02:01	53.77%	Northeast Asia	· ·			
BL .	WNKKKYSSY	HLA-A*02:01, HLA-A*02:03, HLA-A*03:01	52.70%	China Oriental				
		HTL Epitopes		Hong Kong Hong Kong Orie	eat v	Class Land II combined		
	ameEpitopes	Alleles	Population coverage	Addresses	D. Choose File No file chosen			
BL	LKTLDIHYNESKPTT	HLA-DRB3*02:02, HLA-DRB1*13:02	29.83%					
3L	KTLDIHYNESKPTTI	HLA-DRB3*02:02, HLA-DRB1*13:02	29.83%	Enter ophope / MHC rest	iction data in the form below or select a file			
3L	WNKKKYSSYEEAKKH	HLA-DPA1*02:01/DPB1*05:01, HLA-DPA1*02:01/DPB1*01:01	29.40%			Submit Reset.		
					meravaly pravided by Derek Middleton a			
				Ephope		C Rentric and Alledw(s)		
				SIFOFQAEV	HLAA'23.01, HLAA'02.01,	HLA-A101.01, HLA-8144.03, HL/ Browse		
				THISAFLAR	HEAA11.01. HEAA102.01	Brosse		
				RUKTLOHY	HLAA101.01, HLAA102.08.	HLA A102 01 Browse		
				WWWWWYSY	HLA ATO2 01, HLA ATO2 03.	HLA A103.01 BIOMBE		
				UKTLDIHINESKPTT	HLADRED'02 62, HLADRE	II*12 02 Browne		
				KTLOHMNESKPTTI	HADRENNE CE HADRE	11*13.02 Browne		
	All 00(01 129 L Net MHC part 8 combine Association branchade	of MMC Economical Anti and alter Combined MMC 2 Poul page on result ()	THE R L					
	 A line server topic with any input in Maps Tandate Tandate 		ର୍ଦ୍ ୦ ୦ ୫୦ :	D The Hone Inum	Calles - [15 -] A [*] A [*]	weg bos na var tag blat ý telesadysevertale ⊐ ∰ Φ+ Filma hat <u>Gener</u> 10 [2] y tanna <u>bet Gener</u> baste	itera = =	
ulation	Coverage Calculatio	n Result	€¢ • 6 * • i	V Te Hone tour V Col Pate & Coly - Pate & Family Coly - Colybard Tailor	$ \begin{array}{ c_{\rm HM}} & -(m-r) \mathcal{K}^{\prime} \mathcal{K}^{\prime} \\ \hline \theta & \mathcal{E} & \theta & -(m-r) \frac{1}{2} + \left \frac{\Delta r}{\Delta r} + \frac{\Delta r}{r_0} \right \\ \hline \end{array} $	Non Vere High State () Editers want by the State of State ()		
ulation	Coverage Calculatio	9	€.¢) ♥ Q ★ ♥ I	D The Hone Unor S Cot Pader France Formal Pader	$ \begin{array}{ c_{\rm HM}} & -(m-r) \mathcal{K}^{\prime} \mathcal{K}^{\prime} \\ \hline \theta & \mathcal{E} & \theta & -(m-r) \frac{1}{2} + \left \frac{\Delta r}{\Delta r} + \frac{\Delta r}{r_0} \right \\ \hline \end{array} $	Non Vere High State () Editers want by the State of State ()	E The The State - by ρ	
ulation	Mays & tander & Arrow Coverage Calculatio coverage Calculatio coverage case of the reference of the coverage arrows with pathy	n Result	Q 0 0 0 4 0 1	V Te Hone tour V Col Pate & Coly - Pate & Family Coly - Colybard Tailor	$ \begin{array}{ c_{\rm HM}} & -(m-r) \mathcal{K}^{\prime} \mathcal{K}^{\prime} \\ \hline \theta & \mathcal{E} & \theta & -(m-r) \frac{1}{2} + \left \frac{\Delta r}{\Delta r} + \frac{\Delta r}{r_0} \right \\ \hline \end{array} $	Non Vere High State () Editers want by the State of State ()	E The The State - by ρ	
alation	Coverage Calculatio	n Result	€0 0 4 € 1	D The Mana Count Part Count Parts Optimizer	$ \begin{array}{c} \operatorname{Cons} & -\left[m-1\right) \mathcal{K} \cdot \mathcal{K} \\ \mathfrak{s} \neq 0 & s & s \\ \mathfrak{s} \neq 0 & s & s \\ rest & s \\ \end{array} \\ \end{array} $	The Taylor of the Standard St	La	. 2.60-1 2.600-1
antion	Mays & tander & Arrow Coverage Calculatio coverage Calculatio coverage case of the reference of the coverage arrows with pathy	n Result	€0 € 4 * € I	Contraction Name	(cma + (m +)K K = 8 X H + (D + (D + A) K = reat = K K H + (D + A) K = For K = B	No. No. <th>Deputation coverage</th> <th>. 2.60-1 2.600-1</th>	Deputation coverage	. 2.60-1 2.600-1
	Image: Springer Prime Image: Springer	n Result Bild by Andread and Hard and Hard and an parameter	€0 • a * • i	A 1 Protein Nar 3 A30L	(cma + (m +) K K =	No. No. <td>Construction Coverage Population coverage 61.93%</td> <td>. 2.60-1 2.600-1</td>	Construction Coverage Population coverage 61.93%	. 2.60-1 2.600-1
Intion	If vigit By Tanking Provide Provide Coverage Calculation Data not practice and Streetives not not Coverage Calculation Coverage Calculation Coverage Calculation Coverage Calculation Coverage Calculation Station Station	n Result Bild by Andread and Hard and Hard and an parameter	€0 0 4 × 0 1	A 2 Protein Nar 3 A30L 4 A358	Comis -(u -) K K =	No. No. <td>D Population coverage 61,93%</td> <td>. 2.60-1 2.600-1</td>	D Population coverage 61,93%	. 2.60-1 2.600-1
	And An Annual Control of Con	n Result Bild by Andread and Hard and Hard and an parameter	(4,0) ♥ Ø # ♥ I	A 1 2 Protein Nar 3 A30L 4 A35R 5 E8L	Come -(m -) K K # # Z W - □ + ≥ - ▲ - □ # > Im Epitopes SIFGFQAEV TMSAFLUVR RLKTLDIHY	No. No. <td>Population coverage 61.93% 53.77%</td> <td></td>	Population coverage 61.93% 53.77%	
	And An Annual Control of Con	n Result Bild by Andread and Hard and Hard and an parameter	60 90 +91	A 1 Protein Name A 30 A 30 A 4 A35R 5 E8L 6 E8L	Comis -(u -) K K =	No. 100 No. 100 <t< th=""><th>D Population coverage 61,93%</th><th></th></t<>	D Population coverage 61,93%	
Average Construction Construction	A result	n Result Berry Guiden and Ann Ann and Ann	40 0 4 + 0 I	Comparison of the second	(max -(m-r) < c	No. 100 No. 100 <t< td=""><td>Population coverage 6.193% 1.00% 1</td><td>1</td></t<>	Population coverage 6.193% 1.00% 1	1
Intion	And An Annual Control of Con	n Result Bild by Andread and Hard and Hard and an parameter	40 00 00	Comparison of the second	(me) -(m-) (c) b / (c) (c) me Epitopes (c) (c) SIFGRAEV TMSAFLVR (c) (c) RUSTLDIHY WNKKKYSSY (c) (c) me Epitopes (c) (c)	No. 10 No. 10<	Population coverage Popula	1
Intion	A result			Protein Nars Protein Protein Protein Protein Protein Protein Protein Protein Protein Protein Pr	(max (m) (m) <td>100 100<td>Population coverage 22.27%</td><td>1</td></td>	100 100 <td>Population coverage 22.27%</td> <td>1</td>	Population coverage 22.27%	1
Intion	A result in the second se		40° 0 0° + • 1	Comparison of the second	Gass - (b - c) + c (c) I I - (b - c) (c) I I I (c) (c) (c) I I I (c) (c) (c) (c) I I I I (c) (c) (c) (c) I I I I	No. 100 No. 100 <t< td=""><td>Description Description Image: Second Second</td><td>1</td></t<>	Description Description Image: Second	1
Intion	A result in the second se		40 00 00 00 1	Protein Nas Protein Protein Pro	Gass - (b - c) + c (c) I I - (b - c) (c) I I I (c) (c) (c) I I I (c) (c) (c) (c) I I I I (c) (c) (c) (c) I I I I	100 100 <td>Population coverage 22.27%</td> <td>1</td>	Population coverage 22.27%	1
Intion	A result in the second se		40 0 0 0 + 0 I	Comparison of the second	Gass - (b - c) + c (c) I I - (b - c) (c) I I I (c) (c) (c) I I I (c) (c) (c) (c) I I I I (c) (c) (c) (c) I I I I	No. 100 No. 100 <t< td=""><td>Description Description Image: Second Second</td><td>1</td></t<>	Description Description Image: Second	1
Intion	A result in the second se		40 00 00	Protein Nar Protein Nar Prote	Gass - (b - c) + c (c) I I - (b - c) (c) I I I (c) (c) (c) I I I (c) (c) (c) (c) I I I I (c) (c) (c) (c) I I I I	No. 100 No. 100 <t< td=""><td>Description Description Image: Second Second</td><td>1</td></t<>	Description Description Image: Second	1
Average Construction Construction	A result in the second se		40 00 00 1	Comparison of the second	Gass - (b - c) + c (c) I I - (b - c) (c) I I I (c) (c) (c) I I I (c) (c) (c) (c) I I I I (c) (c) (c) (c) I I I I	No. 100 No. 100 <t< td=""><td>Description Description Image: Second Second</td><td>2440 V 2440 V 2440 V</td></t<>	Description Description Image: Second	2440 V 2440 V 2440 V
Intion	A result in the second se			Comparison of the second	Gass - (b - c) + c (c) I I - (b - c) (c) I I I (c) (c) (c) I I I (c) (c) (c) (c) I I I I (c) (c) (c) (c) I I I I	No. 100 No. 100 <t< td=""><td>Description Description Image: Second Second</td><td>1 Add 10 Add 10</td></t<>	Description Description Image: Second	1 Add 10 Add 10
Internet of the second	A result in the second se			Comparison of the second	Gass - (b - c) + c (c) I I - (b - c) (c) I I I (c) (c) (c) I I I (c) (c) (c) (c) I I I I (c) (c) (c) (c) I I I I	No. 100 No. 100 <t< td=""><td>Description Description Image: Second Second</td><td>2440 V 2440 V 2440 V</td></t<>	Description Description Image: Second	2440 V 2440 V 2440 V
Number	A result in the second se			Comparison of the second	Gass - (b - c) + c (c) I I - (b - c) (c) I I I (c) (c) (c) I I I (c) (c) (c) (c) I I I I (c) (c) (c) (c) I I I I	No. 100 No. 100 <t< td=""><td>Description Description Image: Second Second</td><td>2440 V 2440 V 2440 V</td></t<>	Description Description Image: Second	2440 V 2440 V 2440 V
Number	A result in the second se			Comparison of the second	Gass - (b - c) + c (c) I I - (b - c) (c) I I I (c) (c) (c) I I I (c) (c) (c) (c) I I I I (c) (c) (c) (c) I I I I	No. 100 No. 100 <t< td=""><td>Description Description Image: Second Second</td><td>1</td></t<>	Description Description Image: Second	1
Internet of the second	A result in the second se		40 00 00 00 1	A A	Gass - (b - c) + c (c) I I - (b - c) (c) I I I (c) (c) (c) I I I (c) (c) (c) (c) I I I I (c) (c) (c) (c) I I I I	No. 100 No. 100 <t< td=""><td>Description Description Image: Second Second</td><td>1</td></t<>	Description Description Image: Second	1
substance		а Result историсальной полина и на полина МСССССССССССССССССССССССССССССССССССС		Comparison of the second	Gass - (b - c) + c (c) I I - (b - c) (c) I I I (c) (c) (c) I I I (c) (c) (c) (c) I I I I (c) (c) (c) (c) I I I I	No. 100 No. 100 <t< td=""><td>Description Description Image: Second Second</td><td>2440 V 2440 V 2440 V</td></t<>	Description Description Image: Second	2440 V 2440 V 2440 V
A monthly and a	A result in the second se	а Result историсальной полина и на солонические МСССССССССССССССССССССССССССССССССССС		Comparison of the second	See Control of the American Sector Se	No. 100 No. 100 <t< td=""><td>Description Description Image: Second Second</td><td>te</td></t<>	Description Description Image: Second	te

Figure 17. Overall population coverage of selected epitopes

(A) Excel sheet of epitopes that passes the cutoff (CTL>50% and HTL>25%).

(B) Manually entered epitopes and HLA alleles in IEDB population coverage server.

(C) Screenshot of population coverage calculation result.

(D) Excel sheet of overall population coverage.

108. Add ions: Add new ions by copying the text from the given link (http://www.mdtutorials.com/ gmx/complex/Files/ions.mdp) and paste it into a newly created document named "ions.mdp" in the docking folder (Create a new notepad file in the docking folder and save it as ions.mdp).

a. Run the following command in terminal.

gmx grompp -f ions.mdp -c solv.gro -p topol.top -o ions.tpr

(a new ions.tpr file will be formed).

b. Command to pass your .tpr file to genion.

gmx genion -s ions.tpr -o solv_ions.gro -p topol.top -neutral -pname NA -nname CL -neutral -conc 0.15

Note: In GROMACS, the .tpr file, or portable binary run input file, contains all the necessary information to perform a molecular dynamics (MD) simulation. This file is essential when using the genion tool in GROMACS to add or replace ions in your system, allowing you to neutralize charge or reach a desired ionic concentration.

 c. Now select the group of solvent molecules (Figure 34B).
 From the obtained list choose the SOL (13) In terminal type:

13 q



- 109. Energy minimization (EM) of the system: Create the binary input using the tool grompp and this input parameter file:
 - a. Copy the text from the given link to perform energy minimization (http://www.mdtutorials. com/gmx/complex/Files/em.mdp) and paste it into a newly created document named "em.mdp" in the docking folder (Create a new notepad file in the docking folder and save it as em.mdp).
 - b. Convert .mdp file to .tpr file, run the following command.

gmx grompp -f em.mdp -c solv_ions.gro -p topol.top -o em.tpr

c. Run command to carry out Energy minimization (EM) of the system.

gmx mdrun -v -deffnm em

Note: -deffnm em: Sets "em" as the default prefix for file names. GROMACS will look for an "em.tpr" file (created with 'gmx grompp') and will generate output files such as "em.gro," "em.edr," "em.log," etc., all using "em" as the base name.

- 110. Equilibration of the protein ligand complex:
 - a. Restrain the ligand by running the following command in terminal.

gmx genrestr -f ligand.gro -o posre_jz4.itp -fc 1000 1000 1000

b. Include a position restraint file, such as "posre.itp", in your topology file.

▲ CRITICAL: This allows you to manage when restraints are applied in GROMACS simulations. This approach is useful for selectively restraining certain atoms during specific stages, like energy minimization or equilibration, while letting the system evolve without restraints during the production phase.

To do this go to GROMACS tutorial copy the following text ; Include Position restraint file #ifdef POSRES #include "posre.itp" #endif

- c. Open topol.top file. Paste the above copied text in topol.top file below "; Include ligand topology" and save it (Figure 34C).
- d. Make an index file: Run the following command.

gmx make_ndx -f em.gro -o index.ndx

From the obtained list choose the protein (1) and ligand (13) In terminal type:

1 13 0

Note: This index file defines specific groups of atoms within your system, which you can then use in other GROMACS commands for analysis or for applying restraints, selections,



Protocol

						N 8 0 1	B ← → Q C Anterna Secondary Second				5	🗠 🔹 🙆	
	Contra de casa						M Grail 😆 Poullable 🛃 Mages 🎭 Transform 😭 Hanas 🔛 leg						
							Bepipred Linear Epitope Prediction 2.0 Re						
v New Kaseyle	ysis Resource						Bepipred Linear Epitope Prediction 2.0 Re Input Sequences	ults					
e Nelp Example							1 POPUMIE OLAPHON STOLENTS ORDERING UNLOST GITTATION COMPLY STOLENTS APPLICATIONS						
	e Reference Described Content												
							Center position: 4 Threshold () 503 Receiving						
libody Epito	tope Prediction						645						
	Specify least						199						
a Beau Pol D	(example: PEI/15)												
	a in plain format (50000 recidues maximum, 250 recidues for Beponet 2.0)						0.55						
	TSTeadersHTTNREADsteadObsETLegitsTsubsETTNTTNT00DExCC art[subsc]pu0f08mPrg												
							0.50						
							2 au						
							6.46						
	Choose a method:						0.25	1					
leaonst Linear Ealbon Pr							6.20						
Inner Lines Labor Pr Inne & Casman Data Turn	LTmbdan Int Padrice						6.56						
own Surface Accessible.	(PLZ)#0.0(4)						6 20 40 60	80 100					
And A South Products	aid "Exitidat						Position						
alariar & Torogeniar Art aniar Indontichi Prede	Activities (Average 0.505 Minimum 0.200 Maximum 0.637						
	Submit Resat						Predicted peoples:						
							No.2 Sect End to Papers to Long						
S-29241 (CCC Hone Hel	Net+ Context The Systems Indiate of Alterny, and Infectious Diseases, a component of the National Indiates of Headth in the Department of	Plant and Margan Resources					1 5 6 CHIEROLADHICHYSTOLADHICHICHEDHEROLOG 6						
							3 56 597 032xq705x 59						
							Predicted residue scores: Pedice Ender Score Adaptement						
							0 A 0.200 - 5 0 0.341 -						
							1 0 0341						
							2 G 0407						
Ny Cont	Ngelagaat Antonias Sata Rocar Van Hog XISSE 🖉 Saturaharyouwatada	E CELLANISONO IV - Gue			Spin 0	e .	■ 4y= 1 + . Por Hone Inst Papelant Tomular Bas Room Ver Tom Hone Inst Papelant Tomular Bas Room Ver	ECCARISON Hay 16527 Q Ministry wants in		1100.0	S teste	Spin .	
No Cont Hare Inst X Con Copy - Cont Painter	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		Seed Neutral Dolinatory Post	The Post Stand		e .	D The Hone Inset Pagelagnet Somular Data Review Vie	Help 11592 Q Tel mender you want to de		Newford Dates D	Karran Karran		
Non Chart Non Chart Con Con Chart Cont Patter Stand Patter Non Chart Non Cha	$\begin{array}{c c c c c c c c c c c c c c c c c c c $		Seed Neutral Decimatory Paget	Diat Diffe Ford				Help 11592 Q Tel mender you want to de		NewStall	No Formation The formation		
X On Di Copy - S famat Painter castore 10 - 1 X	$\begin{array}{c cccc} constraint & constraint \\ constraint & constraint \\ s \neq 0 & constraint \\ rate & s \\ \hline \end{array} \\ \hline \end{array} \\ \begin{array}{c cccc} constraint \\ s \neq 0 \\ rate \\ s \\ \hline \end{array} \\ \hline \end{array} \\ \begin{array}{c ccccc} constraint \\ s \neq 0 \\ rate \\ s \\ \hline \end{array} \\ \begin{array}{c cccccc} constraint \\ s \neq 0 \\ rate \\ s \\ \hline \end{array} \\ \hline \end{array} \\ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		D E	F		- ABD-IN MERIN		No.0 No.0 No.0 Contrast of the sector of	Normal Bed Gee Labolation Process Days Bytes	E	Kartar Nortari n F	² Δηγ ρ Int-la Food Falser Inten Lating	0 48 40 40 40 40 40 40 40 40 40 40 40 40 40
X Or Di Coy - ef famit hister optione ni - X	$\begin{array}{c cccc} constraint & constraint \\ constraint & constraint \\ s \neq 0 & constraint \\ rate & s \\ \hline \end{array} \\ \hline \end{array} \\ \begin{array}{c cccc} constraint \\ s \neq 0 \\ rate \\ s \\ \hline \end{array} \\ \hline \end{array} \\ \begin{array}{c ccccc} constraint \\ s \neq 0 \\ rate \\ s \\ \hline \end{array} \\ \begin{array}{c cccccc} constraint \\ s \neq 0 \\ rate \\ s \\ \hline \end{array} \\ \hline \end{array} \\ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Conditional Formatic Remarking * Store *	D E	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN	D to the not reproduce the form the term to the form the term term to the form the term term term term term term term ter	Hop BLD2 Q Information you write to it. P P may that Immediate you write to it. Immediate you write to it. P P may that Immediate you write you	Normal Bed Gee Labolation Process Days Bytes			² Δηγ ρ Int-la Food Falser Inten Lating	0 48 40 40 40 40 40 40 40 40 40 40 40 40 40
A con Constant Partie Constant Partie Constant Partie A proteins	$\begin{array}{c cccc} constraint & constraint \\ constraint & constraint \\ s \neq 0 & constraint \\ rate & s \\ \hline \end{array} \\ \hline \end{array} \\ \begin{array}{c cccc} constraint \\ s \neq 0 \\ rate \\ s \\ \hline \end{array} \\ \hline \end{array} \\ \begin{array}{c ccccc} constraint \\ s \neq 0 \\ rate \\ s \\ \hline \end{array} \\ \begin{array}{c cccccc} constraint \\ s \neq 0 \\ rate \\ s \\ \hline \end{array} \\ \hline \end{array} \\ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	C antigenicity score antij	D E	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN	D D Description Page label Control Main	109 2010 0 Monorham 101 Monorham Image: Compared to the second sec	namal and See circleduce (Control of the Control Dyes) Pyres (Control of the Control of the Cont	E Allergenicity		² Δηγ ρ Int-la Food Falser Inten Lating	Add in 4.6
A proteins of A and A an	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN	D Torman Torma Torma Torma	100 100 <td>re Antigenicity ANTIGEN</td> <td>E Allergenicity NON-ALLERGEN</td> <td></td> <td>² Δηγ ρ Int-la Food Falser Inten Lating</td> <td>Add in 4.6</td>	re Antigenicity ANTIGEN	E Allergenicity NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Inten Lating	Add in 4.6
A proteins	(case (1)<	C antigenicity score antij	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN		Пр. С. И по ибусности то променя По ибусности променя	Normal Def Generation Def Construction Construction Dypes Types	E Allergenicity NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Inten Lating	0 86 8- 8000
A proteins	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN		Imp EXP Or And An advertise Import Impo	re Antigenicity ANTIGEN ANTIGEN	E Allergenicity NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Inten Lating	0 48 40 40 40 40 40 40 40 40 40 40 40 40 40
A proteins	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN	D C C C C C C C C C C C C C C C C C C C	Implement C Manufacture C C Manufacture C <th< td=""><td>re Antigenicity Antigen Antigenicity Antigen Antigen Antigen</td><td>E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN</td><td></td><td>² Δηγ ρ Int-la Food Falser Inten Lating</td><td>0 86 8- 8000</td></th<>	re Antigenicity Antigen Antigenicity Antigen Antigen Antigen	E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Inten Lating	0 86 8- 8000
A proteins	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN		Image State	re Antigenicity Antigen Antigen Antigen Antigen Antigen Antigen Antigen Antigen Antigen	E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Inten Lating	0 48 40 40 40 40 40 40 40 40 40 40 40 40 40
A proteins A A29L	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN		Image: Section 2 Manual Acceleration 3 Image: Section 2 Image: Section 3	re Antigenicity Antigen Antigenic Antigen Antigen Antigen Antigen Antigen Antigen Antigen Antigen Antigen	E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Inten Lating	Add in 4.6
A proteins A A29L	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN		Image: Sec: Sec: Sec: Sec: Sec: Sec: Sec: Se	Antroigen Antroigen Antroigen Antroigen Antroigen Antroigen Antroigen Antroigen Antroigen Antroigen Antroigen Antroigen Antroigen	E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Lobal Lating	0 48 40 40 40 40 40 40 40 40 40 40 40 40 40
A proteins	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN		Image: Second	Antricen Antricen Antricen Antricen Antricen Antricen Antricen Antricen Antricen Antricen Antricen Antricen	E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Lobal Lating	0 48 40 40 40 40 40 40 40 40 40 40 40 40 40
A proteins	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN		Image: Sec: Sec: Sec: Sec: Sec: Sec: Sec: Se	Annual Ball Groups of the second seco	E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Lobal Lating	0 48 40 40 40 40 40 40 40 40 40 40 40 40 40
A Good Constraints of A Proteins Constraints of A Proteins Constraints of A A A29L	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN		Image: Second	And	E Allergenicity NON-ALLERGEM NON-ALLERGEM NON-ALLERGEM NON-ALLERGEM NON-ALLERGEM NON-ALLERGEM NON-ALLERGEM NON-ALLERGEM NON-ALLERGEM		² Δηγ ρ Int-la Food Falser Lobal Lating	Add in 4.6
A proteins	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN		Image: Sec: Sec: Sec: Sec: Sec: Sec: Sec: Se	Antroit III III III III III III III III III I	E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Lobal Lating	0 46 40 40 40 40 40 40 40 40 40 40 40 40 40
A proteins c A29L	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN	Constraints Constrain	Image: Second	rendering for the second secon	E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Lobal Lating	Add in 4.6
A proteins	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN	A Reserve Processory Control Processory A A Reserve Procesory A A A Reserve Processory A A Reserve Processory	Image: Sec: Sec: Sec: Sec: Sec: Sec: Sec: Se	Antroit III III III III III III III III III I	E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Lobal Lating	0 46 40 40 40 40 40 40 40 40 40 40 40 40 40
A proteins A29L	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN		Image: Second	rendering for the second secon	E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Lobal Lating	Add in 4.6
A proteins c A29L	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN	A RES A	Image: Second	rendering for the second secon	E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Lobal Lating	Add in 4.6
A proteins c	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN	A STANDARD STANDARD A STANDARD	Image: Second	rendering for the second secon	E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Lobal Lating	Add in 4.6
A Son Son Son Son Son Son Son Son	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN	O O Noted Noted </td <td>Image: Second Second</td> <td>rendering for the second secon</td> <td>E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN</td> <td></td> <td>² Δηγ ρ Int-la Food Falser Lobal Lating</td> <td>Add in 4.6</td>	Image: Second	rendering for the second secon	E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Lobal Lating	Add in 4.6
A proteins C	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN	A Res Altra Altra Altra Altra Altra Altra Altra Altra	Image: Second	rendering to the second	E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Lobal Lating	
A proteins C	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN	A Function of the second	Image: Second	rendering to the second	E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Lobal Lating	Add in 4.6
A Son Son Son Son Son Son Son Son	See Control of Control	C antigenicity score antig Q -0.0561 NON	D E igenicity allergenicity N-ANTIGEN NON-ALLER	F	∑Annolum * Arr P RA+ Lot B And B P Car* Lot B And B RA+ Lot B RA+ Lot B	- ABD-IN MERIN	A Res Altra Altra Altra Altra Altra Altra Altra Altra	Image: Second	rendering to the second	E Allergenicity NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN NON-ALLERGEN		² Δηγ ρ Int-la Food Falser Lobal Lating	Add ins

Figure 18. Representation of B cell epitope

Selection of B cells epitopes was performed using "Antibody Epitope Prediction" tool of IEDB Analysis Resource. (A) Entered protein sequence in dialogue box of homepage.

- (B) Bepipred linear epitope prediction result.
- (C) Excel sheet containing antigenicity and allergenicity of selected epitopes.

(D) Excel sheet containing final selected epitopes of all proteins.

or calculations. This flexibility is especially helpful for analyses, restraints, or other custom selections that may involve only a subset of the total system.

111. Proceed with NVT equilibration.

Note: number of particles (N), system volume (V), and temperature (T).

a. Copy the text from given link for NVT equilibration (http://www.mdtutorials.com/gmx/ complex/Files/nvt.mdp) and paste the text into a newly created document "nvt.mdp" in the docking folder (Create a new notepad file in the docking folder and save it as nvt.mdp).

Note: Change and note down no. of steps and time duration of MD simulation you want to run.

b. Convert .mdp file to .tpr file. Open GROMACS tutorial and run the following command.

gmx grompp -f nvt.mdp -c em.gro -r em.gro -p topol.top -n index.ndx -o nvt.tpr

c. MD run command to carry out NVT equilibration of the system.

gmx mdrun -deffnm nvt

112. Proceed with NPT equilibration number of particles (N), system pressure (P), and temperature (T).



Protocol

| |
 | IFNepitope
A server for predicting and des
interferon-gamma inducing epi
Home Design Predict | igning
topes
 | ploaton Dulaset Help Team | Contact
 | | A server
 | FNepitope
for predicting and des
in-gamma inducing op | igning | 5
 | CD4+
Tcell
Exogenous
Antigen Processing | |
--
--|--|--
--
--
---	--
---	--
 | This tool has been developed to
multiple peptide sequences and
more help please visit lick. | Epitope predicti
predict the IFNophope, where us
each sequence would be the pre-
 | Ion
ers are allowed to paste or upload file with
dicted according to the model selected. For |
 | |
 | | Scan Algorith |
 | Dataset Help Team | Contact |
| |
 | An Name (spinne) (ob) |
 | | 1
 | | Shaw 25
 | v entries
Serial Na. * Epitope Na | | Method
 | Search Result Score | |
| |
 | Enal allons (Story) |
 | |
 | |
 | Eptope_10
Eptope_11 | KSOVLTTHE DYVED | MERCI
 | NEGATIVE 1
NEGATIVE 1 | |
| |
 | | replaces in FASTA homes Use example Tesper
 | |
 | |
 | Eptope_1 | MITTENOECOTISVES | 5MI
 | NEGATIVE -0.72290504 | |
| |
 | visitionit
visitionet
visitionet
visitionet |
 | ÷ |
 | |
 | Epitope_2
Epitope_3
Epitope_4 | ATVYCOROCCIMION
RVKK,CRISINSK
LSMITMSM/LMKN | 5VH
SVH
SVH
 | POSITIVE 0.23912237
POSITIVE 1.0136965
POSITIVE 0.94187265 | |
| |
 | OR Uplead the contains people's seguration
here. Please speed the contains people way | Choose File No file choose and a start the second
 | |
 | |
 | Ephope_6
Ephope_7 | GONEANE AALTOSAV
AMAAASSTHEROASS
TTOYDHRESONGLYY | 5VM
5VM
5VM
 | POSITIVE 0.5403844
NEGATIVE 0.6043873
POSITIVE 0.0043873 | |
| |
 | |
 | |
 | |
 | 10 Ephope_6 | DOSCYLHSDWOFFE
DMXMC24ESSTUPN | 5MI
5MI
 | POSITIVE 0 19590005
POSITIVE 0 19590005 | |
| |
 | Please solid approach for producing PK p | anna sphere: 🔒 - Malfaned - D
 | Missee Roll and Difficult |
 | |
 | 12 Ephope_9
12 Ephope_12
13 Ephope_13 | T
T
T
T
T | 5VM
8VM
 | POSITIVE 0.50134001
NEOATIVE 0.50134001 | |
| |
 | Searchite Rocality prototion |
 | | 1
 | | -
 | Serial No. Epitope Na
to 13 of 13 entries | ne Sequence | Method
 | Result Score
@ Previous New | |
| |
 | | Weigermanen aber chaine 🔿 Wei
 | gamma watsus random |
 | |
 | | |
 | 4 | |
| |
 | | Dear Form Submit
 | Papides for Productor |
 | |
 | | |
 | | |
| e e e
la re | s
haat Feyslapad Ferrida Des
Color - 10 - 11 - 11 -
0 F U + 1 - 12 - 11 -
 | form the red test Q
$= = \frac{1}{2} \frac{Q}{Q} - \frac{1}{2} \frac{2}{2} \frac{Q}{Q} \frac{Q}{Q}$ | ۲۲ (۵۵۵۵۰۰ - ۱
۲ Indires and you work in do
۲ Indires and you work in do
۲ Indires and you work in do
۲ Indires and you work in do
 | | دوب کې د دوب
د کې د دوب کې
د د د د د د د د د د د د د د د د د د د
 | | n
Name Page Layout Township Data Be
(Lafaba - (M) K. A.
 | ne Van May Acada Si
⊟ = Pr- 2 Say bat | | ngandy FN - Loci | w waa 1 7 7 7 1
 | ΣAuton - Δημ. μ. |
| Cut
Cupy -
Normat Pat | s
nen fisplägnd famila Das
<u>Galan (M.)</u> K &
<u>Jak</u> (M.) + <u>A</u> <u>A</u>
pat
x = √ K
 | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
 | | The set of
 | Contract Contract |
 | ner Ven fög Ander X
an R ² - R ² Naphet
an R ² - R ² Naphet
Repeat | | | |
 |
Ga Gay - Samata Soot		$ = = \bigoplus_{i=1}^{m} \bigoplus_{j=1}^{m} \dots \bigoplus_{j=1}^{m} \bigoplus_{i=1}^{m} \bigoplus_{j=1}^{m} \bigoplus_{j=1}^{m} \bigoplus_{i=1}^{m} \bigoplus_{j=1}^{m} \bigoplus_{j=1}^{m} \bigoplus_{i=1}^{m} \bigoplus_{j=1}^{m} \bigoplus_{j=1}^{$	The result of the second to the second secon	andat <u>Countidos Diference</u> i polonitoro <u>Estantidos Panelins</u> v New	te Dora han on Control Contro	Datient 28		B = 0 ⁺ ≤ 2 Map Int = 0 ≤ 0 ≤ 0 ⊆ Map Int Contra Mapment	M States and you want to do	format in Table - Normal C Table - Normal C		and Zahana - Ang O Zahana - Ang O Zahana - Sank Fach Alabia Cone - Earling Alabia Earling
Cat Capy - tamartu Nett		C Sequence	Notes of the second sec		A Der Frank di Der Frank Om	A Converties of the convertient	$\begin{bmatrix} \frac{\partial \partial u}{\partial t} & \frac{\partial u}{\partial t$	E C Method	20 Statemente por veri la de Senati	Parmat Pa	G H I Antigenici Antigenici Allergenicity	Market State
Ga Dayy - tamat Pa Nort A	Context - 1(1 - 1) K = A a = X = 4 + 1 + 2 + 4 + 4 Text - Text F Context - 10 Epitope_10 Epitope_11	Image: Control of the second	A bit as table you work to do a a b b b b b b b b c b c	Addref Considers Exercised Addref Considers Basedian New Consider Constant Constant New Constant Constant Constant New Constant Constant Constant New Constant Constant Constant Constant New Constant Constant Constant Constant Constant Constant Constant New Constant Consta	A Data Tanak Canada Sana Canada San Sana Canada Sana Canada San Sana Canada Sana Canada San	2 5 60 5 600 5 7 7 7 5 7 7	$\begin{bmatrix} cons & -(n-1)X & z \\ + x & 0 & -(n-1)X & z \\ - n & -(n-1)X & 0 \\ - n & -(n-1)X & -(n-1)X & 0 \\ - n & -(n-1)X & -(n-1)X & 0 \\ - n & -(n-1)X & -(n-1)X & -(n-1)X & 0 \\ - n & -(n-1)X & -(n-1)X & -(n-1)X & -(n-1)X & -(n-1)X & -$	E = 0 - 2 Naplet = 2 E E E E HapkGree Naport C C C C C Method SD00QSCNOXX SMM	0 0 0 Million and you want to do	Format Fo	G H I Antigenici Artigenici Allergenicity 0.7911 ANTISEN NON-ALLERG	Elling
Ga Day - tamarite Nort A	Color - (1 -) K = K A A = I = (1 -) K = K Fort	= = = 0 - 2 togets = = = 2 ≥ 2 ≥ 1 Usept (one - 0) report	Verfore study per verifie del (************************************	And Consider Sector Research R	The second secon	X Gay Gay Univer 1 x No 2 4 3 5 4 6	Inters 0 </td <td>C Murrer SVM C Murrer SVM C Murrer SVM C Model V SVM C Model V SVM C MODEL V SVM SVM C MODEL V SVM SVM</td> <td>C V More state you want to do Constant on the state of the st</td> <td>Roomat Bar- Roomat C Bar- Score 0.25912237 1.015945 0.9112285</td> <td>G H I Antigenici Antigenici Altergenicity 0.7911 ANTIGEN NON-ALLERG 0.8162 ANTIGEN NON-ALLERG 0.8162 ANTIGEN NON-ALLERG</td> <td>E Ander & Arrow Ander Ener & Court Barro South Ander Ellina K L EN N N N</td>	C Murrer SVM C Murrer SVM C Murrer SVM C Model V SVM C Model V SVM C MODEL V SVM SVM C MODEL V SVM SVM	C V More state you want to do Constant on the state of the st	Roomat Bar- Roomat C Bar- Score 0.25912237 1.015945 0.9112285	G H I Antigenici Antigenici Altergenicity 0.7911 ANTIGEN NON-ALLERG 0.8162 ANTIGEN NON-ALLERG 0.8162 ANTIGEN NON-ALLERG	E Ander & Arrow Ander Ener & Court Barro South Ander Ellina K L EN N N N
Get Dayy - tumur fu Hert A	an		Marandad you wark to di The standard you wark to di Construct of Assessment The standard of Assesssment The standard of Assesssment	Makal Connection (Marcella) (X X	Control Contro	B Sequence	E 0 ** 27 May Not E E E Margin II: Same ** Represent Margin II: Same ** Same ** C Mathematic Same ** Discoglicity/Size Same ** Same ** Margin II: Same ** Same ** Same **	O O	Normal N Instant Normal Normal Instant Normal Normal F Score 0.20912237 1.0105045 0.5401845 0.5401845 0.54187285 0.5403844	G H I Antigenici Antigenici Micropenicity 0.9111 ANTIGEN NON-ALLERG 0.5162 ANTIGEN NON-ALLERG 0.43162 ANTIGEN NON-ALLERG	Statement of the second
Get Dayy - tumur Pa Hort A	Color (11 −) K ≤ 0 F = 0 + 1 + 2 + ± 0 F = 0 + 2 + ± 0	C Sequence C Sequence C Sequence C Sequence C Sequence C Sequence C Sequence C Sequence C Sequence C Sequence C Sequence C Sequence Signature Signature Sequence Signature Sequenc	Verse and a prevent in the	Anal Constant Constan	X - non- Y - no- Y - non- Y - non-	X Gay Gay Univer 1 x No 2 4 3 5 4 6	B 0 5	C Murrer SVM C Murrer SVM C Murrer SVM C Model V SVM C Model V SVM C MODEL V SVM SVM C MODEL V SVM SVM	C V More state you want to do Constant on the state of the st	Roomat Bar- Roomat C Bar- Score 0.25912237 1.015945 0.9112285	G H I Antigenici Antigenici Altergenicity 0.7911 ANTIGEN NON-ALLERG 0.8162 ANTIGEN NON-ALLERG 0.8162 ANTIGEN NON-ALLERG	Statement of the second
Get Gapy - tamar Fe NorT	Image: Section 1 Image: Section 2	Image: Proc. III Trans. Mat. Secure 2014 Image: Proc. IIII Trans. Mat. Secure 2014 Image: Proc. IIIII Trans. Mat. C Secure 2014 Secure 2014 Image: Proc. IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	Note to be a work to be a series of the series of	Martinia Constraints and a second sec	Statute Statute <t< td=""><td>A A</td><td>β (i) (i)<td>C Distance of the set of the set</td><td>O O</td><td>F Score 0.25912237 0.01182/055 0.5403844 0.02000011</td><td>G H I Antigenet Antigenet Alterpretery 0.7911 ANTIGEN NON-ALLING 0.8162 ANTIGEN NON-ALLING 0.4798 ANTIGEN NON-ALLING 0.4798 ANTIGEN NON-ALLING</td><td>Statement of the second second</td></td></t<>	A A	β (i) (i) <td>C Distance of the set of the set</td> <td>O O</td> <td>F Score 0.25912237 0.01182/055 0.5403844 0.02000011</td> <td>G H I Antigenet Antigenet Alterpretery 0.7911 ANTIGEN NON-ALLING 0.8162 ANTIGEN NON-ALLING 0.4798 ANTIGEN NON-ALLING 0.4798 ANTIGEN NON-ALLING</td> <td>Statement of the second second</td>	C Distance of the set	O O	F Score 0.25912237 0.01182/055 0.5403844 0.02000011	G H I Antigenet Antigenet Alterpretery 0.7911 ANTIGEN NON-ALLING 0.8162 ANTIGEN NON-ALLING 0.4798 ANTIGEN NON-ALLING 0.4798 ANTIGEN NON-ALLING	Statement of the second
Get Copy - Tamat Fe Hert A	Image:		More that you want to be a set of the set o	Next Conversion Restrict Conversion Restring Restrict Conversion Restrict Conversion Restrict Conversion R	Constant of the second se	A 1 5 60 Control Control Cont	β (i) (i) <td>C Method construction of the second reported of the second reported of the second report of t</td> <td>20 O Detendencemente los</td> <td>F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001</td> <td>G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN</td> <td>Statement of the second second</td>	C Method construction of the second reported of the second reported of the second report of t	20 O Detendencemente los	F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001	G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN	Statement of the second
A	Image: Section 1 Image: Section 2	Image: Proc. III Trans. Mat. Secure 2014 Image: Proc. IIII Trans. Mat. Secure 2014 Image: Proc. IIIII Trans. Mat. C Secure 2014 Secure 2014 Image: Proc. IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	Note to be a work to be a series of the series of	Martinia Constraints and a second sec	Statute Statute <t< td=""><td>Image: Control of the second second</td><td>β (i) (i)<td>C Method construction of the second reported of the second reported of the second report of t</td><td>20 O Detendencemente los</td><td>F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001</td><td>G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN</td><td>Statement of the second second</td></td></t<>	Image: Control of the second	β (i) (i) <td>C Method construction of the second reported of the second reported of the second report of t</td> <td>20 O Detendencemente los</td> <td>F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001</td> <td>G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN</td> <td>Statement of the second second</td>	C Method construction of the second reported of the second reported of the second report of t	20 O Detendencemente los	F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001	G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN	Statement of the second
(a Gay - Tamata A Gay	Image: Second	Image: Proc. III Trans. Mail Security Control Image: Proc. IIII Trans. Mail Security Control Image: Proc. IIIII Trans. Mail Control Image: Proc. IIIIII Trans. Mail Control Image: Proc. IIIII Trans. Mail Control Image: Proc. IIIIII Trans. Mail Control Image: Proc. IIIIII Trans. Mail Control Image: Proc. IIIII Trans. Mail Control Image: Proc. IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	Vertication Verticati	And Antonia Control of	P P	Comparison of the second	β (i) (i) <td>C Method construction of the second reported of the second reported of the second report of t</td> <td>20 O Detendencemente los</td> <td>F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001</td> <td>G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN</td> <td>Statement of the second second</td>	C Method construction of the second reported of the second reported of the second report of t	20 O Detendencemente los	F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001	G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN	Statement of the second
64 0app - 1amp 10 0000 A	Defension Defension <t< td=""><td>C C C C C C C C C C C C C C C C C C C</td><td>Not and a provide the difference of the sector of</td><td>We want water wate</td><td>No. X Addition X Addition<td>Control 10 10 10 10 10 10 10 10 10 10 10 10 10</td><td>β (i) (i)<td>C Method construction of the second reported of the second reported of the second report of t</td><td>20 O Detendencemente los</td><td>F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001</td><td>G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN</td><td>Statement of the second second</td></td></td></t<>	C C C C C C C C C C C C C C C C C C C	Not and a provide the difference of the sector of	We want water wate	No. X Addition X Addition <td>Control 10 10 10 10 10 10 10 10 10 10 10 10 10</td> <td>β (i) (i)<td>C Method construction of the second reported of the second reported of the second report of t</td><td>20 O Detendencemente los</td><td>F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001</td><td>G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN</td><td>Statement of the second second</td></td>	Control 10 10 10 10 10 10 10 10 10 10 10 10 10	β (i) (i) <td>C Method construction of the second reported of the second reported of the second report of t</td> <td>20 O Detendencemente los</td> <td>F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001</td> <td>G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN</td> <td>Statement of the second second</td>	C Method construction of the second reported of the second reported of the second report of t	20 O Detendencemente los	F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001	G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN	Statement of the second
(a Gay - Tamata A Gay	Image: Second	C C C C C C C C C C C C C C C C C C C	Vertication Verticati	And Antonia Control of	No. X Addition X Addition <td>Control 10 10 10 10 10 10 10 10 10 10 10 10 10</td> <td>β (i) (i)<td>C Method construction of the second reported of the second reported of the second report of t</td><td>20 O Detendencemente los</td><td>F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001</td><td>G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN</td><td>Statement of the second second</td></td>	Control 10 10 10 10 10 10 10 10 10 10 10 10 10	β (i) (i) <td>C Method construction of the second reported of the second reported of the second report of t</td> <td>20 O Detendencemente los</td> <td>F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001</td> <td>G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN</td> <td>Statement of the second second</td>	C Method construction of the second reported of the second reported of the second report of t	20 O Detendencemente los	F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001	G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN	Statement of the second
(a Gay - Tamata A Gay	Image: Second	C C C C C C C C C C C C C C C C C C C	Vertication Verticati	And Antonia Control of	No. X Addition X Addition <td>Control 10 10 10 10 10 10 10 10 10 10 10 10 10</td> <td>β (i) (i)</td> <td>C Method construction of the second reported of the second reported of the second report of t</td> <td>20 O Detendencemente los</td> <td>F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001</td> <td>G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN</td> <td>Statement of the second second</td>	Control 10 10 10 10 10 10 10 10 10 10 10 10 10	β (i)	C Method construction of the second reported of the second reported of the second report of t	20 O Detendencemente los	F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001	G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN	Statement of the second
Ger - Louis House	Image: Second	C C C C C C C C C C C C C C C C C C C	Vertication Verticati	And Antonia Control of	No. X Address X Addres <thx address<="" th=""> <thx addre<="" td=""><td>A set of the set</td><td>β (i) (i)</td><td>C Method construction of the second reported of the second reported of the second report of t</td><td>20 O Detendencemente los</td><td>F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001</td><td>G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN</td><td>Statement of the second second</td></thx></thx>	A set of the set	β (i)	C Method construction of the second reported of the second reported of the second report of t	20 O Detendencemente los	F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001	G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN	Statement of the second
Ger - Louis House	Image: Second	C C C C C C C C C C C C C C C C C C C	Vertication Verticati	And Antonia Control of	No. X Address X Addres <thx address<="" th=""> <thx addre<="" td=""><td>(1) A (1) A (</td><td>β (i) (i)</td><td>C Method construction of the second reported of the second reported of the second report of t</td><td>20 O Detendencemente los</td><td>F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001</td><td>G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN</td><td>Statement of the second second</td></thx></thx>	(1) A (β (i)	C Method construction of the second reported of the second reported of the second report of t	20 O Detendencemente los	F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001	G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN	Statement of the second
Ger - Louis House	Image: Second	C C C C C C C C C C C C C C C C C C C	Vertication Verticati	And Antonia Control of	No. X Address X Addres <thx address<="" th=""> <thx addre<="" td=""><td>A state of the state of th</td><td>β (i) (i)</td><td>C Method construction of the second reported of the second reported of the second report of t</td><td>20 O Detendencemente los</td><td>F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001</td><td>G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN</td><td>Statement of the second second</td></thx></thx>	A state of the state of th	β (i)	C Method construction of the second reported of the second reported of the second report of t	20 O Detendencemente los	F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001	G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN	Statement of the second
a and a second sec	Image: Second	C C C C C C C C C C C C C C C C C C C	Vertication Verticati	And Antonia Control of	No. X Address X Addres <thx address<="" th=""> <thx addre<="" td=""><td>A black A black A</td><td>β (i) (i)</td><td>C Method construction of the second reported of the second reported of the second report of t</td><td>20 O Detendencemente los</td><td>F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001</td><td>G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN</td><td>Statement of the second second</td></thx></thx>	A black A	β (i)	C Method construction of the second reported of the second reported of the second report of t	20 O Detendencemente los	F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001	G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN	Statement of the second
de lange - and and a second and	Image: Second	C C C C C C C C C C C C C C C C C C C	Vertication Verticati	And Antonia Control of	No. X Address X Addres <thx address<="" th=""> <thx addre<="" td=""><td>A state of the state of th</td><td>β (i) (i)</td><td>C Method construction of the second reported of the second reported of the second report of t</td><td>20 O Detendencemente los</td><td>F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001</td><td>G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN</td><td>Statement of the second second</td></thx></thx>	A state of the state of th	β (i)	C Method construction of the second reported of the second reported of the second report of t	20 O Detendencemente los	F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001	G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN	Statement of the second
A b	Image: Second	C C C C C C C C C C C C C C C C C C C	Vertication Verticati	And Annual Annua	No. X Address X Addres <thx address<="" th=""> <thx addre<="" td=""><td> A black A black A</td><td>β (i) (i)</td><td>E P P P P P P P P P P P P P P P P P</td><td>20 O Detendencemente los</td><td>F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001</td><td>G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN</td><td>Statement of the second second</td></thx></thx>	 A black A	β (i)	E P P P P P P P P P P P P P P P P P	20 O Detendencemente los	F Score 0 229/2237 1 0/29450 0 229/2237 1 0/2945 0 510/2285 0 54023044 0 0/20200011 0 0/2000001	G H I Antigreici Artigenici Altergenicity 0.7911 ANTIGEN NON-ALLENG 0.8162 ANTIGEN NON-ALLENG 0.4798 ANTIGEN NON-ALLENG 0.7333 ANTIGEN NON-ALLENG 0.5644 ANTIGEN NON-ALLENG 0.5644 ANTIGEN ALLENGEN	Statement of the second

1	200	net Designed Arms			And BID O Manufact						Sysia		
	A Cut Tacong Optiment	Callel + 11	8.6	n		1 🖪 👳	Normal Bad Neutral Calcular Batts	Seed C	Singer Deber Fare Cath	al ∑hadas - try p BA- Set Path P Care Set - Sets	e Addrine Addrine	Contro Creator a Pilir and Sta Adulte Root	a NGP
125		1 × × 4		D			6	н		XL	M	N	0
1	Protein	Loitope	Method	Result	Score	Antigenicity Score	Antierrichy	Alerenicity					0
2	AHA	TUKORUTNUEKKITN	SVM	POSITIVE	0.8579	0.2991	ANTIGEN	NON-ALLERGEN					
	ASOL	DVNDTISOVKQKW/IC	MERCI	POSITIVE	5.0000	1.5276	ANTIGEN	NON-ALLERGEN					
4	A358	ATVYGENOLOGANOOK	SVM	POSITIVE	0.2391	0.7911	ANTIGEN	NON-ALLERGEN					
s		EVIGLORISMVISI	SVM	POSITIVE	1.0136	1.5629	ANTIGEN	NON-ALLERGEN					
6		LIMITMISAFUNITIN	\$1M	POSITIVE	0.9419	0.8162	ANTIGEN	NON-ALLERGEN					
7		QCMSANEAA/TDSAV	SVM	POSITIVE	0.5404	0.4798	ANTIGEN	NON-ALLERGEN					
8		TTOYONKESCNGLYY	SVM.	POSITIVE	0.0263	0.7333	ANTIGEN	NON-ALLERGEN					
9	LIR	TTNOPVRYDPRRD	SVM	POSITIVE	0.1259	0.6472	ANTIGEN	NON-ALLERGEN					
20	MIR	QUTTKATTQSAPROV	MORCE	POSITIVE	1,0000	1.0048	ANTIGEN	NON-ALLERGEN					
22		QTKCDIEKSNEYINQ	SVM	POSITIVE	0.2754	1.2368	ANTIGEN	NON-ALLERGEN					
12		NHGCNITVININGSAD	SVM	POSITIVE	0.2900	0.2992	ANTIGEN	NON-ALLERGEN					
13		YSGLTPEQKAYVPA	SVM	POSITIVE	0.1313	0.9329	ANTIGEN	NON-ALLERGEN					
	EBL												
15													

Figure 19. Finding of IFN- γ epitopes from pan-glycoproteins of MPXV

IFN-gamma specific epitopes were selected using the "IFNepitope" tool.

- (A) Homepage containing entered protein sequences.
- (B) Prediction result for IFNepitope server.
- (C) Excel containing SVM scores.
- (D) Excel sheet containing antigenicity and allergenicity of epitopes.
- (E) Excel sheet containing all the selected epitopes.
 - a. Copy the text from given link for NPT equilibration (mdtutorials.com/gmx/complex/Files/ npt.mdp) and paste the text into a newly created document "npt.mdp" in the docking folder (Create a new notepad file in the docking folder and save it as npt.mdp).
 - b. Convert .mdp file to .tpr file. Open GROMACS tutorial and run the following command.

gmx grompp -f npt.mdp -c nvt.gro -t nvt.cpt -r nvt.gro -p topol.top -n index.ndx -o npt.tpr

c. MD run command to carry out NPT equilibration of the system.

gmx mdrun -deffnm npt

Note: After completing the two equilibration phases, the system is now well-equilibrated at the target temperature and pressure. We are ready to remove the position restraints and begin the production MD phase for data collection. At this stage, we will use the checkpoint file with grompp to prepare for the run (a 50 ns MD simulation will be conducted).






Figure 20. Extraction of protein sequences

(A) Searched protein sequence in NCBI.

(B) Protein sequence in FASTA format.

(C) Notepad file of all the different entries of single protein.

113. Production MD:

- a. Copy the text from given link for protein-ligand complex MD simulation (mdtutorials.com/gmx/complex/Files/md.mdp) and paste the text into a newly created document "md.mdp" in the docking folder (Create a new notepad file in the docking folder and save it as md.mdp).
- b. Convert .mdp file to .tpr file. Open GROMACS tutorial and run the following command.

gmx grompp -f md.mdp -c npt.gro -t npt.cpt -p topol.top -n index.ndx -o md_0_1.tpr

c. MD run command.

gmx mdrun -deffnm md_0_1

Note: After running the MD command, following output files will be obtained:

md_0_1.xtc, md_0_1.edr, md_0_1.trr, md_0_1.log, md_0_1.cpt, md_0_1.gro, md_0_1.dhdl

II Pause Point: - It might take 6–7 days to finish the run.

114. RMSD (Root mean square deviation) analysis.



Protocol

Clabord	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	5 * 12 21 Conditional Formation Notices	Calculation 0.000	Can	Set & Find & Her - Filter - Select - Cotting	Add ins Could all all all all all all all all all a	ater Countria FDF DF and Share Inti.	IEDB Analysis Resource
	× × k stration							Twee [366] [Resettion] [Resettion] [Resettion]
A	8	c	D	E	F	G	н	Epitope Conservancy Analysis
	Epitopes	Antigenicity score	Antigenicity	Allergenicity				Top 1 Sphile Topological
A29L								
	YGNIKEFNATHAAFEYSKSIGGTPALDRRVQDVNDTISDVKQK	0.8059	ANTIGEN	NON-ALLERGEN				
	EAAITDSAVAVAAASSTHRKVASSTTQYDHKESCN	0.6612	ANTIGEN	NON-ALLERGEN				Erite splage stageney) is PLAR or PASH lower (2)
A35R	HSDYKSFE	0.5871	ANTIGEN	NON-ALLERGEN				
	STLPNKSDVL	0.7299	ANTIGEN	NON-ALLERGEN				
	YVEDTWGSDGNP/TKTTSDYQDSDVSQEVRKY KKESALATTAID	0.4725	ANTIGEN	NON-ALLERGEN NON-ALLERGEN				Or updated galagest angular programming from a file
L1R M1R	EQEANASAQT	0.5889	ANTIGEN	NON-ALLERGEN				Say J. Prote Separately
	FYIRONHG	0.4708	ANTIGEN	NON-ALLERGEN				
M1R	LTPEQKAY	1,4971	ANTIGEN	NON-ALLERGEN				
	KATTQIAPRQVAGT	0.6607	ANTIGEN	NON-ALLERGEN				Exter parties reserving in PLattice EASTA faired (*)
	IHYNESKP	0.4582	ANTIGEN	NON-ALLERGEN				
ESL	KIKYSSYEEAKKH	0.4493	ANTIGEN	NON-ALLERGEN				Or samply press instances that a first Convert File to the determin
	LSSSNHEGKPHYITENYRNPYKLND	0.5836	ANTIGEN	NON-ALLERGEN				O watedpare specific tex bits (Colori Fill) to its Chain
								Anothe Specific Control Contro
								faces and the second (* 1997 v 1997 v
								Record diguicant participantian segurators ()
								Soona Based
								2 2010 XXXX EXERCISE XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
								Dependently sentent for the <u>Science Sentence</u> and <u>Science and Science Science</u> and and the Science Science Science
inal 🛛 Ind	▲ Met www tachichesphoresenerp! de 18 Man Se benden @ kon Se ip	_			Q	\$ 0	a . * •	C ← → ○ (▲ Annen Habilaguemented) Note = 0 for \$ 0 = 0 = 0 = 0 = 0 = 0 = 0 = 0 = 0 = 0
DB Ans					•	\$ 0	Q 8 9	New Walks Piece & New See See IEDB Analysis Resource More May Known Sewman Semma Contact Epitope Conservancy Analysis Result Demical mad B
DB Ans	an Billion de Konzel de Bon (2014) skylais Resources Marine Manane Hammer (1999) Sascratzey Anabyla Sascratzey Anabyla Sa				0	Ŷ 0	Q & •	New Wey Compton to the State New State State State State New State State State State New State State State State New State State State New State State New State State New New State New State
DB Ans					9	<u></u> Ω 0	Q : # •	New Webs Proc & Levine (%) IEDB Analysis Resource Imme Webs (Emple Memore Dentitie) (Center) Epitope Conservancy Analysis Result Dentitient (%) Total Statement (%) Statement
DB Ans DB Ans (DB Ans (tope Cor (tope Cor					٩	φ 0	Q & 0	Vertility of the line of
DB Ans DB Ans (resp) (free (tope Cor states tops one)					۵	 Ŷ Ø 	Q & 9	
DB Ans DB Ans (resp) (free (tope Cor states tops one)	the off the Alexan Alexan Black Black Hysis Resources Hys				2	Ŷ 0	Q & 9	
Con	the set of the se					Ŷ 0	Q 8 9	
Company C	the off the Alexan Alexan Black Black Hysis Resources Hys				•	Ŷ 0	Q & 9	
	Image:					Ŷ 0	Q : 4 9	
Company C	Image Series Series (Series Series (Series Series					Ŷ 0	Q : * •	

Figure 21. Epitope conservancy analysis using IEDB analysis resource

(A) Excel sheet of B-cell epitopes used for conservancy analysis.

(B) Homepage of Epitope conservancy analysis.

(C) Screenshot showing entered protein sequence and parameters.

(D) Epitope conservancy analysis result.

a. Calculate the RMSD values, using the following command.

gmx rms -f md_0_1.xtc -s md_0_1.tpr -o rmsd.xvg

Enter the value "4" to select "backbone" option (Figure 35A).

b. View the rmsd graph of the analysis (Figure 35B).

xmgrace rmsd.xvg

c. Use the command for probability distribution (Figure 35C).

gmx analyze -f rmsd.xvg -dist prob_rmsd.xvg

- 115. R_g (Radius of gyration) analysis.
 - a. Calculate the R_g using the command line.

gmx gyrate -f md_0_1.xtc -s md_0_1.tpr -o rg.xvg

Enter the value "1" to select "protein" option (Figure 36A).

b. View the R_g graph of the analysis (Figure 36B).

xmgrace rg.xvg

c. Use the command for probability distribution (Figure 36C).

gmx analyze -f rg.xvg -dist prob_rg.xvg





Protocol

		Sprin 00 - 0 X	8.510 1		Sprin 60 - O
	er Ver Hig KSW 🗘 felseshelgereellede	ç		at References Multings Review View Help Endhest 20 Q Tell-net-whetpen-weekthede	
	I D - They be Devel - By P - Manual Md David Neurol - By P - Manual And David Neurol - By P - Manual - By P	Expedian - Any O Ske- See & Find & Addrine	Part of family Parts Parts	A A A- タ 日・日・元・日日 日 C Amazon America Agence Ag	Addicute dations
Ophied 5 Pert 5	III III (Despet Const UP - S. + M. J) Continue frame. Control frame.	Cear - Editing Addies .		A A A A A A A A A A A A A A A A A A A	
805 × 1 ×			-		and a second
		10 10 10 10 10			
	B cell epitopes Li HTL epitopes Li HTL epitop Li		1	Vaccine 2 sequence with linkers [GPGPG (for B-cell epitopes), AAY (for CTL), GPGPG	
2 Adjuvant AKEVAA			÷	(for HTL and IFN gamma epitopes)]	
WILKAA				AKFVAAWTLKAAAEAAAKYGNIKEFNATHAAFEYSKSIGGTPALGPGPGDRRVQDV NDTISDVKQKGPGPGEAAITDSAVAVAAASSTHRKVAGPGPGSSTTQYDHKESCNGP	
^	Т Р V Р ПР Т Р V Р Р Р Р S Р S Р S Р S Р S Р S Р S Р		1	GPGHSDYKSFEGPGPGSTLPNKSDVLGPGPGYVEDTWGSDGNPITKTTSDYQDGPGP	
	E D S Y S K W E L A H K I S S H D A U D Y S V B L S C P I		-	GSDVSQEVRKYGPGPGKKESALATTAIDGPGPGEQEANASAQTGPGPGFYIRQNHGG	
	N N V H E D S R T A Y P P E O Y R H S Y B N V R R C		2	PGPGLTPEQKAYGPGPGKATTQIAPRQVAGTGPGPGIHYNESKPGPGPGKKKYSSYE	
	N V H E D S R T A Y P P C O V R H S Y B N N N K R C A 0 K T 0 K T C C V K H S K			EAKKHGPGPGLSSSNHEGKPHYITENYRNGPGPGPYKLNDGPGPGSIFGFQAEVAAY TMSAFLIVRAAYRLKTLDIHYAAYWNKKKYSSYGPGPGWNKKKYSSYEEAKKHGP	
	N V N C O S A T A Y P P C V A N V N		*	GPGKTLDIHYNESKPTTIGPGPGLKTLDIHYNESKPTTGPGPGTLKQRLTNLEKKITNG	
			. <u>.</u>	PGPGDVNDTISDVKQKWRCGPGPGRVIGLCIRISMVISLGPGPGTTAIDPVRYIDPRRD	
				GPGPGQTKCDIEIGNFYIRQ	
	S N S		÷.		
			-		
PADRE	W				
e peptide					
			÷		
vacine 1 vacine 2 vacine1, adjuvant Vac	edined adjunct. epitoper solicited Arr. EARC SPEPS (8)	100 00 01 0 0000 0 100	- Freehold all and the freehold and the former	NN IndiaN	a list of a second second
Vactora 1. Vactora 2. Vactorat, adjuvant Vac Rody Souttan QLAssenbilitycheorityde	adhad Adjunant annual ann annual ann annual an	(i) (iii) (iii) (i	- Popriari Hisson II Septembrie Sydeemal	Niv Svedgar	1 10 A
Roady South Lock (Q. Antoenibility: Neurolipade					
teaty Section Quberrillerbertiget		1 = 1	B (· · · · · · · · · · · · · · · · · · ·	anymbor yah Malon Luorga Malon dugi	
Roady South Lock (Q. Antoenibility: Neurolipade				anymbor yah Malon Luorga Malon dugi	a m s ·
teaty Section Quberrillerbertiget			B (· · · · · · · · · · · · · · · · · · ·	anymbor yah Malon Luorga Malon dugi	
hear bestan (gAnesthishenstein) (> Q (((()))) ta dapptantheoretrasjon/tradition) N (nu) ● solute (f rigs) (g but > 0 too) (f g)			C → C SS E deparatements N true = tuble = Ways & turker @	nayonang halang ang kalanda di s	
teaty Section Quberrillerbertiget			C → C SS E deparatements N true = tuble = Ways & turker @	anymbor yah Malon Luorga Malon dugi	
hear bestan (gAnesthishenstein) (> Q (((()))) ta dapptantheoretrasjon/tradition) N (nu) ● solute (f rigs) (g but > 0 too) (f g)	2011 1 2.0		C → C SS E deparatements N true = tuble = Ways & turker @	nayonang halang ang kalanda di s	
ten beine Quantitationagen C -> 0 C -> 1 algebreiteterentingentation M den D-Lee Q tage & tene & tene & y Vascifie	where $298 + 2, 0$ in the product the set of		C → C → L digstanduction N true = tuble = Ways & tuble = 0	nayonang halang ang kalanda di s	
ten balle i balle i ten	where $\mathbf{2R} + 2,0$ we suggest and the set the first the set of t		C → C → L digstanduction N true = tuble = Ways & tuble = 0	international and the second sec	
Example and an analysis of the second	and the second		C -> C C to departmenters	nyerosetakis sensekalantz * * Jen √2.0	
Example and an analysis of the second	and and a second s		C -> C C to departmenters	international and the second sec	
Example and the second	and the second s			nyerosetakis sensekalantz * * Jen √2.0	
Example and an analysis of the second	and the second s			ant-out-balance substantial ijjen v2.0 sectored: bacteria	
Example and the second	encome 277 2.0 Marine and the Marine Section of the Section of t			ant-out-balance substantial ijjen v2.0 sectored: bacteria	
Example and the second	and the second s		D C C C C C C C C C C C C C C C C C C C	anterestration substantial ¹ <i>ijen</i> v2.0 ¹² elected: bacterin the work to	
	and the second s		D C C C C C C C C C C C C C C C C C C C	severant have paraboland at a several seve	
	entered 27. 2.0 Marce and Name Towards and a second and		D C C C C C C C C C C C C C C C C C C C	anterespective substantial Second Second Se	
	and the second s		D C C C C C C C C C C C C C C C C C C C	average taken van anderskandel ¹ Jen 2.0 ¹⁰ electrict: bacteria ¹⁰	
	And and a second			anverserversende automatikel Ter JJ en v2.0 to to to to to to to t	
	encome 22 2 2 0 Antiper 2 2 0 Ant		D C C C C C C C C C C C C C C C C C C C	average Training and Andread Andre Andread Andread And	
	encome 22 2 2 0 Antiper 2 2 0 Ant			anterestation and advantual de la construcción de l	
	encome 22 2 2 0 Antiper 2 2 0 Ant			anterestation and advantual de la construcción de l	

Figure 22. Construction of vaccine and antigenicity prediction

(A) Excel sheet of joined selected epitopes with linkers and adjuvants to form final vaccine.

- (B) Word file showing primary sequence of vaccine.
- (C) Vaccine antigenicity prediction.

(D) Vaccine antigenicity result.

d. Observe probability distribution curve using this command (Figure 36D).

```
xmgrace prob_rg.xvg
```

- 116. RMSF (Root mean square fluctuation) analysis.
 - a. Calculate the RMSF use the command line.

gmx rmsf -f md_0_1.xtc -s md_0_1.tpr -o rmsf.xvg -res

Enter the value "3" to select "C-alpha" option (Figure 37A). b. View the RMSF graph of the analysis (Figure 37B).

xmgrace rmsf.xvg

- 117. SASA (Solent accessible surface area) analysis.
 - a. Calculate the SASA values using the command line.

gmx sasa -f md_0_1.xtc -s md_0_1 -o sasa.xvg

Enter the value "8" to select "SideChain" option (Figure 38A).

b. View the SASA graph of the analysis (Figure 38B).

xmgrace sasa.xvg



Protocol

() Q Con E ddyphan M Grai E Halate 🖉 Maya 🔖 Iar	endazine(Ville/ODV) iendize 🖶 News 🚺 lig		Ω ⁰ Ω	B ↔ 0 ∞ 1 m	g phanmlacure; Horr Coll Herobackpy	1 0 0 ±
	down ************************************	c allergenicity of the second				
> -> -> -> -> -> -> -> -> -> -> -> ->		Postware O Statemore	tà 🛛 🖉	L ∆ # ♥ D ← → ○ ◯ L 1044	Py4 (0) 9 9.05 5cc (0) 9 8.05 (8) 8 8.05 (8) 8 8.05	a • a . s :
Grad 🗰 Nachabe 🔮 Mapa 💁 Sar	Compared and a set of the se	Proteins Profession	Contact		b heads D files D files D file D fi	• • a s
Grad 🗰 Nachabe 🔮 Mapa 💁 Sar	Committee Committee	Proteins Profession	Contact		$\label{eq:second} \begin{split} b_{1} & = 0 & b_{1} & b_{2} & b_{3} & b_{4} \\ \hline & & & & & & & & b_{4} \\ \hline & & & & & & b_{4} \\ \hline & & & & & & b_{4} \\ \hline & & & & & & b_{4} \\ \hline & & & & & & & b_{4} \\ \hline & & & & & & & b_{4} \\ \hline & & & & & & & b_{4} \\ \hline & & & & & & & & b_{4} \\ \hline & & & & & & & & b_{4} \\ \hline & & & & & & & & b_{4} \\ \hline & & & & & & & & & b_{4} \\ \hline & & & & & & & & & b_{4} \\ \hline & & & & & & & & & & & \\ \hline & & & & &$	0 9 0 5

Figure 23. Allergenicity and physiochemical characterization of designed vaccine sequence

(A) Vaccine allergenicity prediction.

(B) Vaccine allergenicity result.

(C) Physiochemical characterization of designed vaccine.

(D) Result of physiochemical characterization of vaccine.

c. Use the command for probability distribution (Figure 38C).

gmx analyze -f sasa.xvg -dist prob_sasa.xvg

d. Observe probability distribution curve using command (Figure 38D).

xmgrace prob_sasa.xvg

118. H-bond analysis.

a. Calculate the Hydrogen bond values, using the command line.

gmx hbond -f md_0_1.xtc -s md_0_1.tpr -num protein.xvg

Enter the value "1" and "13" to select "protein" and "SOL" option respectively (Figure 39A).

b. Command to view the H- bond graph (Figure 39B).

xmgrace protein.xvg

119. PCA (Principal component analysis).



A Q (100) 15 websiteduality/system/toring/agreen/pp	
inal 😐 Nolate 🛃 Napa 🦕 Sanatan 😰 Napa 🔛 Ig	B M fair B halas B has a baras B has B is
ToxinPred Designing and prediction of toxic peptides we because available and participation of toxic periods	
Prediction of Taxic Regions in a Protein	Moute over the amino acts of query protein to see the POUTICN
page is distigated for assisting users in identifications of highly tools regions is a given protein sequence. This tool prodic regions is a protein, an assessment production of the production of highly tools regions. This other way model, here users and assass a protein sequences and the production of the production	
nt Baardanaf Maran (2016 aurbas) Chronopolitic chronis visit. Chronopolitic (1915); Chipanelie (1915); Chipa	Among A 1 Norw 4 1 4 5 1 <th1< td=""></th1<>
une visual de la formada la faite antenia de la forma de la forma de la forma de la formada de la formada de la constructura de la formada de la forma de la forma de la forma de la forma de de la forma de la	Description d/d Solution d/d L/d L/d <thl d<="" th=""> L/d L/d</thl>
alinge Up U Aleasaan Height C.A. ■ Renders ♥ Sebular O Graphically	Proved 16 Nov. 60 16 16 16 16 16 16 16 16 16 16 16 16 16
and Berlages	Allower the second
	• Teaching day teaching day and day and day and day and teaching day and day an
	- New York (a) when (a) (b) (b) (b) (b) (b) (b) (b) (b) (b) (b
G (h) Insultadmitudes/metatularni (A) (h)	
	. Samo 40 and 57 at at at at
At Sector of studie protocologies in 5 Andre 2010	
Address of adults grades regression in Exclusion and Control adults and Control adults grades regression in Exclusion and Control adults and Contr	
Addate of adult product regression to fact the state of t	
Adda and adda proteining and adda and adda and adda and adda adda Adda adda a	
<text></text>	
<image/>	
<page-header></page-header>	
<image/>	I de la

Figure 24. Toxicity and solubility prediction using ToxinPred and SOLUPROT of designed vaccine, respectively (A) Toxicity prediction of desired vaccine.

(B) Result of Toxicity prediction. (C) Prediction of solubility of designed vaccine candidate (D) Result of solubility prediction.

- - a. Execute the PCA and its graphical representation, following the command.

gmx make_ndx -f npt.gro -o c_alpha.ndx

Enter the value "3" to select C-alpha (Figure 40A).

b. Run the following command for covariance analysis.

$\verb"gmx covar -fmd_0_1.xtc-smd_0_1.tpr-nc_alpha.ndx-o eigenval.xvg-veigenval.tpr-lcovar-smd_0_1.xtc-smd_0_1.tpr-nc_alpha.ndx-o eigenval.xvg-veigenval.tpr-lcovar-smd_0_1.xtc-smd_0_1.tpr-nc_alpha.ndx-o eigenval.xvg-veigenval.tpr-lcovar-smd_0_1.xtc-smd_0_1.tpr-nc_alpha.ndx-o eigenval.xvg-veigenval.tpr-lcovar-smd_0_1.tpr-nc_alpha.ndx-o eigenval.xvg-veigenval.tpr-lcovar-smd_0_1.tpr-nc_alpha.ndx-o eigenval.xvg-veigenval.tpr-lcovar-smd_0_1.tpr-nc_alpha.ndx-o eigenval.xvg-veigenval.tpr-lcovar-smd_0_1.tpr-nc_alpha.ndx-o eigenval.xvg-veigenval.tpr-lcovar-smd_0_1.tpr-nc_alpha.ndx-o eigenval.xvg-veigenval.tpr-lcovar-smd_0_1.tpr-nc_alpha.ndx-o eigenval.xvg-veigenval.tpr-lcovar-smd_0_1.tpr-nc_alpha.ndx-o eigenval.xvg-veigenval.tpr-lcovar-smd_0_1.tpr-nc_alpha.ndx-o eigenval.tpr-nc_alpha.ndx-o eigenval.tpr-nc_alpha.ndx-ndx-o eigenval.tpr-nc_alpha.ndx-o eigenval.tpr-nc_alpha$
r.log-xpm covar.xpm

Enter the value "19" to select C-alpha (Figures 40B and 40C).

 E -> Q (100) 5 malaminantica intera association (105) real association 	A 0 G 4 6 0 1 m (+ → C (2012) E ngashparagenAngalanyhargalanyhargida jangal	0 0 4 8 0 1
A Hour Bhale Bhase Bhase Bhase Bhase	O O O O O O O O O O O O O O O O O	
NPS@: Network Protein Sequence @nalysis Tanania sharif an unjud RAM 1238 mmm	NPS@: Network Protein Sequence @nalysis Texate is a find after major (PMB 356 prime	İ
NEONEL BERNERSEN PHELIN (SERVER) (SERVER) (SERVER)	DADARE DESCRIPTION (DELA) (NEWS) CONTACTI (Sumats)	
Net 90, 2004: 2018 updated (szt. 22/23).	July 50, 1014 XPR-32 aplaned Carl XERS3.	
SOFEA profile vocadary stretures profilection Example of the streture of the s	With the second seco	
terreter to Frances Rocker Conference of Lenson Rocker Andread Enclose Andre		

Figure 25. Secondary structure prediction of designed candidate (A) Prediction of secondary structure using SOPMA. (B) Result of secondary structure prediction.

Protocol




Figure 26. Tertiary structure prediction of designed vaccine using Robetta

(A) Homepage of structure prediction software Robetta.

(B) Screenshot of entered protein sequence.

(C) Results showing structure of predicted models in Robetta.




Figure 27. Refining of tertiary structure by GalaxyRefine

(A) Home page of GalaxyRefine webserver.

(B) Uploaded pdb file in GalaxyWEB server.

(C) Result showing refined structure of vaccine.

CellPress OPEN ACCESS



0 🚳 🗚 0 🖾 🕯 в U U Dage Guid-lines These with survice C) • с 1 0 G ± * 0 U Choose the outputs you want: Definit spins here been selected based on the content of the solvest follow the ² symbols for more information on the validation options Claikes 7 Holingen bonds 7 Van der Wark contacts C3 4 0 + . . Е Duke Biochemistry 1**0**1, Analysis output: geometry for V-2_adju Pareis Malti-critorian kinomage

Figure 28. Evaluation of Ramachandran plot using MolProbity

(A) Homepage containing the refined predicted vaccine structure.

- (B) Screenshot showing uploaded pdb file.
- (C) Web page showing trimmed uploaded pdb file.
- (D) Input parameters.
- (E) Analysis output.
 - c. Extract the data from "eigenval.xvg" file in notepad, copy and paste it in an Excel sheet (Figure 41A).
 - d. Auto sum the eigen values to evaluate the trace value (Figure 41B).
 - e. Plot the graph in GraphPad Prism by designating the x and y axis as eigenvector index and eigen values (Figures 41C and 41D).
 - f. Evaluate the trajectory projections onto eigenvectors, follow the commands. For eigenvector 1

gmx anaeig -v eigenval.trr -f md_0_1.xtc -s md_0_1.tpr -n c_alpha.ndx -eig eigenval.xvg -rmsf rmsf_evl.xvg -proj proj_evl.xvg -first 1 -last 1

Select index group, enter "19" to select "C-alpha" option for both 'least squares fit in g_covar' and 'elements that corresponds to the eigenvectors' respectively (Figures 42A and 42B).

For eigenvector 2

gmx anaeig -v eigenval.trr -f md_0_1.xtc -s md_0_1.tpr -n c_alpha.ndx -eig eigenval.xvg -rmsf rmsf_evl.xvg -proj proj_evl2.xvg -first 2 -last 2



Protocol




Figure 29. 3D structure of receptor

(A) PDB homepage.

(B) Crystal structure of TLR4.

(C) Steps to download receptor.

(D) Visualization of downloaded receptor file in PyMOL.




Figure 30. Preparation of receptor for docking

(A) Display sequence.

(B) Additional molecule removal.

(C) Removal of extra arm.

(D) Cleaned receptor file.



Protocol




Figure 31. Molecular docking using ClusPro

- (A) Homepage of ClusPro.
- (B) Uploaded receptor-ligand files.
- (C) Screenshot of mail showing result intimation.
- (D) Result page showing displayed models.




Figure 32. Validation of protein-protein interaction in PRODIGY server

(A) Homepage of PRODIGY web server.

(B) Uploaded files and parameters for submission.

(C) Result page of selected molecules.

Protocol






Figure 33. Analysis of interaction sites in protein-protein docked file Ligplot+ (A) Start page of Ligplot+ software (B) Selection of docked model (C) Chain and parameters selection (D) Result page showing intra-molecular interaction between amino acids.

Select the Force Field: From current directory: 1: CHARMM5 all-atom force field (July 2022)	; Command line: ; gmx pd02gmx -f xyzpdb -o protein.gro -ignh -water tip3p ; Force field was read from the standard GROWACS share direc ;
<pre>1: Characterization for factor /pre>	<pre>; Include forcefield parameters #include "amber99sb-ildn.ff/forcefield.itp" ; Include chain topologies</pre>
 AMBER96 protein, nucleic AMBER94 (Kollman et al., Acc. Chem. Res. 29, 461-469, 1996) SHBER99 protein, nucleic AMBER94 (Wang et al., J. Comp. Chem. 21, 1049-1074, 2000) AMBER958 protein, nucleic AMBER94 (Hornak et al., Proteins 65, 712-725, 2006) 	#include "topol_Protein_chain_A.itp" #include "topol_Protein_chain_8.itp" : Include water topology
7: AMBER99SB-ILDN protein, nucleic AMBER94 (Lindorff-Larsen et al., Proteins 78, 1950-58, 2010) 8: AMBERGS force field (Garcia & Sanbonmatsu, PNAS 99, 2782-2787, 2002) 9: CHARMM27 all-atom force field (CHARM22 plus CMAP for proteins)	finclude "amber99sb-ildn.ff/tip3p.itp" #ifdef POSRES_WATER
10: GROUSS6 43al force field	; Position restraint for each water oxygen [position restraints]
11: GROMOS96 43a2 force field (improved alkane dihedrals)	; i funct fcx fcy fcz
12: GROMOS96 45a3 force field (Schuler JCC 2001 22 1205) 13: GROMOS96 53a5 force field (JCC 2004 vol 25 pag 1656)	1 1 1000 1000 1000 #endif
14: GROMOS96 53a6 force field (JCC 2004 vol 25 pag 1656) 15: GROMOS96 54a7 force field (Eur. Biophys. J. (2011), 40., 843-856, DOI: 10.1007/s00249-011-0700-9) 16: OPLS-AA/L all-atom force field (2001 aminoacid dihedrals)	; Include ligand topology #include "drg.itp"
10: OPLS-AA/L all-atom force field (2001 aminoacid dinedrals)	Before
Command line: gmx genion -s ions.tpr -o solv_ions.gro -p topol.top -pname NA -nname CL -neutral -conc 0.15	; gmx pdb2gmx -f xyzpdb -o protein.gro -ignh -water tip3p ; Force field was read from the standard GROWACS share dire ; . Label force field according
	; Include forcefield parameters #include "amber99sb-ildn.ff/forcefield.itp"
Reading file ions.tpr, VERSION 2022 (single precision) Reading file ions.tpr, VERSION 2022 (single precision)	#include amber/955-iidn. rf/forcerieid.icp
Will try to add 289 NA ions and 290 CL ions.	; Include chain topologies
Select a continuous group of solvent molecules	#include "topol_Protein_chain_A.itp"
Group 0 (System) has 314180 elements	<pre>#include "topol_Protein_chain_B.itp"</pre>
Group I (Protein) has 16/84 elements	
Group 1 (Protein) has 16784 elements Group 2 (Protein-H) has 8468 elements	; Include water topology
	; Include water topology #include "amber99sb-ildn.ff/tip3p.itp"
Group 2 (Protein-H) has 8468 elements Group 3 (C-alpha) has 1104 elements Group 4 (Backbone) has 3312 elements	<pre>#include "amber99sb-ildn.ff/tip3p.itp"</pre>
Group 2 (Protein-H) has 8468 elements Group 3 (C-alpha) has 1104 elements Group 4 (Backbone) has 3312 elements Group 5 (MainChain) has 4418 elements	#include "amber99sb-ildn.ff/tip3p.itp" #ifdef POSRES_WATER
Group 2 (Protein-H) has 8468 elements Group 3 (C-alpha) has 1104 elements Group 4 (Backbone) has 3312 elements Group 5 (MainChain) has 4418 elements Group 6 (MainChain+Cb) has 5408 elements	#include "amber99sb-ildn.ff/tip3p.itp" #ifdef POSRES_WATER ; Position restraint for each water oxygen
Group 2 (Protein-H) has 8468 elements Group 3 (C-alpha) has 1104 elements Group 4 (Backbone) has 3312 elements Group 5 (MainChain) has 4418 elements Group 6 (MainChain+Cb) has 5408 elements Group 7 (MainChain+H) has 5443 elements	#include "amber99sb-ildn.ff/tip3p.itp" #ifdef POSRES_WATER
Group 2 (Protein-H) has 8468 elements Group 3 (C-alpha) has 1104 elements Group 4 (Backbone) has 3312 elements Group 5 (MainChain+G) has 5408 elements Group 6 (MainChain+H) has 5443 elements Group 8 (SideChain) has 11341 elements	<pre>#include "amber99sb-ildn.ff/tip3p.itp" #ifdef POSRES_WATER ; Position restraint for each water oxygen [position_restraints]</pre>
Group 2 C Protein-H) has 8468 elements Group 3 C-alpha) has 1104 elements Group 4 Backbone) has 3312 elements Group 5 MainChain) has 4418 elements Group 6 MainChain+Cb) has 5408 elements Group 7 MainChain+Ch has 5408 elements Group 7 SideChain) has 1341 elements Group 8 SideChain) has 1341 elements Group 9 SideChain) has 4050 elements	<pre>#include "amber99sb-ildn.ff/tip3p.itp" #ifdef POSRES_NATER ; Position restraint for each water oxygen [position_restraints] ; i funct fcx fcy fcz</pre>
Group 2 (Protein-H) has 8468 elements Group 3 (C-alpha) has 1104 elements Group 4 (Backbone) has 3312 elements Group 5 (MainChain+Cb) has 5408 elements Group 6 (MainChain+Cb) has 5408 elements Group 7 (MainChain+H) has 5404 elements Group 8 (SideChain) has 11341 elements Group 9 (SideChain-H) has 4050 elements Group 10 (Prot-Massed) has 16784 elements	<pre>#include "amber99sb-ildn.ff/tip3p.itp" #ifdef POSRES_NATER ; Position restraint for each water oxygen [position_restraints] ; 1 funct fcx fcy fcz 1 1 1000 1000 1000 #endif</pre>
Group 2 Protein-H) has 8468 elements Group 3 C-alpha) has 1104 elements Group 4 Backbone) has 3312 elements Group 5 MainChain) has 4418 elements Group 6 MainChain+Cb) has 5408 elements Group 7 MainChain+Cb) has 5408 elements Group 7 SideChain) has 11341 elements Group 8 SideChain) has 11341 elements Group 9 SideChain-H) has 11989 elements Group 10 Prot-Masses) has 16784 elements Group 10 non-Protein) has 297396 elements Group 10 non-Protein) has 297396 elements	<pre>#include "amber99sb-ildn.ff/tip3p.itp" #ifdef POSRES_NATER ; Position restraint for each water oxygen [position_restraints] ; i funct fcx fcy fcz 1 1 1000 1000 1000 #endif ; Include ligand topology</pre>
Group 2 Protein-H) has 8468 elements Group 3 C-alpha) has 1104 elements Group 4 Backbone) has 312 elements Group 5 MainChain) has 4118 elements Group 6 MainChain-H2 has 5408 elements Group 7 MainChain-H2 has 5404 elements Group 8 SideChain) has 1311 elements Group 9 SideChain-H3 has 4950 elements Group 10 Prot-Masses) has 197396 elements Group 10 Water) has 297396 elements Group 12 Water) has 297396 elements	<pre>#include "amber99sb-ildn.ff/tip3p.itp" #ifdef POSRES_NATER ; Position restraint for each water oxygen [position_restraints] ; 1 funct fcx fcy fcz 1 1 1000 1000 1000 #endif</pre>
Group 2 Protein-H) has 84/86 elements Group 3 C-alpha) has 1104 elements Group 4 Backbone) has 3312 elements Group 5 MainChain) has 4418 elements Group 6 MainChain+Cb) has 5408 elements Group 7 MainChain+Cb) has 5408 elements Group 7 SideChain+D) has 5408 elements Group 9 SideChain+D has 11341 elements Group 9 SideChain+D has 11678 elements Group 10 Prot-Masses) has 16784 elements Group 10 Not-Protein) has 297396 elements Group 12 Water) has 297396 elements Group 12 SUL) has 297396 elements Group 12 SUL Nats 297396 elements	<pre>#include "amber99sb-ildn.ff/tip3p.itp" #ifdef POSRES_NATER ; Position_restraint for each water oxygen [position_restraints] ; i funct fcx fcy fcz 1 1 1000 1000 1000 #endif ; Include ligand topology #include ligand topology #include ?drg.itp"</pre>
Group 2 C Protein-H) has 84/88 elements Group 3 C-alpha) has 1104 elements Group 4 Backbone) has 3312 elements Group 5 MainChain) has 4318 elements Group 6 MainChain+Cb) has 5408 elements Group 7 MainChain+Cb) has 5408 elements Group 7 MainChain+Dh has 5408 elements Group 8 SideChain Has 11341 elements Group 9 SideChain Has 13941 elements Group 10 Prot-Masses) has 16784 elements Group 10 Con-Protein) has 297396 elements Group 12 Water) has 297396 elements Group 13 Con-Water) has 16784 elements	<pre>#include "amber99sb-ildn.ff/tip3p.itp" #ifdef POSRES_MATER ; Position restraint for each water oxygen [position restraints] ; i funct fcx fcy fcz 1 1 1000 1000 1000 #endif ; Include ligand topology #include "drg.itp" ; Ligand position restraints</pre>
Group 2 Protein-H) has 8468 elements Group 3 C-alpha) has 1104 elements Group 4 Backbone) has 3312 elements Group 5 MainChain has 3312 elements Group 6 MainChain has 5408 elements Group 6 MainChain+Cb) has 5408 elements Group 7 MainChain+Cb) has 5408 elements Group 7 SideChain + has 11341 elements Group 9 SideChain + has 11348 elements Group 9 SideChain + has 11698 elements Group 10 Protr-Masses) has 16784 elements Group 11 non-Protein) has 297396 elements Group 12 Water has<297396 elements	<pre>#include "amber99sb-ildn.ff/tip3p.itp" #ifdef POSRES_NATER ; Position_restraint for each water oxygen [position_restraints] ; i funct fcx fcy fcz 1 1 1000 1000 1000 #endif ; Include ligand topology #include "drg.itp" ; Ligand position restraints #ifdef POSRES</pre>
Group 2 C Protein-H) has 84/88 elements Group 3 C-alpha) has 1104 elements Group 4 Backbone) has 3312 elements Group 5 MainChain) has 4318 elements Group 6 MainChain+Cb) has 5408 elements Group 7 MainChain+Cb) has 5408 elements Group 7 MainChain+Dh has 5408 elements Group 8 SideChain Has 11341 elements Group 9 SideChain Has 13941 elements Group 10 Prot-Masses) has 16784 elements Group 10 Con-Protein) has 297396 elements Group 12 Water) has 297396 elements Group 13 Con-Water) has 16784 elements	<pre>#include "amber99sb-ildn.ff/tip3p.itp" #ifdef POSRES_NATER ; Position restraint for each water oxygen [position restraints] ; i funct fcx fcy fcz 1 1 1000 1000 1000 #endif ; Include ligand topology #include "drg.itp" ; Ligand position restraints</pre>

Figure 34. MD simulation in GROMACS

(A) Screenshot for force field selection (B) Screenshot for options to add ions in system.(C) Screenshot of notepad file to retrain the ligand.



STAR	Protocols
	Protocol

Command		md_0_1.xtc -s md	0.1	top -o pred viva
gmx rm	s -т	ma_o_r.xcc -s ma	_⊎_т	.tpr -o rmsa.xvg
Reading	file	md 0 1.tpr. VERS	ION :	2022 (single precisio
Reading	file	md 0 1.tpr. VERS	ION	2022 (single precisio 2022 (single precisio
Select o	roup	for least squares	s fit	E
Group	Θ			313022 elements
Group	1			16784 elements
Group	2			8468 elements
Group	3	(C-alpha)		1104 elements
Group	4	Backbone)		3312 elements
Group	56	(MainChain)		4418 elements
Group	6	(MainChain+Cb)	has	5408 elements
Group	7	(MainChain+H)		5443 elements
Group	8	(SideChain)	has	11341 elements
Group	9		has	4050 elements
Group	10		has	16784 elements
Group	11	(non-Protein)		296238 elements
Group	12	(Water)		295659 elements
Group	13	(SOL)	has	295659 elements
Group	14	(non-Water)		17363 elements
Group	15	(Ion)	has	579 elements
Group	15 16	CAN D	has	289 elements
Group	17	(CL)	has	290 elements
Group	18	(Water_and_ions)	has	296238 elements
Select a	qro	up: 4		
		'Backbone'		
Select q	roup	for RMSD calculat	tion	
Group	Ø			313022 elements
Group	1			16784 elements
Group	2	(Protein-H)		8468 elements
Group	3 4	(C-alpha)	has	1104 elements
Group	4	(Backbone)		3312 elements
Group	5	(MainChain)		
Group	6			5408 elements
Group	7	(MainChain+H)		5443 elements
Group	8	(SideChain)	has	11341 elements
Group	9	(SideChain-H)		4050 elements
Group	10			16784 elements
Group	11	(non-Protein)		296238 elements
Group	12	(Water)		295659 elements
Group	13			295659 elements
Group	14			17363 elements
Group	15			
	16		has	
Group	17			290 elements
Group		(Water_and_ions)	has	296238 elements
Select a				
Salacted	4:	'Backbone'		
Last fra		1000 time 50		




Figure 35. RMSD determination of predicted MPXV vaccine

Time-Dependent RMSD graph and probability distribution analysis for structural stability assessment.

- (A) Screenshot for backbone selection to calculate RMSD.
- (B) RMSD graph.
- (C) Probability distribution command.

Select index group, enter "19" to select "C-alpha" option for both 'least squares fit in g_covar' and 'elements that corresponds to the eigenvectors' respectively (Figure 42C and 42D).

- g. Open the proj_evl.xvg and proj_evl2.xvg files, and copy the data into Excel (Figure 43A).
- h. Remove the time frame (first column) and keep only the data from the second column in each file.
- i. Paste this data into GraphPad Prism to create a scatter plot (Figure 43B and 43C).

Note: Here we have assigned the data from proj_eval as PC1 and from proj_eval2 as PC2.

j. Generate the MD simulation trajectory movie, executing the commands one after the other. Remove the PBC artifacts and center the molecule in the box to create a "cleaned" trajectory by running the command.


gmx trjconv -f md_0_1.xtc -s md_0_1.tpr -o md_pbc.pdb -pbc mol -center

k. Convert the trajectory to a PDB format movie based on specific groups from the index file.

gmx trjconv -f md_ pbc.xtc -s md_0_1.tpr -o movie.pdb -n index.ndx



Command		/mnt/d/Anupan/n	onke	y_pox_data/FINAL VACCINE/MD simulation/TLR4-V2
				0 1.tpr -o rg.xvg
giiix g	yrace -	T WU_0_1.XCC -S	110_	e_1.cpr =o ig.xvg
Reading	file m	d_0_1.tpr, VERS	ION :	2022 (single precision)
Reading	file m	d_0_1.tpr, VERS	ION	2022 (single precision)
Group	Θ(313022 elements
Group	1 (Protein)	has	16784 elements
Group	2 (Protein-H)	has	8468 elements
Group	3 (C-alpha)	has	1104 elements
Group	4 (has	3312 elements
Group	5 (4418 elements
Group	6 (5408 elements
Group	7 (5443 elements
Group	8 (11341 elements
Group	9 (4050 elements
Group	10 (16784 elements
Group				296238 elements
Group	12 (295659 elements
Group	13 (295659 elements
Group				17363 elements
Group				579 elements
Group	16 (289 elements
Group	17 (290 elements
Group			has	296238 elements
	a group			
	d 1: 'P			
		0 time		00 to ./#rg.xvg.1#



С

set	average	standard deviation	sqrt(n-1)		from those o distribitio
				cum. 3	cum. 4
SS1	3.454537e+00	5.722499e-02	1.809613e-03	0.119	-0.217
SS2	2.825511e+00	6.144906e-02	1.943190e-03	-0.774	0.782
SS3	2.500846e+00	8.315981e-02	2.629744e-03	0.203	-0.237
SS4	3.100749e+00	1.054625e-01	3.335017e-03	-0.466	0.194
Makir	na distribution	s with 16 bins			





Figure 36. Determination of Rg

- (A) Calculation of Rg.
- (B) R_g graph.
- (C) Probability distribution command.
- (D) Probability distribution graph.

		~		_			
			_0_1.tpr, VERS				
			_0_1.tpr, VERS				
2	Select g		for root mean				
	Group	Θ(
0	Group	1 (Protein)	has	16784	elemer	nts
0	Group	2 (Protein) Protein-H)	has	8468	elemer	nts
0	Group	3 (C-alpha)	has	1104	elemer	nts
0	Group	4 (Backbone)	has	3312	elemer	nts
0	Group	5 (MainChain)	has	4418	elemer	nts
0	Group	6 (MainChain+Cb)	has	5408	elemer	nts
0	Group	7 (MainChain+H)				
0	Group	8 (SideChain)	has	11341	elemer	nts
0	Group	9 (SideChain-H)	has	4050	elemer	nts
0	Group	10 (Prot-Masses)				
0	Group	11 (non-Protein)	has	296238	3 eleme	ents
0	Group	12 (Water)		295659		
0	Group	13 (SOL)	has	295659	eleme	ents
0	Group	14 (SOL) non-Water)	has	17363	elemer	nts
	Group				579		
0	Group	16 (NA)	has	289	elemer	nts
0	Group	17 (CL)	has	290	elemer	nts
0	Group	18 (W	ater_and_ions)	has	296238	3 eleme	ents
	Select a						
	Selected						
			1000 time 50	000.0	000		

Figure 37. Determination of RMSF


Analysis of RMSF and its graph of predicted vaccine candidate. (A) Screenshot to select C-alpha option RMSF. (B) RMSF graph.







A Command line:
gmx sasa -f md_0_1.xtc -s md_0_1 -o sasa.xvg
Reading file md_0_1.tpr, VERSION 2022 (single precision)
Reading file md_0_1.tpr, VERSION 2022 (single precision)
Available static index groups:
Group 0 "System" (313022 atoms)
Group 1 "Protein" (16784 atoms)
Group 2 "Protein-H" (8468 atoms)
Group 3 "C-alpha" (1104 atoms)
Group 4 "Backbone" (3312 atoms)
Group 5 "MainChain" (4418 atoms)
Group 6 "MainChain+Cb" (5408 atoms)
Group 7 "MainChain+H" (5443 atoms)
Group 8 "SideChain" (11341 atoms)
Group 9 "SideChain-H" (4050 atoms)
Group 10 "Prot-Masses" (16784 atoms)
Group 11 "non-Protein" (296238 atoms)
Group 12 "Water" (295659 atoms)
Group 13 "SOL" (295659 atoms)
Group 14 "non-Water" (17363 atoms)
Group 15 "Ion" (579 atoms)
Group 16 "NA" (289 atoms)
Group 17 "CL" (290 atoms)
Group 18 "Water_and_ions" (296238 atoms)
Specify a selection for option 'surface'
(Surface calculation selection):
<pre>(one per line, <enter> for status/groups, 'help' for help)</enter></pre>
> 8
Selection '8' parsed



с




Figure 38. Determination of solvent accessibility by SASA analysis (A) Selection of side chain for SASA analysis.

(B) SASA graph.

- (C) Probability distribution command of SASA.
- (D) Probability distribution graph of SASA.

Δ	Command	lin	e:								
A	gmx hb	ond	-f	md_0_1.xtc -s r	nd_0	1.tpr	-num prote	ein.xvg			
	Reading	fil	e md	_0_1.tpr, VERS	ION 2	2022 (s:	ingle pred	ision)			
				s to analyze:							
	Group			System)	has	313022	elements				
	Group	1		Protein)							
	Group	2	C	Protein-H)	has	8468	elements				
	Group	3	C	C-alpha)	has	1104	elements				
	Group	4	C	Backbone)	has	3312	elements				
	Group	5	C	MainChain)	has	4418	elements				
				MainChain+Cb)	has	5408	elements				
	Group	7	C	MainChain+H)	has	5443	elements				
	Group	8	C	SideChain)	has	11341	elements				
	Group	9	C	SideChain-H)	has	4050	elements				
	Group		C								
	Group	11	C	non-Protein)	has	296238	elements				
	Group	12	C	Water)	has	295659	elements				
	Group	13	C				elements				
	Group	14	C	non-Water)	has	17363	elements				
		15					elements				
	Group	16	C				elements				
	Group						elements				
	Group			later_and_ions)	has	296238	elements				
	Select a										
	Selected										
	Select a										
	Selected										
				verlap in atoms							
	Calculat	ing	hyd	rogen bonds bet	twee	n Prote	in (16784	atoms)	and SOL	(295659	at




Figure 39. H-bond analysis

(A) Selection of protein and SOL groups for H-bond determination. (B) H-bond graph.



120. Clustering.

a. Perform clustering on the generated trajectory movie.

```
gmx cluster -f md_0_1.xtc -s md_0_1.tpr -o cluster15_4.xpm -g cluster15_4.log -sz clus-
ter15_4.xvg -cl cluster15_4.pdb -cutoff
```

- b. Select group for least square fit and RMSD calculation, enter value "4" to select ``backbone'' option (Figures 44A and 44B).
- c. Copy and paste the data from the Cluster15_4.xvg file to an Excel sheet and calculate the percentage of each cluster # and arrange them in decreasing order on the basis of their # structures (Figures 45A and 45B).
- d. The cluster # with the highest percentage of structure # is microstate m1. Open the cluster15_4.pdb to fetch the m1 microstate.
- e. Edit the chain color for better visualization in PyMOL and save it as m1.pdb (Figures 45C and 45D).

Part 11: Backtranslation and codon optimization

© Timing: 3 h

This section details the procedure to perform and analyze backtranslation and codon optimization of the designed vaccine sequence to perform *in silico* cloning in subsequent steps.

121. Convert the protein to nucleotide sequence using EMBOSS Backtranseq webserver (Figure 46A).

	B Command line: gmx covar -f md_0_1.xtc -s md_0_1.tpr -n c_alpha.ndx -o eigenval.xvg -v eigenval.trr -l cc	ovar.log -xpm covar
Command line: gmx make_ndx -f npt.gro -o c_alpha.ndx	Reading file md_0_1.tpr, VERSION 2022 (single precision) Reading file md_0_1.tpr, VERSION 2022 (single precision)	
Reading structure file Going to read 0 old index file(s) Analysing residue names: There are: 1044 Protein residues There are: 1044 Protein residues There are: 579 Ion residues Analysing Protein Analysing residues not classified as Protein/DNA/RNA/Wat 0 System : 313022 atoms 1 Protein-H : 8468 atoms 3 C-alpha : 1104 atoms 4 Backbone : 3312 atoms 5 MainChain-Ch : 54008 atoms 7 MainChain-Ch : 54008 atoms 8 SideChain : 11341 atoms 9 SideChain : 4059 atoms 10 Prot-Masses : 106784 atoms	Choose a group for the least squares fit Group 0 (System) has 13020 elements Group 1 (System) has 13020 elements Group 3 (System) has 13020 elements Group 3 (System) has 13120 elements Group 4 (Backdown) has 3312 elements Group 5 (HainChainChain has 3312 elements Group 5 (HainChainChain has 1308 elements Group 5 (Sistechain-1) has 1308 elements Group 5 (Sistechain-1) has 1308 elements Group 7 (Sistechain-1) has 1308 elements	
11 non-Protein : 29633 atoms 12 Water : 295459 atoms 13 SOL : 295659 atoms 14 non-Water : 17453 atoms 15 Ion : 579 atoms 16 NA : 289 atoms	C Back Off! I just backed up average.pdb to ./#average.pdb.2# Constructing covariance matrix (3312x3312) Last frame 1000 time 50000.000 Read 1001 frames	
17 CL : 290 atoms 18 Water_and_ions : 296238 atoms	Trace of the covariance matrix: 137.893 (nm^2)	
nr:group '!':not 'name'nrname 'splitch'nr 'a':atom '5':and 'del'nr 'splitres'n 't':atom kype 'l':or 'keep'nr 'splitat'nr 'r:residue 'res'nr 'chain'char 'rase":group 'case':case sensitive	Enter: list groups 'l': list residues 'h': help 'g': save and quit Back OFF! I just backed up covar.xpm to ./#covar.xpm.l# D00% Diagonalizing Sum of the eigenvalues: 137.893 (nm^2)	
'ri': residue index > 3	WARNING: there are fewer frames in your trajectory than there ar degrees of freedom in your system. Only generating the first 1000 out of 3312 eigenvectors and eigenvalues.	e
Copied index group 3 'C-alpha'	Writing eigenvalues to eigenval.xvg	
19 C-alpha : 1104 atoms	Writing reference, average structure & eigenvectors 11000 to e	igenval.trr
	Back Off! I just backed up eigenval.trr to ./#eigenval.trr.1#	

Figure 40. Commands for PCA plot

- (A) Screenshot for selection of C-alpha for PCA plot generation.
- (B) Screenshot of C-alpha selection for covariance analysis.
- (C) Screenshot showing sum of eigen values.



Protocol




Figure 41. PCA of the designed vaccine

PCA analysis was performed and generated a movie of the MD simulation trajectory.

(A) Data extraction from eigen value files.

(B) Auto sum of eigen values.

(C) Plot of eigen values in graph pad prism.

(D) Graph of eigen values vs. eigen vector index.

- 122. Submit the protein sequence in FASTA format in the "Input sequence" column of the webserver.
- 123. Choose the "Escherichia coli K12" option from the dropdown list of "codon table" and "Submit" to get results in DNA format (Figures 46B and 46C).
- 124. Copy the viewed result (vaccine construct sequence) in a Word file (Figure 46D).
- 125. Access the Codon Optimization Tool from the VectorBuilder webserver (Figure 47A).
- 126. Paste the DNA sequence for the vaccine construct, selecting "DNA/RNA sequence," and choose "Escherichia coli K-12" as the organism (Figure 47B).
- 127. Click on submit button. Your results will be displayed in FASTA format. Save the sequence for further analysis (Figure 47C).

Part 12: In silico cloning

© Timing: 2 h


This section details the procedure to perform in silico cloning of the optimized sequence in pET-28a.

- 128. Download and install SnapGene (Figure 48A).
- 129. Open the application go to new select DNA file (Figure 48B).
- 130. Paste your sequence (codon-optimized)- Click on create (Figures 48C and 48D).

Note: If no restriction is available at start and end sites create restriction sites at starting and ending positions. Here, since the first nucleotide is G we added Ncol site at start position (CCATGG) and we added BamHI site (GGATCC) as the last nucleotide was G.

Protocol





	an index group of 1104 elements that corresponds to the eigenve
Group	0 (System) has 313022 elements 1 (Protein) has 16784 elements
Group	2 (Protein-H) has 8468 elements
Group	3 (C-alpha) has 1104 elements
Group	4 (Backbone) has 3312 elements
Group	5 (MainChain) has 4418 elements
Group	6 (MainChain+Cb) has 5408 elements
Group	7 (MainChain+H) has 5443 elements
Group	8 (SideChain) has 11341 elements
Group	9 (SideChain-H) has 4050 elements
Group	10 (Prot-Masses) has 16784 elements
Group	11 (non-Protein) has 296238 elements
Group	12 (Water) has 295659 elements
Group	13 (SOL) has 295659 elements
Group	14 (non-Water) has 17363 elements
Group	15 (Ion) has 579 elements
Group	16 (NA) has 289 elements
Group	17 (CL) has 290 elements
Group	18 (Water_and_ions) has 296238 elements
Group	19 (C-alpha) has 1104 elements
	a group: 19
Select	ed 19: 'C-alpha'
1 eige	nvectors selected for output: 1
	g rmsf to rmsf_evl.xvg
WI I CIN	g 1m31 co 1m31_cvc.xvg
Pack O	ff! I just backed up rmsf_evl.xvg to ./#rmsf_evl.xvg.3#
Dack U	IT: I Just backed up Imst_evt.xvg to ./#Imst_evt.xvg.s#
Last f	rame 1000 time 50000.000
	an index group of 1104 elements that corresponds to the eigenvecto
Group	0 (System) has 313022 elements
Group Group	0 (System) has 313022 elements
Group Group Group	0 (System) has 313022 elements 1 (Protein) has 16784 elements 2 (Protein-H) has 2468 elements
Group Group Group Group	0 (System) has 313022 elements 1 (Protein) has 16784 elements 2 (Protein-H) has 8468 elements 3 (C-alpha) has 1104 elements
Group Group Group Group Group	0 (System) has 313022 elements 1 (Protein) has 16784 elements 2 (Protein+H) has 8468 elements 3 (C-alpha) has 1184 elements 4 (Backbone) has 3312 elements
Group Group Group Group Group Group	0 (System) has 313022 elements 1 (Potein) has 105784 elements 2 (Potein) has 8468 elements 3 (C-alpha) has 31104 elements 4 (Backbone) has 3312 elements 5 (MairChain) has 4312
Group Group Group Group Group Group	0 (System) has 13022 elements 1 (Protein) has 10528 elements 2 (Protein-H) has 8468 elements 3 (C-alpha) has 3112 elements 4 (Backbons) has 3112 elements 5 (Waindhainach) has 5318 elements 6 (Waindhainach) has 5318 elements
Group Group Group Group Group Group Group	0 (System) has 13022 elements 1 (Protein) has 10528 elements 2 (Protein-H) has 8468 elements 3 (C-alpha) has 3112 elements 4 (Backbons) has 3112 elements 5 (Waindhainach) has 5318 elements 6 (Waindhainach) has 5318 elements
Group Group Group Group Group Group Group Group	0 (System) has 13022 elements 1 (Pottin) has 10524 elements 2 (Pottin) has 8468 elements 3 (Calpha) has 3112 elements 4 (Backbono) has 3112 elements 5 (Kalpha) has 5112 elements 5 (Kalpha) has 5112 elements 5 (Kalpha) has 5443 elements 5
Group Group Group Group Group Group Group Group Group	0 (System) has 313922 elements 1 (Potein) has 105784 elements 2 (Potein) has 8068 elements 3 (C-alpha) has 3104 elements 4 (Backbone) has 3312 elements 5 (MainChain) has 3132 elements 6 (MainChain) has 5008 elements 7 (MainChain) has 11341 elements 8 (SideChain) has 11341 elements 9 (SideChain) has 11341 elements
Group Group Group Group Group Group Group Group Group	0 (System) has 313022 elements 1 (Protein) has 10302 elements 2 (Protein) has 8468 elements 3 (C-alpha) has 8468 elements 4 (Backbone) has 3312 elements 5 (MainChain) has 3408 elements 6 (MainChain) has 5408 elements 6 (SideChain) has 1041 elements 7 (SideChain) has 4058 elements 9 (SideChain) has 4058 elements 9 (SideChain) has 1058 elements
Group Group Group Group Group Group Group Group Group Group	0 (System) has 313922 elements 1 (Protein) has 105784 elements 2 (Protein) has 8068 elements 3 (C-alpha) has 3104 elements 4 (Backbone) has 3312 elements 5 (MainChain) has 3132 elements 6 (MainChain) has 5008 elements 7 (MainChain) has 11341 elements 8 (SideChain) has 11341 elements 9 (SideChain) has 11341 elements 10 (Prot-Masses) has 16784 elements 11 (non-Protein) has 596238 elements
Group Group Group Group Group Group Group Group Group Group Group	0 (System) has 313022 elements 1 (Protein) has 10302 elements 2 (Protein) has 8068 elements 3 (C-alpha) has 8068 elements 4 (Backbone) has 3312 elements 5 (MainChain) has 3018 elements 6 (MainChain) has 5008 elements 7 (MainChain) has 1001 elements 9 (SideChain+1) has 4050 elements 9 (SideChain+1) has 4050 elements 9 (SideChain+1) has 20528 elements 11 (non-Protein) has 29528 elements 12 (Water) has 29559 elements
Group Group Group Group Group Group Group Group Group Group Group Group	0 (System) has 313022 elements 1 (Protein) has 113022 elements 2 (Protein) has 3068 elements 3 (C-alpha) has 3068 elements 4 (C-alpha) has 3068 elements 5 (MainChain) has 4048 elements 6 (MainChainnch) has 4048 elements 6 (MainChainnch) has 5048 elements 7 (MainChainnh) has 5048 elements 8 (SideChain) has 1041 elements 9 (SideChain) has 4050 elements 9 (SideChain) has 4050 elements 9 (SideChain) has 5048 elements 10 (Prot-Haises) has 10508 elements 11 (non-Priview) has 295659 elements 13 (SiQ) has 295659 elements
Group Group Group Group Group Group Group Group Group Group Group Group	0 (System) has 313022 elements 1 (Protein) has 10302 elements 2 (Protein) has 8068 elements 3 (C-alpha) has 8068 elements 4 (Backbone) has 3312 elements 5 (MainChain) has 3312 elements 6 (MainChain) has 1034 elements 8 (SideChain) has 1134 elements 8 (SideChain) has 1134 elements 9 (SideChain) has 1134 elements 8 (SideChain
Group Group Group Group Group Group Group Group Group Group Group Group Group	0 (System) has 313022 elements 1 (Protein) has 10302 elements 2 (Protein) has 8068 elements 3 (C-alpha) has 3131 elements 4 (Rackbono) has 3131 elements 4 (Rackbono) has 3131 elements 5 (MainGchainch) has 5008 elements 6 (MainGchainch) has 5008 elements 7 (MainGchainch) has 5008 elements 8 (SideChain) has 5008 elements 9 (SideChain) has 1034 elements 9 (SideChain) has 5098 elements 10 (Prot-Hassen) has 10508 elements 11 (non-Protein) has 250238 elements 12 (SideChain) has 250238 elements 13 (non-Protein) has 250238 elements 14 (non-Mates) has 17563 elements 15 (In) has 579 elements
Group Group Group Group Group Group Group Group Group Group Group Group Group	0 (System) has 13022 elements 1 (Protein) has 10502 elements 2 (Protein) has 1054 elements 3 (C-alpha) has 8168 elements 4 (Backbone) has 3312 elements 5 (MainChain has 1314 elements 6 (MainChain has 1314 elements 7 (MainChain has 1314 elements 8 (SideChain has 1314 elements 9 (SideChain has 1314 elements 9 (SideChain has 1314 elements 10 (SideChain has 1314 elements 11 (Mos elements 12 (SideSide elements 13 (SideSide elements 14 (mon-Waters) has 195659 elements 15 (Ion) has 579 elements 15 (Ma) has 298 elements
Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group	0 (System) has 13922 elements 1 (Protein) has 13922 elements 2 (Protein) has 8468 elements 3 (C-alpha) has 3112 elements 4 (Backbono) has 3112 elements 5 (Kaindhainch) has 3112 elements 6 (Maindchainch) has 5488 elements 5 (Maindchainch) has 5488 elements 5 (Stadchain) has 9488 elements 9 (Stadchain) has 9488 elements 9 (Stadchain) has 9488 elements 10 (Prot-Hasses) has 1394 elements 11 (non-Protein) has 29623 elements 13 (Statc) has 295659 elements 13 (Matc) has 295659 elements 14 (non-Hackb) has 2978 elements 15 (Matc) has 2989 elements 16 (Ma) has 298 elements 16 (Ma) has 298 elements 16 (Ma) has 298 elements
Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group	0 (System) has 313022 elements 1 (Protein) has 10302 elements 2 (Protein) has 8068 elements 3 (C-alpha) has 8068 elements 4 (Backbone) has 3312 elements 5 (MainChain) has 3312 elements 6 (MainChain) has 1034 elements 6 (SideChain) has 1039 elements 8 (SideChain) has 1039 elements 9 (SideChain) has 1039 elements 10 (Prot-Masses) has 10703 elements 11 (Nort-Masses) has 10703 elements 12 (Nort-Masses) has 10703 elements 13 (Mater, and, and
Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group	0 (System) has 13022 elements 1 (Protein) has 13022 elements 2 (Protein) has 1064 elements 3 (C-alpha) has 312 elements 4 (Backbono) has 312 elements 5 (Mainfordini) has 312 elements 5 (Mainfordini) has 5043 elements 5 (Mainfordini) has 5043 elements 6 (SideChain, has 1050 elements 9 (SideChain, ha) has 1050 elements 10 (Prot-Hasses) has 1050 elements 11 (non-Protein) has 296238 elements 12 (Mater) has 296509 elements 13 (Souther States) has 1753 elements 14 (non-Mater) has 29650 elements 15 (Amon, has 5961 elements 16 (Non has 5961 elements 17 (C) has 2966 elements 18 (Mater, and Jonn) has 296238 elements 19 (C-alpha) has 1040 elements 10 (Note, and 1040 elements 10 (C) has 19620 elements 10 (Note, and 1040 elements 10 (C) has 19620 elements 10 (C) has 1
Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group	0 (System) has 313922 elements 1 (Protein) has 113922 elements 2 (Protein) has 11394 elements 3 (C - Alpha) has 8168 elements 4 (C - Alpha) has 11394 elements 5 (C - Alpha) has 11394 elements 5 (MainChainn) has 40418 elements 6 (MainChainn) has 40418 elements 6 (MainChainn) has 5048 elements 7 (MainChainn) has 5048 elements 8 (SideChain) has 5048 elements 9 (SideChain) has 5048 elements 9 (SideChain) has 4050 elements 10 (Prot-Hasses) has 10508 elements 11 (non-Waters) has 7058 elements 13 (SoU) has 295659 elements 14 (non-Waters) has 1755 elements 15 (10n) has 299 elements 16 (Mater_and_ince) has 1203 elements 16 (Mater_and_ince) has 1203 elements 16 (Mater_and_ince) has 1203 elements 16 (Mater_and_ince) has 1204 elements 19 (C-alpha) has 1104 elements 19 (C-alpha) has 1104 elements
Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group	0 (System) has 13022 elements 1 (Protein) has 13022 elements 2 (Protein) has 1064 elements 3 (C-alpha) has 312 elements 4 (Backbono) has 312 elements 5 (Kalinchain) has 312 elements 5 (Kalinchain) has 5043 elements 6 (SideChain has 1304 elements 7 (NainChainth) has 5043 elements 8 (SideChain has 1304 elements 9 (SideChain has 1304 elements 10 (Prot-Hasses) has 1304 elements 11 (non-Protein) has 296238 elements 12 (Mater) has 296539 elements 13 (Soll has 295639 elements 14 (non-Mater) has 29658 elements 15 (Jon has 596 elements 16 (Jon has 596 elements 17 (C) has 296 elements 18 (Water, and Jonn) has 296238 (lements 19 (C-alpha) has 104 elements 10 (C) has 196238 (lements) 10 (C) has 196238 (lements) 10 (C) has 196238 (lements) 10 (C) (C) has 196238 (lements) 10 (C) has 196238 (lements) 10 (C) (C) has 196238 (lements) 10 (C) has 196238 (l
Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Steet Select	0 (System) has 313922 elements 1 (Protein) has 113922 elements 2 (Protein) has 8068 elements 3 (C-alpha) has 8068 elements 4 (Nacchonon has 31118 elements 5 (Katchain-Ch) has 31118 elements 6 (MainGchain-Ch) has 3018 elements 7 (MainGchain-Ch) has 5008 elements 8 (SideChain) has 5008 elements 9 (SideChain-H) has 9089 elements 9 (SideChain-H) has 9090 elements 10 (Prot-Hasses) has 1750 elements 11 (non-Protein) has 396398 elements 13 (South System) has 1763 elements 14 (non-Wates) has 1763 elements 15 (Ion) has 299 elements 16 (Noh has 289 elements 16 (C) has 290 elements 17 (C) has 396398 elements 18 (Water_and_ions) has 1000 elements 18 (Water_and_ions) has 1000 elements 19 (C-alpha)
Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group Group	0 (System) has 13022 elements 1 (Protein) has 13022 elements 2 (Protein) has 1084 elements 3 (C-alpha) has 8068 elements 4 (Backbone) has 3312 elements 5 (MainChain) has 3000 elements 6 (MainChain) has 3000 elements 6 (SideChain) has 1041 elements 7 (SideChain) has 1050 elements 9 (SideChain) has 1050 elements 10 (Prot-Hassea) has 1050 elements 11 (non-Protein) has 296509 elements 12 (Water) has 296509 elements 13 (SOL) has 296509 elements 15 (Ion) has 579 elements 15 (Ion) has 299 elements 16 (MA has 299 elements 17 (Water_mod_ion) has 209 elements 16 (Calpha) has 1104 elements 17 (Calpha'
Group 1 Group	0 (System) has 313922 elements 1 (Protein) has 113922 elements 2 (Protein) has 8068 elements 3 (C-alpha) has 8068 elements 4 (Nacchonon has 31118 elements 5 (Katchain-Ch) has 31118 elements 6 (MainGchain-Ch) has 3018 elements 7 (MainGchain-Ch) has 5008 elements 8 (SideChain) has 5008 elements 9 (SideChain-H) has 9089 elements 9 (SideChain-H) has 9090 elements 10 (Prot-Hasses) has 1750 elements 11 (non-Protein) has 396398 elements 13 (South System) has 1763 elements 14 (non-Wates) has 1763 elements 15 (Ion) has 299 elements 16 (Noh has 289 elements 16 (C) has 290 elements 17 (C) has 396398 elements 18 (Water_and_ions) has 1000 elements 18 (Water_and_ions) has 1000 elements 19 (C-alpha)
Group Group	0 (System) has 313022 elements 1 (Protein) has 10302 elements 2 (Protein) has 1040 elements 3 (C-alpha) has 3104 elements 4 (Backbone) has 3312 elements 5 (MainChain) has 3104 elements 6 (MainChain) has 3000 elements 7 (MainChain) has 3000 elements 8 (SideChain+1) has 40050 elements 9 (SideChain+1) has 40050 elements 10 (Prot-Massen) has 10500 elements 11 (non-Protein) has 296230 elements 12 (Water) has 296509 elements 13 (SOL) has 295659 elements 14 (non-Mater) has 195630 elements 15 (Ion) has 579 elements 16 (NA) has 290 elements 16 (NA) has 290 elements 18 (Water_and_ion) has 1040 elements 19 (C-alpha) has 1104 elements 19 (C-alpha) 20 (SCL) has 290 elements 10 (SCL) has 290 elements 10 (C-alpha) 20 (SCL) has 2000 (SCL) has 1000 elements 10 (SCL) has 290 elements 10 (C-alpha) 20 (SCL) has 1040 elements 20 (SCL) has 290 elements 2
Group Group	0 (System) has 13022 elements 1 (Protein) has 13022 elements 2 (Protein) has 1084 elements 3 (C-alpha) has 8068 elements 4 (Backbone) has 3312 elements 5 (MainChain) has 3000 elements 6 (MainChain) has 3000 elements 6 (SideChain) has 1041 elements 7 (SideChain) has 1050 elements 9 (SideChain) has 1050 elements 10 (Prot-Hassea) has 1050 elements 11 (non-Protein) has 296509 elements 12 (Water) has 296509 elements 13 (SOL) has 296509 elements 15 (Ion) has 579 elements 15 (Ion) has 299 elements 16 (MA has 299 elements 17 (Water_mod_ion) has 209 elements 16 (Calpha) has 1104 elements 17 (Calpha'
Group Group	0 (System) has 313022 elements 1 (Protein) has 10302 elements 2 (Protein) has 1040 elements 3 (C-alpha) has 3104 elements 4 (Backbone) has 3312 elements 5 (MainChain) has 3104 elements 6 (MainChain) has 3000 elements 7 (MainChain) has 3000 elements 8 (SideChain+1) has 40050 elements 9 (SideChain+1) has 40050 elements 10 (Prot-Massen) has 10500 elements 11 (non-Protein) has 296230 elements 12 (Water) has 296509 elements 13 (SOL) has 295659 elements 14 (non-Mater) has 195630 elements 15 (Ion) has 579 elements 16 (NA) has 290 elements 16 (NA) has 290 elements 18 (Water_and_ion) has 1040 elements 19 (C-alpha) has 1104 elements 19 (C-alpha) 20 (SCL) has 290 elements 10 (SCL) has 290 elements 10 (C-alpha) 20 (SCL) has 2000 (SCL) has 1000 elements 10 (SCL) has 290 elements 10 (C-alpha) 20 (SCL) has 1040 elements 20 (SCL) has 290 elements 2
Group Group	0 (System) has 313922 elements 1 (Protein) has 11392 elements 2 (Protein) has 11394 elements 3 (C - Alpha) has 8068 elements 4 (C - Alpha) has 11394 elements 5 (MainChain) has 4048 elements 6 (MainChainnCh) has 4048 elements 7 (MainChainnCh) has 5048 elements 8 (SideChain) has 5048 elements 9 (SideChain) has 5048 elements 9 (SideChain) has 5048 elements 10 (Prot-Hasses) has 13078 elements 11 (non-Water) has 595659 elements 12 (SoU) has 295659 elements 13 (SoU) has 295659 elements 14 (non-Water) has 13052 elements 15 (Ion) has 5956 elements 16 (Mater_and_ion) has 1104 elements 19 (C-alpha) has 1104 elements 19 (C-alpha) has 1104 elements 19 (C-alpha) has 1104 elements 19 (C-alpha) 10 (C-alpha) has 1104 elements 10 (Josepha' 10 (Josepha' 10 (Josepha') 10 (Josepha') 11 (Josepha') 11 (Josepha') 12 (Josepha') 13 (Josepha') 14 (Josepha') 15 (Josepha') 15 (Josepha') 16 (Josepha') 17 (Josepha') 17 (Josepha') 18 (Josepha') 19 (Josepha') 19 (Josepha') 10 (Josepha')

Figure 42. Generation of eigen vector 1 and 2 values (A and B) Selection of index group for eigen vector 1. (C and D) Selection of index group for eigen vector 2.

- 131. Save the file in SnapGene extention format: filename.dna (here mpox.dna) (Figure 18E).
- 132. Download the vector of your interest from SnapGene (here pET-28a+ is used) and save it as a new sequence file pET-28a(+).dna (Figure 49A).
- 133. Open pET-28a (+).dna file. Go to actions- click on restriction cloning- select insert fragment (Figures 49B and 49C).
- 134. Three tabs will open: Vector, Fragment, Product.
- 135. Add restriction sites of your interest (in this case Ncol and BamHI) in the dialogue box of Vector tab and select the region to replace (Figure 49D).
- 136. Go to fragment tab and add the same restriction enzymes that are used to cut the vector and select the region to replace (Figures 50A and 50B).
- 137. Name the clone (Cloned.dna) and select clone in the fragment tab (Figure 50C).
- 138. Go to product tab and save the clone (Figure 50D).


Part 13: Immune simulation

© Timing: 30 min

This section enlists the procedure to perform in silico immune simulation of the designed vaccine.

- 139. Utilize C-ImmSim server to investigate the designed multi-epitope vaccine's immunogenic response (Figure 51A).
- 140. Open the C-ImmSim site and paste the designed protein sequence in "Protein N.1" column.
- 141. Time step of injection should be 1. Rest all parameters will be default.








Figure 43. Generation of PCA plot (A and B) Extraction of PC1 and PC2 values. (C) Graph PC1 vs. PC2.

- 142. For booster doses (Injection N. 2), click "Add Ag Molecule" and keep all parameters at their default settings, except for the injection time step.
- 143. Set injection time step to 31 (the day of the booster dose) (Figure 51B).
- 144. Click on "SUBMIT JOB" and the results will be displayed (Figure 51C).

EXPECTED OUTCOMES

The protocol outlines a roadmap for constructing a multi-epitope vaccine against the MPXV by integrating distinct peptide epitopes with high immunogenicity and antigenicity. Six MPXV glycoprotein were used to predict seven T cell (CTL and HTL), thirteen B cell and five IFN-gamma specific epitopes. These epitopes have potential to bind to multi-MHC alleles and elicit higher immune response. The immune response was further enhanced by cohesively incorporating PADRE peptide as an adjuvant. To cohesively join the adjuvant, epitopes, and linkers (EAAAK, GPGPG and AAY) were used to construct a multi epitope-based peptide subunit vaccine. 3D structure prediction of the constructed vaccine was performed along with physicochemical characterization. Further molecular docking and MD simulation were applied to study the interaction between the vaccine and receptors (TLR-family, MHC class I and II) at atomic level. These studies predict an enhanced immune response through increased activation of immune cells, elevated production of cytokines, and higher IgG and IgM production eliciting an amplified immune response after a booster dose administration. This study is insightful and highly valuable for utilizing a reverse vaccine technology approach to design and validate a novel, robust peptide-based multi-epitope vaccine against global outbreaks of rapidly mutating viruses.

LIMITATIONS

Reverse vaccine technology is a potent tool and multidisciplinary approach paired with experimental validation for designing a multi-epitope-based vaccine. The predictive algorithms may sometimes lead to inaccurate recognition of the epitopes. The variation in MHC molecules can influence the vaccine's potency among populations. Predictions usually consider a restricted set of HLAs for



n1_TLR4 5_4.xvg	-V2\$ gm	KTOP-10HH405:/mmt/d/Anupam/Monkey_pox_data/FINAL_VACCINE/MD_simulation/TLR4-V2/sin x_cluster -f md_0_1.xtc -s md_0_1.tpr -o_cluster15_4.xpm -g_cluster15_4.log -sz_cl uster15_4.pdb -cutoff	
0.15		:-) GROMACS - gmx cluster, 2022 (-:	
Executa	hle:	/usr/local/gromacs/bin/gmx	
		/usr/local/gromacs	
		/mnt/d/Anupam/Monkey_pox_data/FINAL VACCINE/MD simulation/TLR4-V2/simulation1_TLR4	I-V2
Command		/	
		-f md_0_1.xtc -s md_0_1.tpr -o cluster15_4.xpm -g cluster15_4.log -sz cluster15_4. pdb -cutoff 0.15	xvg -o
Usina l	inkage	method for clustering	
		d_0_1.tpr, VERSION 2022 (single precision)	
		d_0_1.tpr, VERSION 2022 (single precision)	
-			
	group f	or least squares fit and RMSD calculation:	
Group	Θ(System) has 313022 elements	
Group	1 (Protein) has 16784 elements	
Group	2 (Protein-H) has 8468 elements	
Group	3 (C-alpha) has 1104 elements	
Group	4 (Backbone) has 3312 elements	
Group	5 (MainChain) has 4418 elements	
Group	6 (MainChain+Cb) has 5408 elements	
Group	7 (MainChain+H) has 5443 elements	
Group	8 (SideChain) has 11341 elements	
Group	9 (SideChain-H) has 4050 elements	
Group	10 (Prot-Masses) has 16784 elements	
Group	11 (non-Protein) has 296238 elements	
Group	12 (Water) has 295659 elements	
Group	13 (SOL) has 295659 elements	
Group	14 (
Group	15 (Ion) has 579 elements	
Group	16 (NA) has 289 elements	
Group	17 (CL) has 290 elements	
Group		Water_and_ions) has 296238 elements	
Select			
Selecte	d 4: 'B	ackbone'	

Select g	roup	for output:		
Group	0 (System)	has	313022 elements
Group	1 (Protein)	has	16784 elements
Group	2 (Protein-H)	has	8468 elements
Group	3 (C-alpha)	has	1104 elements
Group	4 (Backbone)	has	3312 elements
Group	5 (MainChain)	has	4418 elements
Group	6 (MainChain+Cb)	has	5408 elements
Group	7 (MainChain+H)	has	5443 elements
Group	8 (SideChain)	has	11341 elements
Group	9 (SideChain-H)	has	4050 elements
Group	10 (Prot-Masses)	has	16784 elements
Group	11 (non-Protein)	has	296238 elements
Group	12 (Water)	has	295659 elements
Group	13 (SOL)	has	295659 elements
Group	14 (non-Water)	has	17363 elements
Group	15 (Ion)	has	579 elements
Group	16 (NA)	has	289 elements
Group	17 (CL)	has	290 elements
Group	18 (Water_and_ions)	has	296238 elements
Select a	grou	p: 4		
Selected	4: '	Backbone'		
Last fra	me	1000 time 50	900.	900
Allocate	d 401	41440 bytes for ·	fram	25
Read 100	1 fra	mes from traject	ory I	nd_0_1.xtc
		1x1001 RMS devia	tion	matrix
# RMSD c	alcul	ations left: 0		
The RMSD	rang	es from 0.088553	4 to	0.831342 nm
Average	RMSD	is 0.381406		
Number o	f str	uctures for matr	ix 10	901
		matrix is 14.19		
				lowest rmsd value 0.08855
		tures ********		*****
		enumbering clust		

Figure 44. Clustering of MD trajectory

(A) Selection of group for least squares fit and RMSD calculation.

(B) Screenshot of average RMSD values for clustering.

the investigation that may bypass the significant variations crucial for wide-ranging vaccine efficacy. Selecting an immune response-enhancing adjuvant is both challenging and crucial, as not all adjuvants work effectively in combination with the chosen epitopes. *In vitro* and *in vivo* validation of the computationally predicted vaccine construct is required for successful translational studies to ensure its efficacy and safety. Uncertainty surrounds how long a multi-epitope vaccine will confer immunity, warranting more investigation to evaluate the immune response duration and booster requirements.

TROUBLESHOOTING

Problem 1

In the *in silico* cloning analysis, sometimes you may encounter the absence of unique restriction sites at the beginning and end of the peptide. If similar restriction sites are present at the start and end of the peptide in any other region of the peptide, it may result in the generation of mid-region cuts (Ref: Step-135).

Potential solution

In such cases, manually add the unique restriction site at the start and end regions of the peptide, looking for the ones that add the least number of amino acids, as the increased length may impact its structural stability.

Problem 2

During the molecular dynamic simulation analysis, during the addition of ions under the "Next add ions" commands after "gmx grompp -f ions.mdp -c solv.gro -p topol.top -o ions.tpr" command, you may encounter an issue as "Error: Atom type HS14 is not found." (Ref: Step-108).

Potential solution

To resolve this problem, run "Solution: open drg.itp- see "HS14" – change to "H"- Save" to convert it into a readable text format.



Protocol




Figure 45. Analysis of clustered MD trajectory

(A) Extraction of no. of clusters from clustering files.(B) Evaluation of microstates.(C and D) Visualization of selected microstates in PyMOL.

Problem 3

At intervals, sudden spikes in the RMSD trajectory curve are encountered during MD simulation analysis (Ref: Step-114).

Potential solution

To eliminate the jump in RMSD, i.e., use the no jump command – gmx tryconv –f md –f md – o – 1xtc – smd –0–1.tpr–Omd–nojump.xtc-pbc.nojump.

Problem 4

When the 3D predicted epitope and linker combinations don't pass the Ramachandran plot's quality score, i.e., greater than 95%, in that case, the structure is not suggested for the study to be taken forward (Ref: Step-68).

Potential solution

To eliminate this issue, manual reshuffling and annotation of linkers and epitopes are done to create different combinations to generate a 3D structure passing the verified by the Ramachandran plot quality score.

Problem 5

The docked protein file is required in a separate chain readable format to be read as ligand and protein in PRODIGY for validating the protein-protein interactions.

But after docking the two protein chains are labeled same as "A" (Ref: Step 100).




Protocol

O CO 15 eblacukjóspachecht		B total B totals	Alghing and Hervite (Internet) Indonesial Encoderation Encode.out	\$ 0 (
Norrade 💽 Maga 🙀 Tantada 👹 N	🗰 Erhitz-Effi Tourne 🖡 Services 22 Sussanth 🔥 Training 🕑 Albant on 🔍 EMST-1972 🏢			
		Job Dispatcher	telp & Privacy Your Jobs Input form	Feedback
EMBOSS B	acktranser	Welcome to the ne	w Jab Dispatcher website. We'd love to hear your feedback about the new webpages!	
Sequence Translation				
			EMBOSS Backtranseq reads a protein sequence and writes the nucleic acid sequence it is most likely to have	ome from.
Job Dispatcher Help & Priva	acy Your Jobs Input form	Input sequent	Ce ① Paste your sequence here - or use the example sequence	
			31 AKEVAAWTLKAAAEAAAKYGNIKEENATHAAEEYSKSIGGTPALGPGPGDRRVQDVNDTISDVKQKGPGPGEAAITDS/	
Welcome to the new Job Dispat	Mahar website. Wi'd low to hear your feedback about the new webpages! X		SDYKSFEGPGPGSTLPNKSDYLGPGPGYYEDTWGSDGNPITKTTSDYQDGPGPGSDYSQEVRKYGPGPGKKESALATT EQKAYGPGPGKATTQIAPRQVAGTGPGPGIHYNESKPGPGPGKKKYSSYEEAKKHGPGPGLSSSNHEGKPHYTENYR	NGPGPGPYKLNDGPGPGSIFGFQAEVAAYTMSAFLIVR
	EMBOSS Backtranseq reads a protein sequence and writes the nucleic acid sequence it is most likely to have come from.		YRLKTLDIHYAAYWNIKKYSSYGPOPOWNIKKYSSYEEAKKHOPOPOKTLDIHYNESKPTTIOPOPOLKTLDIHYNESK WRCGPOPORVIGLCIRISMVISLGPOPOTTAIDPVRYIDPRRDGPOPOTKCDIEIGNEYIRO	PTTGPGPGTLKQRLTNLEKKITNGPGPGDVNDTISDVK
	Paste your sequence here - or use the example sequence			
Input sequence @	vaste your sequence nere - or use the example sequence		Choose Fite No No No chosee	Use the example Clear sequence More example in
		Parameters	CODON TABLE	
			-	
	Choose File No Size chooses Use the example Clear sequence More example injury	Submit	Title	
			EMBOSS Backmanseq's job	
	CODON TABLE @		Submit	
Parameters				
O 🚺 ti eliscistorente	Interstation V Version/Jammeng/Jam		Apple and the second	ά 9 α
		C → O → I state N Set • Dufter • Note: • No		ά 9 ά
O 🚺 ti eliscistorente	The most trajectory of the second sec	N Small 📾 Koulube 😢 Mapa 🗞		à • G
O 🚺 ti eliscistorente				û 9 Q
O 🚺 ti eliscistorente		N Small 📾 Kouliste 😢 Maps 🗞		0 • C
O 🚺 ti eliscistorente		N Small 📾 Kouliste 😢 Maps 🗞	Annue in the international and an annue international and annue international annue internation	o • a
O 🚺 ti eliscistorente		N Small 📾 Kouliste 😢 Maps 🗞	Note: B Tex B Real Sector S	o) • a
O (M) D macakistynthett		N Small 📾 Kouliste 😢 Maps 🗞	View Image: Comparison of the comparison of	a) • a
C C L escadorariero	The second secon	N Small 📾 Kouliste 😢 Maps 🗞	1 The second	o • a
O (M) D macakistynthett	Were splate Image: Splate Were splate Image: Splate Were splate Image: Splate Image: Splate	N Small 📾 Kouliste 😢 Maps 🗞	A term of the second se	a) • a
C C L escadorariero	The second secon	N Small 📾 Kouliste 😢 Maps 🗞	* * * * * * * * * * * * * * * * * * *	0 • a
C C L escadorariero	Were tageting Image: Control of the	N Small 📾 Kouliste 😢 Maps 🗞	A Tomo Tomo Tomo Tomo Tomo Tomo Tomo Tom	a) • a
C C L escadorariero	The second secon	N Small 📾 Kouliste 😢 Maps 🗞	* * * * * * * * * * * * * * * * * * *	• • a
C C L escadorariero	Were tageting Image: Control of the	N Small 📾 Kouliste 😢 Maps 🗞	1 Television Contraction Co	o) • a
C C L escadorariero	the set of the se	N Small 📾 Kouliste 😢 Maps 🗞	* * * * * * * * * * * * * * * * * * *	∞ • a
C C L escadorariero	Were tageting Image: Control of the second seco	N Small 📾 Koulube 😢 Mapa 🗞	1 Television Contraction Co	o) ● a
C C L escadorariero	Twee sparse Twee	N Small 📾 Koulube 😢 Mapa 🗞	* * * * * * * * * * * * * * * * * * *	• • a
C C L escadorariero		N Small 📾 Koulube 😢 Mapa 🗞	* * * * * * * * * * * * * * * * * * *	o) • a
C C L escadorariero	were uptime Were	N Small 📾 Koulube 😢 Mapa 🗞	* * * * * * * * * * * * * * * * * * *	0 • a
C C L escadorariero	<complex-block></complex-block>		* * * * * * * * * * * * * * * * * * *	(x) • a

Figure 46. EMBOSS transeq based backtranslation

- (A) Homepage of EMBOSS Back transeq server.
- (B) Entered protein sequence and parameters.
- (C) Submission of entered sequence.
- (D) Output result.



6 Design My Vector

Figure 47. Codon optimization using VectorBuilder

a few clicks. Q^a oriety of scales. Q viruses. Q^a

- (A) Homepage of VectorBuilder server.
- (B) Entered DNA sequence in the dialog box.

(C) Output page of improved DNA.






Figure 48. Creating DNA file of codon optimized sequence (A) Homepage of SnapGene software. (B and C) Creation of DNA file. (D) Output file in. dna format.




Figure 49. Creating vector for *in silico* cloning

(A) Vector of interest in SnapGene.

(B) Creating DNA file of vector.

(C and D) Steps to generate sticky end at available restriction sites.







Figure 50. Fragment insertion in created vector

(A and B) Opening the fragment file.

(C) Steps to generate sticky end at available restriction sites in the fragment. (D) Output showing *in silico* cloned product.

Potential solution

Go to notepad plus and manually edit the names of ligand and protein chains to "B" and "H" respectively in the docked protein file.

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Tanmay Majumdar (majumdart@nii.ac.in).

Technical contact

Technical questions on executing this protocol should be directed to and will be answered by the technical contact, Tanmay Majumdar (majumdart@nii.ac.in).

Materials availability

This study did not generate new unique reagents.

Data and code availability

No datasets or code was generated during this study.

ACKNOWLEDGMENTS

We are very grateful to Dr. Debasisa Mohanty, Director, NII for providing full support for computational studies, valuable inputs, and guidance. This study was supported by grants from the CRG-SERB, Govt. of India (CRG/2021/000135) to A. Kaur, K.S., and T.M. and by DBT-NII intramural core grant to T.M.

AUTHOR CONTRIBUTIONS

A. Kumar, G.N., P.B., G.K., R.M., M.D., P.C., A. Kaur, K.S., S.M., R.K., I.K.S., and T.M. performed all the experiments, formal analysis, investigation, and methodology. Data curation, formal analysis, and reviewing the paper were done by A. Kumar, G.N., P.B., G.K., R.M., M.D., P.C., A. Kaur, K.S., S.M., R.K., and I.K.S. Conceptualization of the protocol,










Figure 51. Immune simulation using C-ImmSim

(A) Homepage of C-ImmSim server.

(B) Entered parameters and protein sequences.

(C) Result showing vaccine's immunogenic response.

data curation, formal analysis, funding, investigation, methodology, project validation, writing – original draft, review, editing of the manuscript, and scientific supervision were performed by T.M.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES

- Kaur, A., Kumar, A., Kumari, G., Muduli, R., Das, M., Kundu, R., Mukherjee, S., and Majumdar, T. (2024). Rational design and computational evaluation of a multi-epitope vaccine for monkeypox virus: Insights into binding stability and immunological memory. Heliyon 10, e36154. https://doi.org/10.1016/j.heliyon. 2024.e36154.
- Abraham, M.J., Murtola, T., Schulz, R., Páll, S., Smith, J.C., Hess, B., and Lindahl, E. (2015). GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1– 2, 19–25. https://doi.org/10.1016/j.softx.2015. 06.001.
- Laskowski, R.A., and Swindells, M.B. (2011). LigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug Discovery. J. Chem. Inf. Model. 51, 2778–2786. https://doi.org/10. 1021/ci200227u.
- Doytchinova, I.A., and Flower, D.R. (2007). VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinf. 8, 4. https://doi.org/10. 1186/1471-2105-8-4.

- Dimitrov, I., Flower, D.R., and Doytchinova, I. (2013). AllerTOP - a server for in silico prediction of allergens. BMC Bioinf. 14, S4. https://doi.org/10.1186/1471-2105-14-S6-S4.
- Gasteiger, E., Hoogland, C., Gattiker, A., Duvaud, S., Wilkins, M.R., Appel, R.D., and Bairoch, A. (2005). Protein Identification and Analysis Tools on the ExPASy Server. In The Proteomics Protocols Handbook, J.M. Walker, ed. (Humana Press), pp. 571–607. https://doi. org/10.1385/1-59259-890-0:571.
- Geourjon, C., and Deléage, G. (1995). SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments. Bioinformatics 11, 681–684. https://doi.org/10.1093/ bioinformatics/11.6.681.
- McGuffin, L.J., Bryson, K., and Jones, D.T. (2000). The PSIPRED protein structure prediction server. Bioinformatics 16, 404–405. https://doi.org/10.1093/bioinformatics/16. 4.404.
- 9. Larsen, M.V., Lundegaard, C., Lamberth, K., Buus, S., Lund, O., and Nielsen, M. (2007). Large-scale validation of methods for cytotoxic

T-lymphocyte epitope prediction. BMC Bioinf. 8, 424. https://doi.org/10.1186/1471-2105-8-424

- Vita, R., Mahajan, S., Overton, J.A., Dhanda, S.K., Martini, S., Cantrell, J.R., Wheeler, D.K., Sette, A., and Peters, B. (2019). The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res. 47, D339–D343. https://doi. org/10.1093/nar/gky1006.
- Jensen, K.K., Andreatta, M., Marcatili, P., Buus, S., Greenbaum, J.A., Yan, Z., Sette, A., Peters, B., and Nielsen, M. (2018). Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology 154, 394–406. https://doi.org/10.1111/imm.12889.
- Dhanda, S.K., Vir, P., and Raghava, G.P.S. (2013). Designing of interferon-gamma inducing MHC class-II binders. Biol. Direct 8, 30. https://doi.org/10.1186/1745-6150-8-30.
- Hon, J., Marusiak, M., Martinek, T., Kunka, A., Zendulka, J., Bednar, D., and Damborsky, J. (2021). SoluProt: prediction of soluble protein expression in *Escherichia coli*. Bioinformatics 37, 23–28. https://doi.org/10.1093/ bioinformatics/btaa1102.



- Kim, D.E., Chivian, D., and Baker, D. (2004). Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res. 32, W526–W531. https://doi.org/10.1093/nar/ gkh468.
- Heo, L., Park, H., and Seok, C. (2013). GalaxyRefine: protein structure refinement driven by side-chain repacking. Nucleic Acids Res. 41, W384–W388. https://doi.org/10.1093/ nar/gkt458.
- Williams, C.J., Headd, J.J., Moriarty, N.W., Prisant, M.G., Videau, L.L., Deis, L.N., Verma, V., Keedy, D.A., Hintze, B.J., Chen, V.B., et al. (2018). MolProbity: More and better reference

data for improved all-atom structure validation. Protein Sci. 27, 293–315. https://doi.org/10. 1002/pro.3330.

- Kozakov, D., Hall, D.R., Xia, B., Porter, K.A., Padhorny, D., Yueh, C., Beglov, D., and Vajda, S. (2017). The ClusPro web server for protein– protein docking. Nat. Protoc. 12, 255–278. https://doi.org/10.1038/nprot.2016.169.
- Xue, L.C., Rodrigues, J.P., Kastritis, P.L., Bonvin, A.M., and Vangone, A. (2016). PRODIGY: a web server for predicting the binding affinity of protein–protein complexes. Bioinformatics 32, 3676–3678. https://doi.org/ 10.1093/bioinformatics/btw514.
- Sharma, N., Naorem, L.D., Jain, S., and Raghava, G.P.S. (2022). ToxinPred2: an improved method for predicting toxicity of proteins. Brief. Bioinform. 23, bbac174. https:// doi.org/10.1093/bib/bbac174.
- 20. Rice, P., Longden, I., and Bleasby, A. (2000). EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet. 16, 276–277. https://doi.org/10.1016/s0168-9525(00)02024-2.
- Rapin, N., Lund, O., and Castiglione, F. (2011). Immune system simulation online. Bioinformatics 27, 2013–2014. https://doi.org/ 10.1093/bioinformatics/btr335.